var title_f10_56_11136="Chest x-ray of a pericardial effusion";
var content_f10_56_11136=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chest x-ray of a pericardial effusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 333px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cardiomegaly due to a massive pericardial effusion. At least 200 mL of pericardial fluid must accumulate before the cardiac silhouette enlarges.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Massimo Imazio, MD, FESC.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_56_11136=[""].join("\n");
var outline_f10_56_11136=null;
var title_f10_56_11137="Sezary cells mycosis fungoides";
var content_f10_56_11137=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F75793&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F75793&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sezary cells in mycosis fungoides",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 438px; height: 178px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left panel: Peripheral blood smear from a 58-year-old woman with a two-year history of generalized erythroderma, illustrating the \"cerebriform\" shape of the nucleus of this circulating Sezary cell. Right panel: Electron micrograph showing the markedly irregular nucleus with a single prominent nucleolus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Brunning, RD, McKenna, RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_56_11137=[""].join("\n");
var outline_f10_56_11137=null;
var title_f10_56_11138="Patient information: Pericarditis in children (The Basics)";
var content_f10_56_11138=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83439\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/27/432\">",
"         The pericardium of the heart",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?37/14/38113\">",
"         Patient information: Pericarditis in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?4/45/4819\">",
"         Patient information: Pleuritic chest pain (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?11/53/12115\">",
"         Patient information: Pericarditis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?28/35/29238\">",
"         Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Pericarditis in children (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/pericarditis-in-children-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H101390544\">",
"      <span class=\"h1\">",
"       What is pericarditis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Pericarditis is a condition that causes irritation of the tissue around the heart. This tissue (called the &ldquo;pericardium&rdquo;) forms a sac that protects the heart and keeps it from rubbing against other nearby organs (",
"      <a class=\"graphic graphic_figure graphicRef69323 \" href=\"UTD.htm?0/27/432\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Pericarditis is rare in children. Children who have certain medical conditions have a higher risk of getting it. These conditions include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        An infection with a virus",
"       </li>",
"       <li>",
"        A disease called &ldquo;lupus&rdquo; &ndash; In this disease, the body&rsquo;s infection-fighting system, called the &ldquo;immune system,&rdquo; attacks the body&rsquo;s own healthy tissues.",
"       </li>",
"       <li>",
"        Surgery for a heart condition the child was born with &ndash; Fluid sometimes builds up around the heart after surgery. This can cause pericarditis.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H101390559\">",
"      <span class=\"h1\">",
"       What are the symptoms of pericarditis in children?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Chest pain",
"       </li>",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Feeling weak or tired",
"       </li>",
"       <li>",
"        Having trouble breathing",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Chest pain is the most common symptom of pericarditis. It can be a sharp pain or a dull ache. Your child might have pain in the front of the chest, the shoulder, or the upper back.",
"     </p>",
"     <p>",
"      If your child has sharp chest pain, it might get worse when he or she takes a deep breath. If the pain is a dull ache, it might get better when your child sits up and leans forward.",
"     </p>",
"     <p>",
"      Many other conditions can cause chest pain and fever in children. Because pericarditis is rare, a different condition could be causing these symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H101390574\">",
"      <span class=\"h1\">",
"       Should my child see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Take your child to the doctor or nurse if he or she:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Has chest pain",
"       </li>",
"       <li>",
"        Is a baby, and gets sweaty when breastfeeding or bottle feeding",
"       </li>",
"       <li>",
"        Has trouble breathing",
"       </li>",
"       <li>",
"        Has swelling in the legs or other parts of the body",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H101390591\">",
"      <span class=\"h1\">",
"       Will my child need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The doctor or nurse will do an exam and ask about your child&rsquo;s symptoms. He or she can do one or more of these tests: &nbsp;",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        An electrocardiogram (ECG or EKG)&nbsp;&mdash; This test measures the electrical activity in your child&rsquo;s heart.",
"       </li>",
"       <li>",
"        An echocardiogram&nbsp;&ndash; This test uses sound waves to create a picture of your child&rsquo;s heart as it beats. &nbsp;",
"       </li>",
"       <li>",
"        A chest X-ray &ndash; This test can show if there is a large amount of fluid around your child&rsquo;s heart. &nbsp;",
"       </li>",
"       <li>",
"        Blood tests&nbsp;&mdash; These measure the levels of certain proteins in the blood. The protein levels are a clue to the health of your child&rsquo;s heart. They can also tell the doctor if your child has a disease that is causing the pericarditis, and if the pericarditis is improving.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H101390608\">",
"      <span class=\"h1\">",
"       How is pericarditis in children treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatments for pericarditis in children depend on the cause. Treatments might include: &nbsp;",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines to reduce pain and inflammation, such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6342?source=see_link\">",
"         aspirin",
"        </a>",
"        ,",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        &nbsp;(sample brand names: Advil&reg;, Motrin&reg;), or",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?0/34/550?source=see_link\">",
"         indomethacin",
"        </a>",
"        &nbsp;(brand name: Indocin&reg;)",
"       </li>",
"       <li>",
"        Steroid medicines to reduce inflammation (not the same steroids athletes take to build up muscle)",
"       </li>",
"       <li>",
"        Antibiotics (if an infection is causing the pericarditis)",
"       </li>",
"       <li>",
"        Draining extra fluid from around the heart &ndash; Doctors do this with a thin needle.",
"       </li>",
"       <li>",
"        Rest",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If your child needs more treatment, the doctor can do surgery to remove swollen, irritated tissue from around the heart.",
"     </p>",
"     <p>",
"      If doctors do not already know what is causing your child&rsquo;s pericarditis, they will look for the cause and treat it, if possible. This can help the pericarditis.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H101390623\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/14/38113?source=see_link\">",
"       Patient information: Pericarditis in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/45/4819?source=see_link\">",
"       Patient information: Pleuritic chest pain (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/53/12115?source=see_link\">",
"       Patient information: Pericarditis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/35/29238?source=see_link\">",
"       Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?10/56/11138?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83439 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-4874105216-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_56_11138=[""].join("\n");
var outline_f10_56_11138=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H101390544\">",
"      What is pericarditis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H101390559\">",
"      What are the symptoms of pericarditis in children?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H101390574\">",
"      Should my child see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H101390591\">",
"      Will my child need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H101390608\">",
"      How is pericarditis in children treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H101390623\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83439\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/27/432\">",
"      The pericardium of the heart",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/53/12115?source=related_link\">",
"      Patient information: Pericarditis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/14/38113?source=related_link\">",
"      Patient information: Pericarditis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/45/4819?source=related_link\">",
"      Patient information: Pleuritic chest pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/35/29238?source=related_link\">",
"      Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_56_11139="Proteus syndrome";
var content_f10_56_11139=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83559&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83559&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Proteus syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_56_11139=[""].join("\n");
var outline_f10_56_11139=null;
var title_f10_56_11140="Cerumen or ear foreign body removal by irrigation";
var content_f10_56_11140=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 504px\">",
"   <div class=\"ttl\">",
"    Cerumen or ear foreign body removal by irrigation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 484px; height: 538px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Syringing cerumen or a foreign body from the auditory canal with an intravenous catheter attached to a 20-mL syringe. The irrigating stream is directed at the posterosuperior wall of the external auditory canal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fuerst RS. Removal of cerumen impaction. In: Textbook of Pediatric Emergency Procedures, 2nd edition, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_56_11140=[""].join("\n");
var outline_f10_56_11140=null;
var title_f10_56_11141="Sulfur and sulfacetamide: Drug information";
var content_f10_56_11141=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sulfur and sulfacetamide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?37/14/38116?source=see_link\">",
"    see \"Sulfur and sulfacetamide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F224122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AVAR&trade;;",
"     </li>",
"     <li>",
"      AVAR&trade; LS;",
"     </li>",
"     <li>",
"      AVAR&trade;-e;",
"     </li>",
"     <li>",
"      AVAR&trade;-e Green;",
"     </li>",
"     <li>",
"      AVAR&trade;-e LS;",
"     </li>",
"     <li>",
"      BP 10-1;",
"     </li>",
"     <li>",
"      BP Cleansing Wash;",
"     </li>",
"     <li>",
"      Clarifoam&trade; EF;",
"     </li>",
"     <li>",
"      Claris&trade;;",
"     </li>",
"     <li>",
"      Clenia&reg;;",
"     </li>",
"     <li>",
"      Prascion&reg;;",
"     </li>",
"     <li>",
"      Prascion&reg; FC;",
"     </li>",
"     <li>",
"      Prascion&reg; RA;",
"     </li>",
"     <li>",
"      Rosanil&reg;;",
"     </li>",
"     <li>",
"      SSS 10-4;",
"     </li>",
"     <li>",
"      SulfaCleanse&trade; 8/4;",
"     </li>",
"     <li>",
"      Sumadan&trade;;",
"     </li>",
"     <li>",
"      Sumaxin&reg;;",
"     </li>",
"     <li>",
"      Sumaxin&reg; TS;",
"     </li>",
"     <li>",
"      Zencia&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F224123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Sulfacet-R&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F224135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Acne Products;",
"     </li>",
"     <li>",
"      Antibiotic, Sulfonamide Derivative;",
"     </li>",
"     <li>",
"      Antiseborrheic Agent, Topical;",
"     </li>",
"     <li>",
"      Topical Skin Product, Acne",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F224124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Acne vulgaris, acne rosacea, seborrheic dermatitis:",
"     </b>",
"     Topical: Apply in a thin film 1-3 times/day. Cleansing products should be used 1-2 times/day.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F224132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F224125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F224126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F224108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, foam, topical: Sulfur 5% and sulfacetamide sodium 10% (60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clarifoam&trade; EF: Sulfur 5% and sulfacetamide sodium 10% (60 g, 100 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SSS 10-4: Sulfur 4% and sulfacetamide sodium 10% (100 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cleanser, topical: Sulfur 5% and sulfacetamide sodium 10% (170 g, 340 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     AVAR&trade;: Sulfur 5% and sulfacetamide sodium 10% (227 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     AVAR&trade; LS: Sulfur 2% and sulfacetamide sodium 10% (227 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Prascion&reg;: Sulfur 5% and sulfacetamide sodium 10% (170 g, 340 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Rosanil&reg;: Sulfur 5% and sulfacetamide sodium 10% (170 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AVAR&trade;-e: Sulfur 5% and sulfacetamide sodium 10% (45 g, 57 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AVAR&trade;-e Green: Sulfur 5% and sulfacetamide sodium 10% (45 g) [contains benzyl alcohol; color corrective cream]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AVAR&trade;-e LS: Sulfur 2% and sulfacetamide sodium 10% (45 g, 57 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clenia&reg;: Sulfur 5% and sulfacetamide sodium 10% (28 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prascion&reg; RA: Sulfur 5% and sulfacetamide sodium 10% (45 g) [contains benzyl alcohol and sunscreen]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical: Sulfur 5% and sulfacetamide sodium 10% (45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pad, topical [cleansing cloth]: Sulfur 4% and sulfacetamide sodium 10% (60s)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     Prascion&reg; FC: Sulfur 5% and sulfacetamide sodium 10% (30s, 60s)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     Sumaxin&reg;: Sulfur 4% and sulfacetamide sodium 10% (60s) [contains aloe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, topical: Sulfur 4% and sulfacetamide sodium 8% (473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SulfaCleanse&trade; 8/4: Sulfur 4% and sulfacetamide sodium 8% (473 mL) [contains aloe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sumaxin&reg; TS: Sulfur 4% and sulfacetamide sodium 8% (473 mL) [contains aloe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Wash, topical: Sulfur 4% and sulfacetamide sodium 9% (480 mL); Sulfur 4.5% and sulfacetamide sodium 9% (454 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BP 10-1: Sulfur 1% and sulfacetamide sodium 10% (170 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BP Cleansing Wash: Sulfur 5% and sulfacetamide sodium 10% (480 mL) [contains urea]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clenia&reg;: Sulfur 5% and sulfacetamide sodium 10% (170 g, 340 g) [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sumaxin&reg;: Sulfur 4% and sulfacetamide sodium 9% (473 mL) [contains aloe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zencia&trade;: Sulfur 4% and sulfacetamide sodium 9% (480 mL) [contains aloe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Wash, topical [emulsion-based]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BP Cleansing Wash: Sulfur 4% and sulfacetamide sodium 10% (473 mL) [contains urea]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Claris&trade;: Sulfur 4% and sulfacetamide sodium 10% (473 mL) [contains urea 10%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sumadan&trade;: Sulfur 4.5% and sulfacetamide sodium 9% (454 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F224097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes cream, emulsion-based wash",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F224110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid contact with eyes, lips and mucous membranes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cleanser: Apply to wet skin and massage gently into skin working into full lather; rinse thoroughly and pat dry.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F224109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aid in the treatment of acne vulgaris, acne rosacea, and seborrheic dermatitis",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F224133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not define, but are reported to be rare.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Drug fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Contact dermatitis, dryness, erythema, exfoliative dermatitis, itching, Stevens-Johnson syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, hemolytic anemia (acute), purpura hemorrhagica",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Irritation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F224113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sulfur, sulfonamides, or any component of the formulation; kidney disease",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F224101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias: Severe reactions including agranulocytosis, aplastic anemia and other blood dyscrasias have occurred with sulfonamides (regardless of route).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic reactions: Severe reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis have occurred with sulfonamides (regardless of route).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic necrosis: Fatalities associated with fulminant hepatic necrosis have occurred with sulfonamides (regardless of route).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Rarely, systemic hypersensitivity reactions may occur; use caution if applying to denuded or abraded skin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfonamide allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &lt;12 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sodium metabisulfite: Some products may contain sodium metabisulfite.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F13120251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F224106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F224115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies with this combination have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F224127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F224114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Avar-e Emollient External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-5% (45 g): $288.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Avar-e Green External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-5% (45 g): $294.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Avar-e LS External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-2% (45 g): $288.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Prascion RA External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-5% (45 g): $87.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Sulfacetamide Sodium-Sulfur External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-5% (28 g): $140.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Emulsion",
"     </b>",
"     (Avar Cleanser External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-5% (227 g): $288.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Emulsion",
"     </b>",
"     (Claris Clarifying Wash External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-4% (473 mL): $67.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Emulsion",
"     </b>",
"     (Prascion External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-5% (170.3 g): $109.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Emulsion",
"     </b>",
"     (Rosanil Cleanser External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-5% (170 g): $330.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Emulsion",
"     </b>",
"     (Sulfacetamide Sodium-Sulfur External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-5% (170.3 g): $25.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Foam",
"     </b>",
"     (Clarifoam EF External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-5% (60 g): $181.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Foam",
"     </b>",
"     (Sulfacetamide Sodium-Sulfur External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-5% (60 g): $163.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Sulfacetamide-Sulfur in Urea External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-5% (45 g): $220.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Rosanil External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-5% (1): $220.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Avar LS Cleanser External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-2% (227 g): $306.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Sulfacetamide Sodium-Sulfur External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-4% (473 mL): $150.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-4.5% (454 g): $161.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Sumadan Wash External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-4.5% (454 g): $272.59",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Sumaxin Wash External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-4% (473 mL): $271.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Zencia External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-4% (473 mL): $95.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Sulfacetamide Sodium-Sulfur External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-5% (45 g): $48.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pads",
"     </b>",
"     (Prascion FC External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-5% (30): $199.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pads",
"     </b>",
"     (Sulfacetamide Sodium-Sulfur External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-4% (60): $339.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pads",
"     </b>",
"     (Sumaxin External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-4% (60): $402.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Sulfacetamide Sodium-Sulfur External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8-4% (473 mL): $140.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-5% (30 g): $180.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (SulfaCleanse 8/4 External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8-4% (473 mL): $140.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Sumaxin TS External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8-4% (473 mL): $263.29",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F224116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Sulfacet-R (CA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F224100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sulfacetamide, an antibacterial agent that competitively antagonizes para-aminobenzoic acid, a component essential for bacterial growth. Sulfur is a keratolytic. Used in combination to inhibit the growth of",
"     <i>",
"      P. acnes",
"     </i>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F224112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Sulfur, topical: ~1%",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10289 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-2.133.93.82-84A455F99E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_56_11141=[""].join("\n");
var outline_f10_56_11141=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224122\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224123\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224135\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224124\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224132\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224125\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224126\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224108\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224097\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224110\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224109\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224133\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224113\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224101\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300099\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13120251\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224106\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224115\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224127\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224114\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224116\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224100\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224112\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10289\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10289|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/14/38116?source=related_link\">",
"      Sulfur and sulfacetamide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_56_11142="Cardiac device interactions with electromagnetic fields";
var content_f10_56_11142=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cardiac device interactions with electromagnetic fields",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/56/11142/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/56/11142/contributors\">",
"     David L Hayes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/56/11142/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/56/11142/contributors\">",
"     Mark S Link, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/56/11142/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/56/11142/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/56/11142/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;While there has always been concern about the potential for electromagnetic interference with pacemaker, implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy (CRT) function, due to interaction between the device and an electromagnetic field, the risk is quite low (",
"    <a class=\"graphic graphic_table graphicRef51277 \" href=\"UTD.htm?25/15/25852\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11142/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Electromagnetic interference (EMI) can occur in a variety of settings, but overall is more likely in the hospital environment than in the non-hospital environment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11142/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There have been occasional reports of cardiac implantable electronic devices (CIEDs) being impacted by sources of EMI in the non-hospital environment (eg, slot machines, laptop computers, etc). There are also disclaimers that wireless sources could be the source of EMI with CIEDs, even though no published data exists (eg, automobile manufacturers providing \"caution\" for device patients purchasing automobiles with \"keyless\" entry mechanisms, etc). Nonetheless, there are few sources of EMI in the non-hospital environment which are truly concerning. However, with the proliferation of wireless technology, any new device which operates on a new frequency or new technology platform should be assessed in order to determine whether there is indeed any significant potential for EMI with any CIED.",
"   </p>",
"   <p>",
"    Electromagnetic interference with medical sources is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21737?source=see_link&amp;anchor=H27#H27\">",
"     \"Pacing system malfunction: Evaluation and management\", section on 'Electromagnetic interference'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5434?source=see_link&amp;anchor=H24#H24\">",
"     \"Implantable cardioverter-defibrillators: Complications\", section on 'Electromagnetic interference'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HOUSEHOLD APPLIANCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are no studies that have systematically evaluated the effect of household microwave ovens on implanted devices, it is widely accepted that contemporary pacemakers and ICDs are adequately shielded from microwave energy produced by modern appliances [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11142/abstract/3\">",
"     3",
"    </a>",
"    ]. Pacemaker manufacturers",
"    <strong>",
"     do not",
"    </strong>",
"    recommend any special precautions when using common household appliances, such as televisions, radios, toasters, microwave ovens, and electric blankets. As new appliances reach the market that use a new or different energy source, the appliances need to be tested to determine whether there is any potential for device interference.",
"   </p>",
"   <p>",
"    There are circumstances in which a device may be affected by specific sources of energy under narrow circumstances. This was illustrated in a study assessing the potential for induction cook tops to interfere with pacemaker function. Patients with a unipolar, left-sided implant could experience interference if the pot was not concentrically placed on the induction coil and if the patient stood as close as possible to the cook top. The most common response to interference was a reset to an asynchronous interference mode [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11142/abstract/4\">",
"     4",
"    </a>",
"    ]. Most contemporary devices utilize bipolar pacing and sensing configuration, which minimizes the chance of device malfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CELLULAR TELEPHONES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The wide use of cellular telephones resulted in a heightened awareness of the potential adverse effects of their use on device function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Permanent pacemakers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cellular telephones are unlikely to cause clinically significant interference with cardiac devices [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11142/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Signals from the cellular phone originate at the base of the antennae. Therefore, device patients should avoid carrying an activated cellular telephone with the base of the antennae close to the device. For example, patients should avoid carrying the telephone in a breast pocket over the device. Practically speaking, it probably does not matter whether the patient uses the phone at the ear on the same side as the device or the contralateral side, but use on the contralateral side will maximally reduce the risk of interference.",
"   </p>",
"   <p>",
"    The power radiated from the cellular telephone is at its peak for a brief period when the phone is ringing. A study of early generation digital cellular phone technology noted interference produced by a ringing phone in 1.5 percent of tests [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11142/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subsequent study of permanent pacemaker function during \"third generation\" mobile phone use was performed in 100 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11142/abstract/8\">",
"     8",
"    </a>",
"    ]. Investigators programmed the pacemakers to unipolar sensing and pacing modes with maximum sensitivity to simulate the \"worst-case scenario\". Even with this programming, there was no interference in pacemaker function during mobile phone use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Implantable cardioverter-defibrillations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vivo studies and clinical experience suggest that there does not appear to be any significant interference with ICDs from wireless communication devices such as cellular telephones [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11142/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. However, cellular telephones can potentially disturb telemetry when located near the programming head [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11142/abstract/11\">",
"     11",
"    </a>",
"    ]. Nevertheless, as with the recommendations for pacemaker patients, it is recommended that the patient with an ICD not carry or place a digital cellular telephone within 15 cm (6 in) of the device [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11142/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]; they should not be used during ICD interrogation and programming [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11142/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PORTABLE MEDIA PLAYERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of electromagnetic interaction between portable media players and pacemakers and ICDs has been evaluated in small series. In vitro and in vivo data suggest that the media players that have been studied (including various Apple iPod models, SanDisk Sana, and Microsoft Zune) are unlikely to interfere with intrinsic function of pacemakers or ICDs [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11142/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. However, portable media players were found to frequently cause programmer interference, including disabled communication between the",
"    <span class=\"nowrap\">",
"     pacemaker/ICD",
"    </span>",
"    and programmer, noise in ECG recordings and loss of marker channel indicators when the media players were within two inches of the",
"    <span class=\"nowrap\">",
"     pacemaker/ICD",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11142/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. No interference was noted when the portable media players were positioned six inches from the",
"    <span class=\"nowrap\">",
"     pacemaker/ICD",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11142/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therefore, it is recommended that portable media players not be used during device interrogation. As a precaution, it is recommended that patients keep portable media players at least six inches away from pacemakers and ICDs. Interpretation of",
"    <span class=\"nowrap\">",
"     pacemaker/ICD",
"    </span>",
"    stored episodes should be performed with consideration for potential electromagnetic interference.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SECURITY SYSTEMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electromagnetic security systems (eg, antishoplifting gates, metal detectors) are in widespread use, and are often present in or near the workplace, in shopping malls, and at airports. Although device interference is possible, it is unlikely that any clinically significant interference would occur with the transient exposure associated with walking through such a field. There are case reports of inappropriate shocks and pacemaker inhibition associated with continued close exposure to electromagnetic security systems [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11142/abstract/17\">",
"     17",
"    </a>",
"    ]. The best recommendation to patients is \"don't linger, don't lean,\" ie, be aware of the location of security systems and simply move through them at a normal pace [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11142/abstract/1\">",
"     1",
"    </a>",
"    ]. Single-beat inhibition of a device by anti-theft equipment would not be of clinical concern.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Permanent pacemakers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electronic security systems can potentially interfere with pacemakers [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11142/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. The frequency and type of complications that can occur was evaluated in a study of 204 patients who were exposed to an electronic security system for up to 30 seconds [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11142/abstract/18\">",
"     18",
"    </a>",
"    ]. One or more episodes of pacemaker function interference developed in 17 percent of patients. Sensing abnormalities were the most common type of interference, and they were typically transient, lasting only for the duration of exposure. In patients with dual chamber pacemakers, interference at the atrial level was more common than at the ventricular level.",
"   </p>",
"   <p>",
"    In another report, the most common complications were asynchronous pacing, atrial oversensing (producing a tachycardia in the ventricle), ventricular oversensing (with pacemaker inhibition), and paced beats due to direct induction of current in the pacemaker [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11142/abstract/19\">",
"     19",
"    </a>",
"    ]. Symptoms such as palpitations and presyncope occurred in some patients while they were in the security system field. Interference with pacemaker function can occur at a distance of 50 cm from the security system [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11142/abstract/20\">",
"     20",
"    </a>",
"    ]. This is of particular concern for those who are fully pacemaker-dependent; such patients should avoid remaining in close proximity to a security system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Implantable cardioverter-defibrillators",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are case reports of a patient with an ICD in whom interference from an electronic antitheft-surveillance device resulted in the delivery of multiple shocks due to oversensing [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11142/abstract/17,21\">",
"     17,21",
"    </a>",
"    ]. In contrast, no interference was noted in another report of 25 patients with an ICD who were exposed to the fields of six different electronic article surveillance systems using three modes of operation (magnetic audio frequency, radiofrequency, or acoustomagnetic) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11142/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The duration of exposure is an important determinant of risk. This was illustrated in a study in which 170 patients were evaluated during a 10 to 15 second walk-through and an extreme exposure (two minutes within six inches of the gate) to three common systems [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11142/abstract/22\">",
"     22",
"    </a>",
"    ]. No interactions affecting ICD function were observed during the brief walk-through. However, during extreme exposure, an interaction was observed in 19 patients. In seven patients, this interaction was clinically relevant and could have resulted in an inappropriate ICD shock, suggesting that lingering in a surveillance system should be avoided. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=see_link\">",
"     \"General principles of the implantable cardioverter-defibrillator\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    General consensus is that it is safe for patients with an ICD to walk through a metal detector gate, although the alarm may be triggered by the pulse generator case. Although it is safe for airport personnel to use a hand held metal detector or \"wand\", a manual or pat-down search can be requested [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11142/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     EXTERNAL ELECTRICAL EQUIPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential causes of concern in the workplace are welders, industrial welding machines, electric motors, and degaussing coils [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11142/abstract/1,23\">",
"     1,23",
"    </a>",
"    ]. Functional evaluation of pacemakers and ICDs in the work place has rarely demonstrated oversensing of an external electrical field. Nevertheless, since interference remains a concern, it is recommended that assessment of potential electromagnetic sources in the workplace be performed when the patient returns to work. For the non-pacemaker dependent patient this should rarely, if ever, be a problem. For the pacemaker-dependent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ICD patient it may be necessary to monitor the patient with an ambulatory monitor to determine if proximity to",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    use of specific equipment results in any interference. Rarely, for patients that are felt to be at higher risk or using equipment that is known to generate higher electromagnetic fields, it may be necessary to have the work environment assessed by an occupational safety officer or engineer prior to return to work [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11142/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     LEAKAGE OF CURRENT FROM ELECTRICAL EQUIPMENT DRIVEN BY A POWER LINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;For monitoring or therapeutic purposes, a patient may be connected to electromechanical equipment that is connected to a power-line. Such connections may permit accidental flow or leakage of weak alternating current through patients to ground. Similarly, an intracardiac catheter may provide a low-resistance path to ground through the patient's heart and thereby place the patient at risk for electrically induced ventricular tachyarrhythmia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TRANSCUTANEOUS MUSCLE/NERVE STIMULATORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several case reports of electromagnetic interference resulting from transcutaneous muscle or nerve stimulation which caused inappropriate ICD discharges [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11142/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. However, for many patients with implantable devices a transcutaneous stimulator can be used. For the pacemaker dependent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ICD patient, a monitored in-clinic assessment while operating the stimulator in the desired location should be considered prior to allowing the patient to use the equipment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MAGNETIC RESONANCE IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues relating to MR imaging and cardiac devices are discussed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/49/6931?source=see_link\">",
"       \"Patient information: Pacemakers (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/16/20741?source=see_link\">",
"       \"Patient information: Pacemakers (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28508275\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While there is the potential for electromagnetic interference with pacemaker, implantable cardioverter-defibrillator (ICD), and cardiac resynchronization therapy (CRT) function, the risk of a clinically significant problem is extremely low.",
"     </li>",
"     <li>",
"      Pacemaker manufacturers",
"      <strong>",
"       do not",
"      </strong>",
"      recommend any special precautions when using normally functioning common household appliances, such as televisions, radios, toasters, microwave ovens, and electric blankets. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Household appliances'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While some older generation pacemakers and ICDs did occasionally experience interference from cellular telephones, clinical experience suggests that there is no significant interference between implantable cardiac devices and contemporary wireless communication devices or portable media players. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Cellular telephones'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Portable media players'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While inappropriate ICD shocks and pacemaker inhibition have been associated with prolonged (several minutes) exposure to electromagnetic security systems (eg, antishoplifting gates, metal detectors), similar problems are only rarely seen in brief (10-15 second) exposure. Patients should be advised to be aware of the location of security systems and to move through them at a normal pace (ie, \"don't linger, don't lean\"). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Security systems'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Issues relating to magnetic resonance imaging and cardiac devices are discussed separately.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11142/abstract/1\">",
"      Pinski SL, Trohman RG. Interference in implanted cardiac devices, Part I. Pacing Clin Electrophysiol 2002; 25:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11142/abstract/2\">",
"      Kolb C, Zrenner B, Schmitt C. Incidence of electromagnetic interference in implantable cardioverter defibrillators. Pacing Clin Electrophysiol 2001; 24:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11142/abstract/3\">",
"      Goldschlager N, Epstein A, Friedman P, et al. Environmental and drug effects on patients with pacemakers and implantable cardioverter/defibrillators: a practical guide to patient treatment. Arch Intern Med 2001; 161:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11142/abstract/4\">",
"      Irnich W, Bernstein AD. Do induction cooktops interfere with cardiac pacemakers? Europace 2006; 8:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11142/abstract/5\">",
"      Irnich W, Batz L, M&uuml;ller R, Tobisch R. Electromagnetic interference of pacemakers by mobile phones. Pacing Clin Electrophysiol 1996; 19:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11142/abstract/6\">",
"      Hayes DL, Wang PJ, Reynolds DW, et al. Interference with cardiac pacemakers by cellular telephones. N Engl J Med 1997; 336:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11142/abstract/7\">",
"      Trigano A, Blandeau O, Dale C, et al. Reliability of electromagnetic filters of cardiac pacemakers tested by cellular telephone ringing. Heart Rhythm 2005; 2:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11142/abstract/8\">",
"      Ismail MM, Badreldin AM, Heldwein M, Hekmat K. Third-generation mobile phones (UMTS) do not interfere with permanent implanted pacemakers. Pacing Clin Electrophysiol 2010; 33:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11142/abstract/9\">",
"      Barbaro V, Bartolini P, Bellocci F, et al. Electromagnetic interference of digital and analog cellular telephones with implantable cardioverter defibrillators: in vitro and in vivo studies. Pacing Clin Electrophysiol 1999; 22:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11142/abstract/10\">",
"      Chiladakis JA, Davlouros P, Agelopoulos G, Manolis AS. In-vivo testing of digital cellular telephones in patients with implantable cardioverter-defibrillators. Eur Heart J 2001; 22:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11142/abstract/11\">",
"      Occhetta E, Plebani L, Bortnik M, et al. Implantable cardioverter defibrillators and cellular telephones: is there any interference? Pacing Clin Electrophysiol 1999; 22:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11142/abstract/12\">",
"      Hayes DL, Carrillo RG, Findlay GK, Embrey M. State of the science: pacemaker and defibrillator interference from wireless communication devices. Pacing Clin Electrophysiol 1996; 19:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11142/abstract/13\">",
"      Fetter JG, Ivans V, Benditt DG, Collins J. Digital cellular telephone interaction with implantable cardioverter-defibrillators. J Am Coll Cardiol 1998; 31:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11142/abstract/14\">",
"      Bassen H. Low frequency magnetic emissions and resulting induced voltages in a pacemaker by iPod portable music players. Biomed Eng Online 2008; 7:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11142/abstract/15\">",
"      Thaker JP, Patel MB, Jongnarangsin K, et al. Electromagnetic interference with pacemakers caused by portable media players. Heart Rhythm 2008; 5:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11142/abstract/16\">",
"      Webster G, Jordao L, Martuscello M, et al. Digital music players cause interference with interrogation telemetry for pacemakers and implantable cardioverter-defibrillators without affecting device function. Heart Rhythm 2008; 5:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11142/abstract/17\">",
"      Gimbel JR, Cox JW Jr. Electronic article surveillance systems and interactions with implantable cardiac devices: risk of adverse interactions in public and commercial spaces. Mayo Clin Proc 2007; 82:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11142/abstract/18\">",
"      Mugica J, Henry L, Podeur H. Study of interactions between permanent pacemakers and electronic antitheft surveillance systems. Pacing Clin Electrophysiol 2000; 23:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11142/abstract/19\">",
"      McIvor ME, Reddinger J, Floden E, Sheppard RC. Study of Pacemaker and Implantable Cardioverter Defibrillator Triggering by Electronic Article Surveillance Devices (SPICED TEAS). Pacing Clin Electrophysiol 1998; 21:1847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11142/abstract/20\">",
"      Wilke A, Kruse T, Hesse H, et al. Interactions between pacemakers and security systems. Pacing Clin Electrophysiol 1998; 21:1784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11142/abstract/21\">",
"      Santucci PA, Haw J, Trohman RG, Pinski SL. Interference with an implantable defibrillator by an electronic antitheft-surveillance device. N Engl J Med 1998; 339:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11142/abstract/22\">",
"      Groh WJ, Boschee SA, Engelstein ED, et al. Interactions between electronic article surveillance systems and implantable cardioverter-defibrillators. Circulation 1999; 100:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11142/abstract/23\">",
"      Fetter JG, Benditt DG, Stanton MS. Electromagnetic interference from welding and motors on implantable cardioverter-defibrillators as tested in the electrically hostile work site. J Am Coll Cardiol 1996; 28:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11142/abstract/24\">",
"      Glotzer TV, Gordon M, Sparta M, et al. Electromagnetic interference from a muscle stimulation device causing discharge of an implantable cardioverter defibrillator: epicardial bipolar and endocardial bipolar sensing circuits are compared. Pacing Clin Electrophysiol 1998; 21:1996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11142/abstract/25\">",
"      Philbin DM, Marieb MA, Aithal KH, Schoenfeld MH. Inappropriate shocks delivered by an ICD as a result of sensed potentials from a transcutaneous electronic nerve stimulation unit. Pacing Clin Electrophysiol 1998; 21:2010.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 964 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-1A66C01F0E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_56_11142=[""].join("\n");
var outline_f10_56_11142=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28508275\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HOUSEHOLD APPLIANCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CELLULAR TELEPHONES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Permanent pacemakers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Implantable cardioverter-defibrillations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PORTABLE MEDIA PLAYERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SECURITY SYSTEMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Permanent pacemakers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Implantable cardioverter-defibrillators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      EXTERNAL ELECTRICAL EQUIPMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      LEAKAGE OF CURRENT FROM ELECTRICAL EQUIPMENT DRIVEN BY A POWER LINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TRANSCUTANEOUS MUSCLE/NERVE STIMULATORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MAGNETIC RESONANCE IMAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28508275\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/964\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/964|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/15/25852\" title=\"table 1\">",
"      EMI with cardiac devices",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=related_link\">",
"      General principles of the implantable cardioverter-defibrillator",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5434?source=related_link\">",
"      Implantable cardioverter-defibrillators: Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21737?source=related_link\">",
"      Pacing system malfunction: Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/16/20741?source=related_link\">",
"      Patient information: Pacemakers (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/49/6931?source=related_link\">",
"      Patient information: Pacemakers (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_56_11143="Benign lichenoid keratosis";
var content_f10_56_11143=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F73523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F73523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Benign lichenoid keratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This erythematous, scaly macule was a benign lichenoid keratosis. Benign lichenoid keratoses share clinical features with actinic keratoses, squamous cell carcinoma in situ, and superficial basal cell carcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_56_11143=[""].join("\n");
var outline_f10_56_11143=null;
var title_f10_56_11144="Pharmacology of integrase inhibitors";
var content_f10_56_11144=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pharmacology of integrase inhibitors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/56/11144/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/56/11144/contributors\">",
"     Charles B Hicks, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/56/11144/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/56/11144/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/56/11144/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/56/11144/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/56/11144/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H18367920\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The availability of effective combination antiretroviral therapy (ART) has transformed HIV infection from an almost uniformly fatal diagnosis to a manageable chronic disease for persons living in areas of the world with widespread access to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Sustaining treatment success requires antiretroviral drugs that are potent, well tolerated, and convenient. Introduction of the first HIV-1 integrase inhibitor,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    , followed by a second integrase inhibitor, elvitegravir, has expanded the range of efficacious options.",
"   </p>",
"   <p>",
"    This topic will address the pharmacology of HIV integrase inhibitors. Clinical trial data concerning the use of these agents is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/34/7720?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Integrase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523368\">",
"    <span class=\"h1\">",
"     AVAILABLE AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2009,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    was approved for use in treatment-naive and treatment-experienced HIV-infected patients. Elvitegravir was subsequently approved for use in treatment-naive HIV-infected patients in August 2012 as part of a fixed-dose antiretroviral combination regimen that incorporates",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    , elvitegravir, and cobicistat into a single tablet. Cobicistat is an inhibitor of the cytochrome P450 enzyme CYP3A4, which is the primary metabolic pathway for elimination of many drugs, including elvitegravir. As such, it works as a pharmacologic enhancer of elvitegravir; it does not have any intrinsic anti-HIV activity of its own. Tenofovir and emtricitabine are approved antiretroviral drugs that are nucleoside analogs and work by inhibiting HIV reverse transcriptase. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/34/7720?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Integrase inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41209?source=see_link\">",
"     \"Pharmacology of nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18367927\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV integrase is one of three enzymes (reverse transcriptase, protease, and integrase) encoded by the virus, which are essential for HIV replication. After entry into CD4+ T cells, viral RNA is transcribed into DNA by HIV reverse transcriptase. Following this step, the integrase enzyme combines with viral DNA and other cellular cofactors to form the preintegration complex (PIC) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/4-9\">",
"     4-9",
"    </a>",
"    ]. Subsequently, the integrase enzyme removes a nucleotide from each 3&rsquo; DNA terminus, thereby exposing reactive hydroxyl groups. The PIC then enters the host cell nucleus where it binds to host cell DNA. Integrase nicks each strand of the host cell DNA and exposes the 5&rsquo; phosphate groups, enabling covalent bonding of host and viral DNA. After this strand transfer is complete, host cell enzymes repair gaps between the viral and host DNA.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     Raltegravir",
"    </a>",
"    and elvitegravir both target the strand transfer step of viral DNA integration and are sometimes referred to as &ldquo;INSTI&rdquo; (integrase strand transfer inhibitor) drugs. These drugs prevent or inhibit the binding of the pre-integration complex to host cell DNA, thus terminating the integration step of HIV replication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18367934\">",
"    <span class=\"h1\">",
"     SPECTRUM OF ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     Raltegravir",
"    </a>",
"    and elvitegravir are active against a wide range of wild-type and drug-resistant HIV-1 isolates, including HIV-1 clades A, B, C, D, E, F, and G, as well as HIV-2. They are also active against strains that use either coreceptor CCR5 or CXCR4, since HIV tropism has no effect on the activity of HIV integrase inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/4\">",
"     4",
"    </a>",
"    ]. CCR5-tropic viruses generally predominate in primary infection and are usually associated with a less virulent phenotype compared with CXCR4-tropic viruses, which often emerge later in infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24186?source=see_link\">",
"     \"Factors affecting HIV progression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no evidence of in vitro antagonism between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    or elvitegravir and a range of other antiretroviral drugs, including many nucleoside analogue reverse-transcriptase inhibitors (NRTIs), nonnucleoside reverse-transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), the CCR5 co-receptor antagonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    , and the fusion inhibitor,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"     enfuvirtide",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3096271\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized clinical trials among treatment-naive patients have demonstrated that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    -containing antiretroviral therapy (ART) was not inferior, and in some cases was superior, to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    -containing ART in achieving viral suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Among treatment-experienced patients with established drug resistance, the addition of raltegravir to optimized background ART was superior to optimized background therapy alone. These data are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/34/7720?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Integrase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Published data from two phase 3 trials have demonstrated that the combination of elvitegravir,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , and cobicistat was non-inferior to combination ART regimens containing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    plus either boosted",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Noninferiority was also demonstrated among treatment-naive patients with high baseline HIV RNA levels (ie, &gt;100,000",
"    <span class=\"nowrap\">",
"     copies/mL).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/34/7720?source=see_link&amp;anchor=H1981991#H1981991\">",
"     \"Clinical trials of HIV antiretroviral therapy: Integrase inhibitors\", section on 'Elvitegravir'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3096524\">",
"    <span class=\"h1\">",
"     DRUG RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug resistance emerges relatively frequently in patients who fail integrase inhibitor therapy and is associated with mutations in the gene encoding the integrase enzyme [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/14\">",
"     14",
"    </a>",
"    ]. The currently available integrase inhibitors have a relatively low genetic barrier to resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/15\">",
"     15",
"    </a>",
"    ] and there is broad cross-resistance between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    and elvitegravir, which will preclude their sequential use [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/16\">",
"     16",
"    </a>",
"    ]. Among the three primary raltegravir resistance-associated substitutions",
"    <span class=\"nowrap\">",
"     (Y143H/R,",
"    </span>",
"    <span class=\"nowrap\">",
"     Q148H/K/R,",
"    </span>",
"    and N155H), all but one (Y143H) conferred significant reductions in susceptibility to elvitegravir (greater than fivefold) in the phase 3 trials. A third integrase inhibitor, dolutegravir, which is likely to be licensed in 2013, appears to have a higher genetic barrier to resistance and retains activity against many viruses with integrase resistance mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In clinical trials, 13 of the 23 patients (57 percent) who experienced virologic failure while receiving elvitegravir had evidence of resistance to elvitegravir on genotypic testing [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/19\">",
"     19",
"    </a>",
"    ]. The primary resistance mutations included T66I, E92Q, Q148R, and N155H. Of these, three (E92Q, Q148R, and N155H) also conferred significant resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    , confirming the high degree of cross-resistance between these two integrase inhibitors.",
"   </p>",
"   <p>",
"    Drug resistance in clinical practice is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34218?source=see_link\">",
"     \"Primer on interpretation of HIV drug resistance testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=see_link\">",
"     \"Drug resistance testing in the clinical management of HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18367941\">",
"    <span class=\"h1\">",
"     PHARMACOKINETICS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4423789\">",
"    <span class=\"h2\">",
"     Raltegravir",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in healthy volunteers and in HIV-infected patients have demonstrated that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    is rapidly absorbed with a time to maximal absorption (Cmax) of approximately one hour [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/9\">",
"     9",
"    </a>",
"    ]. Steady state concentrations are achieved within two days [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/20\">",
"     20",
"    </a>",
"    ]. Bioavailability is approximately 32 percent, and about 83 percent of raltegravir is bound to human plasma proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. There is a biphasic decline in drug concentrations, with an initial-phase half-life of approximately one hour and a terminal-phase half-life of 7 to 12 hours. Significant drug accumulation has not been observed.",
"   </p>",
"   <p>",
"    Dose-escalation trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    monotherapy among treatment-naive patients identified 400 mg twice daily as the optimum dosage since the maximum serum concentrations and the area under the curve at 12 hours plateaued with higher dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/24\">",
"     24",
"    </a>",
"    ]. All dosages led to drug concentrations that were well above the 95 percent inhibitory concentrations for susceptible HIV isolates.",
"   </p>",
"   <p>",
"    Administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    with a high-fat meal slows the rate of absorption but also increases the area under the curve (AUC) by almost 20 percent. These findings are not felt to be clinically significant and no food recommendations or restrictions are suggested for raltegravir dosing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4423804\">",
"    <span class=\"h2\">",
"     Elvitegravir",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the exception of phase 1 dose-ranging studies of unboosted drug, elvitegravir has not been shown to achieve therapeutic concentrations unless administered with a pharmacologic booster. Clinically the drug is only available as part of a fixed-dose combination tablet that contains 150 mg of elvitegravir and 150 mg of cobicistat (which functions as the pharmacologic booster by inhibiting the activity of the cytochrome p450 enzymes CYP3A and CYP2D6). Cobicistat has no intrinsic HIV activity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/25\">",
"     25",
"    </a>",
"    ]. With pharmacokinetic enhancement, elvitegravir is rapidly absorbed and achieves Cmax after four hours; when given with cobicistat, the median terminal plasma half-life of elvitegravir is approximately 12.9 hours, allowing once-daily dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Relative to fasting conditions, the administration of a single dose of the coformulation product containing elvitegravir and cobicistat (plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    ) with a light meal increased systemic exposure to elvitegravir by 34 percent. The systemic exposure increased to 87 percent if the drug was taken with a high-fat meal of around 800 kcal with 50 percent fat. Thus, patients should be advised to take the combination tablet with food.",
"   </p>",
"   <p>",
"    Of note, cobicistat inhibits tubular secretion of creatinine resulting in small increases in serum creatinine concentrations; however, these modest elevations do not appear to be reflective of any changes in true glomerular filtration rate (GFR). One small pharmacokinetic study of cobicistat used a glomerular filtration probe drug to assess changes in GFR among HIV-seronegative volunteers with normal renal function or mild to moderate renal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/26\">",
"     26",
"    </a>",
"    ]. Although estimated GFR declined with a rise in serum creatinine, actual GFR was unchanged. It should be noted, however, that the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    component of the currently available fixed-dose combination can occasionally cause significant renal injury. Thus, changes in serum creatinine after starting the fixed-dose regimen need to be followed carefully. An increase in serum creatinine of 0.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or more should not be attributed to the effect of cobicistat alone and should prompt a more thorough assessment for acute kidney injury. (See",
"    <a class=\"local\" href=\"#H18367948\">",
"     'Safety and toxicity'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12759?source=see_link&amp;anchor=H6#H6\">",
"     \"Dose modification of antiretroviral agents in adults with renal or hepatic dysfunction\", section on 'Tenofovir and nephrotoxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3095940\">",
"    <span class=\"h1\">",
"     DRUG ELIMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A study in HIV-uninfected volunteers who ingested radiolabeled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    showed that 51 percent of the drug was excreted in feces and 31 percent in urine [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/22\">",
"     22",
"    </a>",
"    ]. Raltegravir is primarily cleared from the body via hepatic glucuronidation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/22\">",
"     22",
"    </a>",
"    ], while elvitegravir undergoes metabolism primarily via the hepatic enzyme CYP3A and also via glucuronidation (uridine glucuronosyltransferase 1A1 and 1A3) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/27\">",
"     27",
"    </a>",
"    ]. Elvitegravir is excreted predominantly in feces (95 percent) with a small amount appearing in the urine (5 percent). (See",
"    <a class=\"local\" href=\"#H3095969\">",
"     'Drug interactions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H127890752\">",
"    <span class=\"h1\">",
"     DOSAGE AND ADMINISTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard dosing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    is 400 mg twice daily. It can be administered without regard to food.",
"   </p>",
"   <p>",
"    Elvitegravir is currently only available as part of a combination single tablet containing elvitegravir (150 mg), cobicistat (150 mg),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    (300 mg), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    (200 mg). Dosage alterations or substitution of any individual component due to adverse events is not possible. It is administered with food.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3095969\">",
"    <span class=\"h1\">",
"     DRUG INTERACTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H127890760\">",
"    <span class=\"h2\">",
"     Raltegravir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     Raltegravir",
"    </a>",
"    is primarily cleared from the body via hepatic glucuronidation, mostly mediated through the isoenzyme uridine diphosphate glucuronosyltransferase (UGT) 1A1; use of this pathway can lead to drug-drug interactions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/22\">",
"     22",
"    </a>",
"    ]. In general, though, raltegravir is notable for having few significant drug-drug interactions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Drugs that are strong inducers of uridine diphosphate glucuronosyltransferase (UGT) 1A1 significantly reduce",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      concentrations and should be used with caution. For example,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      decreases raltegravir concentrations by 38 to 61 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/21\">",
"       21",
"      </a>",
"      ]. If rifampin is required, raltegravir dosing should be increased to 800 mg twice daily [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other drugs that induce UGT1A1 less strongly (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"       phenobarbital",
"      </a>",
"      ) may also reduce concentrations of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      , but this has not been well characterized. No dose modifications are recommended for these situations.",
"     </li>",
"     <li>",
"      Weak UGT1A1 inducers (eg, St. John&rsquo;s wort,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"       rifabutin",
"      </a>",
"      ) are not expected to have a clinically significant impact, and no change in",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      dosing is currently recommended.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     Raltegravir",
"    </a>",
"    has little effect on the cytochrome P450 enzymes, which means that interactions with drugs that are cleared by this system (including many antiretroviral agents) are unlikely. The lack of a clinically relevant effect was verified in vivo in a study of 10 HIV&ndash;uninfected volunteers who were given",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    (a sensitive probe of the cytochrome p450 system) with and without coadministration of raltegravir [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/29\">",
"     29",
"    </a>",
"    ]. There were no statistically significant changes in midazolam AUC concentrations, time to maximal absorption (Cmax), or plasma half-life after two weeks of raltegravir therapy, demonstrating that raltegravir is neither an inducer nor an inhibitor of the cytochrome P450 isoenzyme system (including CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     Raltegravir",
"    </a>",
"    does not inhibit P-glycoprotein&ndash;mediated drug transport [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/21\">",
"     21",
"    </a>",
"    ]. To date, there is no evidence that raltegravir affects the pharmacokinetics of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    , opioids, statins, azole antifungals, proton pump inhibitors, oral contraceptives, erectile dysfunction therapies, or most other antiretroviral drugs. The proton pump inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    increases concentrations of raltegravir but not sufficiently to require dose modification [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H127890767\">",
"    <span class=\"h2\">",
"     Elvitegravir",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast, elvitegravir is principally metabolized through the cytochrome p450 pathway. Thus, drugs that induce or inhibit cytochrome P450 enzymes, especially the CYP3A4 enzyme, are highly likely to have drug-drug interactions with elvitegravir. Since elvitegravir is used only with the CYP3A4 inhibitor cobicistat, other drugs that are substrates for this enzyme are also likely to have drug-drug interactions.",
"   </p>",
"   <p>",
"    Prescribing information for elvitegravir includes a list of drugs for which there are established or potentially significant interactions. Because elvitegravir is only available as part of a complete regimen for HIV treatment, there are no data provided yet on the potential interaction of elvitegravir with other antiretroviral agents. Prior to prescribing elvitegravir, it is important to review the patient&rsquo;s other medications to identify potential drug-drug interactions, which can be severe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3096020\">",
"    <span class=\"h1\">",
"     USE IN PATIENTS WITH HEPATIC AND RENAL INSUFFICIENCY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H127890789\">",
"    <span class=\"h2\">",
"     Hepatic insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;No",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    dose adjustments are recommended for persons with mild-to-moderate hepatic impairment (Child-Pugh Class A and B) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/21,31\">",
"     21,31",
"    </a>",
"    ]. This is also the case for elvitegravir and the four-drug combination in which elvitegravir is currently available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12262508\">",
"    <span class=\"h2\">",
"     Renal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since little drug is excreted in urine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    dose reductions are not required even with severe renal insufficiency. The effect of dialysis on raltegravir concentrations has not been evaluated. Therefore, dosing just prior to dialysis is not recommended.",
"   </p>",
"   <p>",
"    Because elvitegravir is only available as part of a fixed-dose combination single tablet regimen that includes",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    , it is not recommended for patients with a creatinine clearance of &lt;70",
"    <span class=\"nowrap\">",
"     mL/minute.",
"    </span>",
"    If elvitegravir boosted by cobicistat becomes available without tenofovir and emtricitabine, the pharmacokinetics of",
"    <span class=\"nowrap\">",
"     elvitegravir/cobicistat",
"    </span>",
"    are not significantly changed in the presence of renal insufficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3096027\">",
"    <span class=\"h1\">",
"     DISTRIBUTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     Raltegravir",
"    </a>",
"    achieves meaningful drug concentrations in cerebral spinal fluid and genital compartments:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Concentrations in 25 pairs of cerebrospinal fluid (CSF) and plasma samples from 16 HIV-infected persons receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      were measured using liquid chromatography tandem mass spectrometry [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/32\">",
"       32",
"      </a>",
"      ]. Measurable CSF raltegravir levels were identified in all but one sample, and half of the patients had drug concentrations that exceeded the inhibitory concentration (IC95) levels for susceptible HIV strains.",
"     </li>",
"     <li>",
"      Drug concentrations were measured in plasma and semen in 10 HIV-infected men who had received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      for at least 24 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/33\">",
"       33",
"      </a>",
"      ]. HIV RNA was below the level of detection in all plasma and semen samples, and the median semen concentration of raltegravir exceeded that of plasma (median semen to plasma ratio was 1:42 [range 0.52 to 6.66]).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data on elvitegravir concentrations in cerebrospinal fluid and genital secretions are not currently available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18367948\">",
"    <span class=\"h1\">",
"     SAFETY AND TOXICITY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H127890774\">",
"    <span class=\"h2\">",
"     Raltegravir",
"    </span>",
"    &nbsp;&mdash;&nbsp;Safety data from studies of HIV-uninfected volunteers and HIV-infected patients initiating antiretroviral therapy (ART) have established that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    is generally safe and well tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/20,24,34,35\">",
"     20,24,34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a 10-day study of HIV-infected patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    monotherapy, the adverse event profile of raltegravir was similar to that of placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/24\">",
"     24",
"    </a>",
"    ]. In a phase 2 study that compared raltegravir with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    (each given in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ), the incidence of serious adverse events was similar between the groups (6 percent), and no serious event was considered to be drug-related [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Drug-related adverse events occurring in &gt;10 percent of patients were nausea in both groups and dizziness and headache in the efavirenz group. Over 96 weeks, there was a higher percentage of grade 3 and 4 creatine phosphokinase elevations in the raltegravir arm than in the efavirenz arm (6.3 percent versus 2.6 percent), and there was one case of rhabdomyolysis, although the relationship to raltegravir is unclear.",
"   </p>",
"   <p>",
"    The effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    on serum lipid profiles in treatment-naive persons appears to be modest [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/10,36\">",
"     10,36",
"    </a>",
"    ]. In a phase 3 study, changes in lipid levels were less in the raltegravir arm than in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    arm, although there was no significant difference in the total cholesterol to HDL cholesterol ratio between the two treatment arms [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/10\">",
"     10",
"    </a>",
"    ]. A slight decline in triglycerides was noted in the raltegravir recipients. More persons in the efavirenz arm (n = 11) initiated lipid-lowering therapy during the first 48 weeks of the study than in the raltegravir arm (n = 3).",
"   </p>",
"   <p>",
"    Safety data from studies in antiretroviral-experienced patients are also reassuring. In a phase 2 study that compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    with placebo in treatment-experienced persons, the safety profile in the study arms was similar, with no reported dose-related toxicities [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/37\">",
"     37",
"    </a>",
"    ]. In the large phase 3 studies that compared raltegravir with placebo, raltegravir was well tolerated, and the adverse event profile was similar to the placebo arm [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A combined analysis of the BENCHMRK trials, which were conducted among treatment-experienced patients, suggested that there may be an increased risk of cancer with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    use compared with placebo (1.3 percent versus 0.3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/40\">",
"     40",
"    </a>",
"    ]. However, an extended retrospective analysis of more than 6000 patients who had received raltegravir with more than 3900 person-years of follow-up did not suggest any association between raltegravir and malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/41\">",
"     41",
"    </a>",
"    ]. Furthermore, data from the phase 3 STARTMRK trial, which was conducted among treatment-naive patients, found more malignancies among those randomized to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    (9 of 281 patients; 3.2 percent) than among those who received raltegravir (1 of 281 patients; 0.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H127890781\">",
"    <span class=\"h2\">",
"     Elvitegravir",
"    </span>",
"    &nbsp;&mdash;&nbsp;The coformulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/54/8041?source=see_link\">",
"     elvitegravir-cobicistat-tenofovir-emtricitabine",
"    </a>",
"    was generally well tolerated in the two clinical trials for treatment-naive patients that were the basis for its approval by the FDA; only 3.7 percent of those randomized to the elvitegravir-based single tablet regimen discontinued therapy due to adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11144/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The most common adverse events reported were nausea and diarrhea.",
"   </p>",
"   <p>",
"    Cobicistat is associated with modest elevations of serum creatinine that occur early within the course of treatment due to inhibition of proximal tubular secretion; however, cobicistat does not appear to have any adverse effect on glomerular function. Because elvitegravir in its current formulation is always administered with cobicistat,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    , there is potential for drug-induced renal insufficiency associated with tenofovir. Therefore, if serum creatinine elevations of greater than 0.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    are noted, patients should be monitored closely for progressive renal insufficiency due to proximal tubulopathy, an event seen in 0.4 percent of those who received the elvitegravir-based combination single tablet regimen. Patients with suspected tubulopathy should have monitoring for proteinuria, glycosuria, and phosphate wasting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12759?source=see_link&amp;anchor=H6#H6\">",
"     \"Dose modification of antiretroviral agents in adults with renal or hepatic dysfunction\", section on 'Tenofovir and nephrotoxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3096103\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       Raltegravir",
"      </a>",
"      and elvitegravir are active against a wide range of wild-type and drug-resistant HIV-1 isolates. Both drugs also have activity against HIV-2. (See",
"      <a class=\"local\" href=\"#H18367934\">",
"       'Spectrum of activity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Elvitegravir is currently only available as part of a four-drug co-formulated pill, which also includes cobicistat,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      . It is approved for use in treatment-naive HIV-infected patients; its use in treatment-experienced patients is under review. (See",
"      <a class=\"local\" href=\"#H523368\">",
"       'Available agents'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3096271\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       Raltegravir",
"      </a>",
"      is rapidly absorbed with a bioavailability of approximately 32 percent; steady state concentrations are achieved within two days. Elvitegravir does not achieve therapeutic concentrations unless it is administered with a pharmacologic booster, such as cobicistat. (See",
"      <a class=\"local\" href=\"#H18367941\">",
"       'Pharmacokinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pharmacokinetic studies of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      demonstrate that about half of the drug is excreted in feces and one-third is voided in urine. About 95 percent of elvitegravir is excreted in feces and about 5 percent in urine. (See",
"      <a class=\"local\" href=\"#H3095940\">",
"       'Drug elimination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       Raltegravir",
"      </a>",
"      is primarily cleared from the body via hepatic glucuronidation through the isoenzyme uridine diphosphate glucuronosyltransferase (UGT) 1A1. Although UGT also plays a role in clearance of elvitegravir, metabolism of this integrase inhibitor is mainly processed through the CYP3A pathway. (See",
"      <a class=\"local\" href=\"#H3095940\">",
"       'Drug elimination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No dosage adjustment of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      is required for patients with mild to moderate hepatic or renal insufficiency. However, the elvitegravir-containing combination pill cannot be used in patients with a creatine clearance of &lt;70",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      in large part because of the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      component. (See",
"      <a class=\"local\" href=\"#H3096020\">",
"       'Use in patients with hepatic and renal insufficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       Raltegravir",
"      </a>",
"      achieves good concentrations in cerebral spinal fluid and in seminal plasma. There are no comparable data yet on elvitegravir. (See",
"      <a class=\"local\" href=\"#H3096027\">",
"       'Distribution'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Large-scale trials in treatment-naive and treatment-experienced patients demonstrate that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      is generally well tolerated. The most common adverse event is nausea. (See",
"      <a class=\"local\" href=\"#H18367948\">",
"       'Safety and toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical trials have also demonstrated the tolerability of the co-formulation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/54/8041?source=see_link\">",
"       elvitegravir-cobicistat-tenofovir-emtricitabine",
"      </a>",
"      among treatment-naive patients. The most common adverse events are nausea and diarrhea. (See",
"      <a class=\"local\" href=\"#H18367948\">",
"       'Safety and toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cobicistat is associated with modest elevations of serum creatinine that occur early during the course of treatment due to inhibition of proximal tubular secretion; however, cobicistat does not have any adverse effect on glomerular function. Since elvitegravir is currently only available in a single tablet form that also contains",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      , there is potential for the regimen to cause proximal tubular dysfunction. (See",
"      <a class=\"local\" href=\"#H18367948\">",
"       'Safety and toxicity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11144/abstract/1\">",
"      Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11144/abstract/2\">",
"      Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11144/abstract/3\">",
"      Vittinghoff E, Scheer S, O'Malley P, et al. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis 1999; 179:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11144/abstract/4\">",
"      Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000; 287:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11144/abstract/5\">",
"      Hazuda DJ, Felock PJ, Hastings JC, et al. Differential divalent cation requirements uncouple the assembly and catalytic reactions of human immunodeficiency virus type 1 integrase. J Virol 1997; 71:7005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11144/abstract/6\">",
"      Yoder KE, Bushman FD. Repair of gaps in retroviral DNA integration intermediates. J Virol 2000; 74:11191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11144/abstract/7\">",
"      Zhu K, Dobard C, Chow SA. Requirement for integrase during reverse transcription of human immunodeficiency virus type 1 and the effect of cysteine mutations of integrase on its interactions with reverse transcriptase. J Virol 2004; 78:5045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11144/abstract/8\">",
"      Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov 2005; 4:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11144/abstract/9\">",
"      Schafer JJ, Squires KE. Integrase inhibitors: a novel class of antiretroviral agents. Ann Pharmacother 2010; 44:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11144/abstract/10\">",
"      Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374:796.",
"     </a>",
"    </li>",
"    <li>",
"     Rockstroh J, DeJesus E, Saag M, et al. Abstract LEPE19 from XIX International AIDS Conference. Washington, DC, USA July 22-27, 2012.",
"    </li>",
"    <li>",
"     file://www.retroconference.org/2012b/Abstracts/43391.htm (Accessed on May 08, 2012).",
"    </li>",
"    <li>",
"     file://www.retroconference.org/2012b/Abstracts/43143.htm (Accessed on May 08, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11144/abstract/14\">",
"      Powderly WG. Integrase inhibitors in the treatment of HIV-1 infection. J Antimicrob Chemother 2010; 65:2485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11144/abstract/15\">",
"      Blanco JL, Varghese V, Rhee SY, et al. HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis 2011; 203:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11144/abstract/16\">",
"      Garrido C, Villacian J, Zahonero N, et al. Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens. Antimicrob Agents Chemother 2012; 56:2873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11144/abstract/17\">",
"      van Lunzen J, Maggiolo F, Arribas JR, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis 2012; 12:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11144/abstract/18\">",
"      Eron JJ, Clotet B, Durant J, et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis 2013; 207:740.",
"     </a>",
"    </li>",
"    <li>",
"     Stribild [package insert]. Foster City, CA: Gilead Sciences, Inc; August 2012",
"    </li>",
"    <li>",
"     Petry AS, Wenning LA, Laethem M, et al. Safety, tolerabililty, and pharmacokinetics after single and multiple doses of MK-0518 in healthy subjects [abstract A-376]. In: Program and abstracts of 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 2006.",
"    </li>",
"    <li>",
"     Isentress (raltegravir) [package insert]. Whitehouse Station, NJ; Merck, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11144/abstract/22\">",
"      Kassahun K, McIntosh I, Cui D, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 2007; 35:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11144/abstract/23\">",
"      Temesgen Z, Siraj DS. Raltegravir: first in class HIV integrase inhibitor. Ther Clin Risk Manag 2008; 4:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11144/abstract/24\">",
"      Markowitz M, Morales-Ramirez JO, Nguyen BY, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 2006; 43:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11144/abstract/25\">",
"      Mathias AA, German P, Murray BP, et al. Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther 2010; 87:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11144/abstract/26\">",
"      German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Defic Syndr 2012; 61:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11144/abstract/27\">",
"      Mathias AA, West S, Hui J, Kearney BP. Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. Clin Pharmacol Ther 2009; 85:64.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.merck.com/product/usa/pi_circulars/i/isentress/isentress_pi.pdf (Accessed on November 16, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11144/abstract/29\">",
"      Iwamoto M, Kassahun K, Troyer MD, et al. Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation. J Clin Pharmacol 2008; 48:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11144/abstract/30\">",
"      Iwamoto M, Wenning LA, Nguyen BY, et al. Effects of omeprazole on plasma levels of raltegravir. Clin Infect Dis 2009; 48:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11144/abstract/31\">",
"      Iwamoto M, Hanley WD, Petry AS, et al. Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics. Antimicrob Agents Chemother 2009; 53:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11144/abstract/32\">",
"      Yilmaz A, Gissl&eacute;n M, Spudich S, et al. Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS One 2009; 4:e6877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11144/abstract/33\">",
"      Barau C, Delaugerre C, Braun J, et al. High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial. Antimicrob Agents Chemother 2010; 54:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11144/abstract/34\">",
"      Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007; 46:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11144/abstract/35\">",
"      Markowitz M, Nguyen BY, Gotuzzo E, et al. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J Acquir Immune Defic Syndr 2009; 52:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11144/abstract/36\">",
"      Nguyen A, Calmy A, Delhumeau C, et al. A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study). AIDS 2011; 25:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11144/abstract/37\">",
"      Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007; 369:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11144/abstract/38\">",
"      Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11144/abstract/39\">",
"      Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359:355.",
"     </a>",
"    </li>",
"    <li>",
"     Merck Research Laboratories. Briefing Document&mdash;FDA Antiviral Drugs Advisory Committee Meeting. Isentress (raltegravir) 400 mg for treatment of HIV (NDA 22&ndash;145). 5 September 2007. file://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4314b1-02-fda.pdf (Accessed on January 12, 2010).",
"    </li>",
"    <li>",
"     file://www.retroconference.org/AbstractSearch/Default.aspx?Conf=18 (Accessed on November 16, 2010).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13977 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.81.197.98-90AF740064-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_56_11144=[""].join("\n");
var outline_f10_56_11144=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3096103\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18367920\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H523368\">",
"      AVAILABLE AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18367927\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18367934\">",
"      SPECTRUM OF ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3096271\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3096524\">",
"      DRUG RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18367941\">",
"      PHARMACOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4423789\">",
"      Raltegravir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4423804\">",
"      Elvitegravir",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3095940\">",
"      DRUG ELIMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H127890752\">",
"      DOSAGE AND ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3095969\">",
"      DRUG INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H127890760\">",
"      Raltegravir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H127890767\">",
"      Elvitegravir",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3096020\">",
"      USE IN PATIENTS WITH HEPATIC AND RENAL INSUFFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H127890789\">",
"      Hepatic insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12262508\">",
"      Renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3096027\">",
"      DISTRIBUTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18367948\">",
"      SAFETY AND TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H127890774\">",
"      Raltegravir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H127890781\">",
"      Elvitegravir",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3096103\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/34/7720?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Integrase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12759?source=related_link\">",
"      Dose modification of antiretroviral agents in adults with renal or hepatic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=related_link\">",
"      Drug resistance testing in the clinical management of HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24186?source=related_link\">",
"      Factors affecting HIV progression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41209?source=related_link\">",
"      Pharmacology of nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34218?source=related_link\">",
"      Primer on interpretation of HIV drug resistance testing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_56_11145="MPGN Light I";
var content_f10_56_11145=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F67999&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F67999&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Membranoproliferative glomerulonephritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph in membranoproliferative glomerulonephritis showing a lobular appearance of the glomerular tuft with focal areas of increased glomerular cellularity (large arrows), mesangial expansion (*), narrowing of the capillary lumens, and diffuse thickening of the glomerular capillary walls (small arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 253px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD9AYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD1C+8maG3hV8yzNhyOB+NLDYGK4hS0AVm+8c9ua6DU7Ow1LSWu4mWMKCwcetYmnC9uEVoI2YgbRIRjOfSqjO8dD0ozb20OTkvLiLWrm1mJxuIAzU0zxWYaScgAjDZq7q2lPHqCtcoElxuLbuSK4nxsl6+qp5UhW1jT7o/iz61304xqNJM6MRVjGClE6J5rbU4GuLOXdd22CoHcDt71p6dcxwweYwzDcElWPRWxyK53wLZPPfLtzFCeWJ6E46fpW74g019KDNbyCW3lJJi7fh6VM1Hm9ncuhU9vBQn8iadDdho5jiNlzjPWsS+0do3WSEDJJwPQVr6e0MTxLeFmjdf3TE4yP7prnfFOtyQXslrAQhAGST7/AMqdJS5uVBKtLCleYvDJ5U+RjpzVjTojez/u8lf7xPSqOmvLrenzs+GaGXy1b1GBXU+H7EwWkhXkjBPHb0rWcuReZ3fXIzoqa3NKLMUeFO1uAMnmuV1xS/iCzhZgVL54rqpR5ZwzdBkg9RXNaJbnV/FpkiXdFE3J6+3WsaWl5eRlhXZub6I9i8M2i2unpgZ8z5qo/EvQW8ReEbyxTG/AlQHuVOcV0drCIoI0H8KhRzVbXLlLPSLy5kOFjiJ/SvHjUarKcd7nhS/eSfmfNvgfRnsI72Rk2mUiMn2Bz+HP8q760tVkjBn5K9CRWTb+a7NE21Uxkknpntn1qO91grEIY2Kx9B7gV70+apK59Dh8M401Th0Na6uLW3gkkUebMowinoD0ya5uTWpQqI4AZVxlRjJ9T61Rvr7ZDGzKczE7VB+Zqg+yCC2e51aOdZG/494V5L+pNXGmludUnRwseaqJrN/MmnTSpvZQdvHTJ6Cs/QNKvNa1AW9plyhxMx6IT2zXTR2baloCafc25xLKskSoNpLA+tdx4anh8KWgt30prbJDO453kdyfxpVK3JBqKuzzKuLxFaanQ0j08zJg+FBiRZZ5jx2Fb1v8KdLe0Ilkk88jG8Hoa7PTtf0/UFVIrhVc/wAJ61orJGzhEcEeleRUxmI6uxyVcdinpJtHzR4l+FPijT7uQaUourfqGVsHGe+aseHfh/41lUyybbWPHyhm5PPfmvpUAEkg5Pr6UbQV2nqPSr/tSo42aVzGnjK9N3U389T5w1fQ/F+hWjzzQmdFbHyDccDvXMweMNRhk33FjONvRmiI5H4V9aPGrqoYAgeo61Tm0ixlzvtYSPdBzVwzKO043OiWaVn0X3HzXofi681a+FvDCWuGOQMYNWdb8I6jqkzz3WnT5chmw5+YivdrrStF06+guRaW0Uu7aGwBj6CtopE67lCEEDBxVyzBRacI2uEsa5wSqU0z5w0fSYdBlXbp8sPmDBfburTn8RWi7khuZWQjDBjkE969o8R6DFq2kXNomIpZEIV1HKnHX9a8Om+Ht3bXZghgkkC8E45IzW9DEU66bm7MFj4Q+Gn9wlrrWlT7Ujk+dDncBVHxRof9vvHPZ3wMW0R+UBg8d67zwB8MorH7ZcalH/rkCLE3OBUniH4b/ZLSS70W4MUsYLeWTwe9V9apRqcsZG0cRRxUVGto/wADi9A02LRbPynfLjBY+vbFdfp9wsqmIM4Y89f8+v61xpv5UVoNShdJM/ex3Fa2n3a5RkbJ/vg1dSLlqzuqYa0LRWx0wnuPMYI4RRxhTwKsWchkiG7crSjuO1cze37BHOAshbnB+U1oaQ0/2UzzccfL6dun8655U7RueZJOMuVo6q2VIlYgZYcAg+nNc94w1e5so5PsEixytydw681V8YeMH8O2lvDYReZdTL5hdhkYrnbbW77VHtm1yCOWK4k2MqrtK5HB/WlSoS+OS0OKpVTfKty54C1nUh4ktk1GZJbS6PlkE9Seh5ruPGmmLbOk1uSM/Mw7daztO8O6Zp9y0/mkzRMJIhnOCBwKL3xEtzeQ2c0RkRzvZj2A6VM5c9VSprQKfNB+8U7q5by1nOQUGAMc1jxx6jdyM3mlcjjd0Wuh1mCEIHDBiMnH+faqtru+zb0/ixtGOQK0g1bQ9Wjy8nNYW20S18kvezPcP2DHgfhVHW5ILaJAoCpjjHp3qS+u0tI0SWYo+eQvPFc5dLdatOqLG0dsTgFvvNVwi27t6HRRhrzyegyBbjVrgiJmSBeDg9a17LSLRlkadXZl4VvepLO2ESRW8ZCryOnJIqa+uFsrK5k2cKN4XtnFVKTbtEivinq46IqSae0eNruuPX/PrUtrqsmmT/Zr0iSNuME5OK4y317UZb21kDq6u2XHUcdhXS6xp73kqSA4z+anFVKFrKZy08b7XRq6L88SWd6r2xzZTkEHspNbrS6HaHy76eUzdTg1zmiESxz6dcnJB+QmsjUY7gXTrMu9hxuJ6gVk6fO7NmuJozn8Gr/Ndz0y+vx/ZsFjZKWtlG6ZiMZwfuiuptdWsFt4VjYRhhhQRjpWPpC20pX7YM7Y/MUL0Ap+nWtlqFyzIhECOVQH9a82fK1Z9Dz6kY7M5/xP59zdFmk3DG0EDPGeBWZLcwXwEVxGpMaY5HUiu71XR1W3m2sqRbc/N656V5lqltOt1JJEm2IHAK9xXZh5Kasuh1YZQqx5DSEsdrC77dkajp0qCbxHb6pbR20iuityjHgg8c4qmsq39g1vJIIpOeScbqrWOkJbXC+Y2/BDKmf0rdQild7iqRqU6iUVsdJYyQ3EMelanEFmBIjlXo3cfjXnnjDQ7q01mS7ljknjC+XnPB9Ca72/tWubcYwkw+dCD0Yc1NeX1te+FtS1C4C/6Pbu8in+FkUk0qdX2T5unU1qRjVh7+35eZieCdOhtNFkiuWCTzM0gAOdp7D8q6KydrdWXGd3Bz0xXyrpvi+TXNN07Q9TvjZp5mby9klI8yJeVUHsx6E+wPc17vbatearpqHTZYrmzb5RPG4dWxxjIqf4zbTFhqMKqtTemm/+Rp+IdVCL9ntjuuHOAF/Ku7+Gvhk6XYi4uf8Aj5k+Y57Vyngnw6i6hFdXzb3Vg2evP1r1bUdV0/RbYz6hcxW8K8Zc4rnxdSyVKn1FjaqpR9jT+bL4IXcM8Hoa8++Jms+ZCunwsCm8NMR6D+H86pa78QheOsfh9SYf4p2GN30FcVJcyzXHmXYPl5LEt/E3NLC4SUXzzFgsDJtVJ/Ih1G8aCFVj5yfmya5zUbzMYyxV8EcVPq1ws6Lh8EE7hn34rO0qwuNc1eGxtdpkk42166Sirs+khy04c0tEjW8C2z6p4gg81DMhRggPbtmverbwdpx+ySXKebLGmPm6VS8MeArHRJorxmZ7tV+ig49K7AShY8kHgV4+LxXtJfunofJYvEyxEm29P6sed3dqo8exwRAIilQu0dOM1vasvmTSQXSqyg5xjr71538WPFtv4O1u31WRTNcMQLe0T7879gPbkZP/ANYHmfAXiO/utVvvEHii9ml1fUyE+zo5W2s4RyqIueo7t/8AXLXyTnyuPY0lJc0Irt9x2es6c2nkXNo5C5JBHQH/AArkItd1y1v47y3vJJQ0oWSPPA/DtXq1+LebSJGWVDE0ef8ADFeQ3mtroltfQJbxyTzMDE/cfX8q68PL2kWmrs2qxlXp3vbl/I9Un8aSWcKh4t8rYCrnnJ56UQ+K9XKqxs2GRyNnWvIvAXidZPFsA1VknAySwzhOK+j9IW1e0Royknqw5zXLiacMPo43MnOjGCko81+pyUXxAEUoXULVoge4BH8617/xdaQWccyDMbgFSSOa1tZ0fT7+zljvIIyhBO4jkV4DpMzm7lhld5LSCUqr5yAM8Gs6FGjXTaVrGmHoUcVdpWsdTf6teavK08+4xhjsXpxWl4e1+4srm3gu5Ga3ZwOe1WbDTYbpVZG8yNhxt61j+L1gsDbR2uWn3ghAck4710+5P93Y6/3c/wB0keuLcRCBpjKqp3YnAArz/UviEy3k6abYmS2jcp9ok6MfYVmaPZ3niHS0u7y+kWGQEiJOMYJ4NS63ZwxaSkFtDiMHGc9f8e9c1PDU4y5Zas46WFpRnyzd2bdh4z+2AQrHiVjgN2H1rpLC1LhmuZfMDDOCcjmvH4ruLTo95BMzHCAfqa7bwnrFzcQMTG+yNtpJ+hqq+GUI3hoZ4mnCEnCkbeu+G7G/UExKpPAyOTXD6h8OjJAZ9JnMcw48snj/AD/9en+LfiGIpfItgY3ViAGHXFdX4d1/TbyCDfdwx3BUZhLjrilH6xQgpEUsTVoq0X8jyK7hv9NmMWpQNvX+NOnpVzTdXnjXy0KTW+MkE816z4g06HVFXao2MCGfHbtXhvi61n0/U5XskljcHIRVJzz2xXbQqxxCs1qd8cfSqR/fRsdVdLp+vwRJLIYLiFSqE9vY0aZpkseoW0urTrLHAQUEa4DdgDXH2WrTowh1C0kidxgO0ZA+vtVjXrvUrC0im0uV5YXJLKo3FfTitPZSXupnPXwdGzrReh6dqEtvPdbrcHYoyeO5zWFNoUYvxOk5IU4AHp6VyHw/8Ra9qmuGwlsy6PH80zRldldlcPdxNm4JtzG2Gbbj8q53TlSly3MIUo1tYvQdrEqmVUj/ANa20BV9MVBe3v8AZNiqDDO3RF78/wBKqi+s7V3Z1d3X5vTP41Aqte3Rup9pweEU5Ce1Uo6Wex6UaappKey/ESw06W8la5vsbwCwU9BzU1xdGH5oSFwcrx3FTPIVR1J/dg5UZzism7+afcVwGGBjuapLmeo4N1Z3lsSx3uCpbqCST7+tSLNDeW8ltcDCyDBwcGqUds7TCIjk9D14qS6tzbHOf4tvvmraRpOjTl7rIrHwza2NzHJ9oaUK25I26Z/yK3VU5G1hu6DPesOKZxMjMxO08ZPSta2mLhS5wVJPFTPmerZyPCqivdK+sW5iEc8J2zoeTimySvKEeZPMYqPmwOf1qXXJytkoBdguPlPXJ6n+VCpmKLd12CiPw3Z1Un7iua8msQ6dqaQhz5ZwsjDp/wDqrs4NQ02y0hZoZYZJs9Izkk5rzDUE0uK9e03u1wWwMDIq74buRo2p7Lu3DrKoHzAZXNc1SgpK6/4c5q2GjOKavf8AM7W6vptYMSTRNb20mCrE/eqpfW/kzpFEEl3HKAfwjPJPtWjrLpLbWrooEKEYKjhQOgp2jo0UcsoRWcggD+6v/wCuueMuWN0cMW0ro5PVvC15LepJEYokdsbR0WsTWNGu9LjNwzCSMHaXU8d69C1nVFWJVCBQuMjPOcda5DWNaZrNrRSSpJbkDqa66NSpK1z08LVrTaTWhBo98JEEb8MPWuJ+Kl42j+GNdkgLLFd2hiYDuXYJ/Jj+FdVo28yPK2OwPHT6Vb1iQQ3OnzrkSLMFAI7HrWjWriupU4rnlTXVHiHgH4Tm2SLWfG0RS08sSxWAJDk9vN/ujGDtHPPOMEH1238UWqwfY4rJbaGFQqmMAIFHAAHt7Vva3NA9qLORS7OSXycYGeAPyrBXwylzdwzedmMoUMQHAzRRhTjH3jgVGdC0qa0/Myrrxlq9vP8AZ9OAjRidrFMn6j8aLHS7rxKiXPiJp8l/uMeCB04rpNQGlaXfxWgMKXDp8oxyB61oxzpLbuIxwuD0xzWjmkk4K3mbxptvmm7+Rmiwt7FQIz+7QYCDoMVha/J5kkgRgkYHT0Pc10N7dJBC7uyrJ/CP89q5LTNPv/FOom2sYwecM7dFHenDT3pHq4eKgnUnsjC02wutSuxb2kZclvvdB+Jr2z4b+AX8O/8AEyuJVk1B+Bt+6gNZ1n4TlttmmabNDb26MPtV65+dzjlVH1r0q3u7PS9PSITiQRr1LbmNceLxLkuSHU8jMce8S+Sn8K/EmvdStLC0jl1CZIInlSEMxwDI7BFX6lmArmviL4603wJo32q7DXV7cHyrGxh5lupT0VR1xkjJxxkdSQD4L+1p4+juv7I8OaQ7xGKT7fcsp2kN0jHH1Zv++ah+DPjPT/FHi641nxQ17qHjJx5VqTalrazh6YiC52E85ZgOvXlifPVF7M8hay5Tu/DXw41bW5p/FXjV47jxHcpiG2BzFYREZESDpuwTk+565Jbkb/w1NaXMtuD+4LZAY4KV7zpN0nlNG0hL+nWuF+IenSySvNaQlvM6+v8A9avTwdWUJOHQ9KhQhUfsqnyZnwXSWfhyK3SYySJHh887Rj1rlD4avNbha8bMSsSY3Y4zVqz0bUDKkM7BIXx5iqc4HvXeeMdcs7bw9aW9ohSVVCeWOQpHBrp5nTklDW56UoRhH2NON7nkMfhu80oW0cogjIkEgZeZHyMYJr1rwr4X1b7IsiXEsTMAwIkOBmq/gDw5HrN2b/UsuiqNmTzng8V7FahY4FQAKQMVy43GNe6tzhrzhg06NL5nmmu+HfFS2Y261JLFj505Bx9a5aNBo0DWEsKrHKwDNjJ4/wD117pLJkZI4HevLfiCba5LvAAQxxuXpkcZFZ4Wu5+5JF4Gu6suSS+4zbS+a1iYWpcDAPB7Vq2kll4f8P3Gv6sPNu5N0cKNzn/PNc74LhfULyOGbdt6MO+Aefp0rR+K2nDU9X07RdKYrII8yoRlUXoM/lXRNJ1FTfz9EXjJP+HT3ZU+GWotqJ1AurQaezl40XjBPYfWuh8VCe0s088qp+8q/wAWO2fetPwzYWWk2NlYiNP3AyzqMbm9T+Ncz8QtXtB4hiW4f90qZKqc5YDoKyUvaV7xWhnTm/aXlsl+RzWraJqhnjcRTG3lRWjlQZKHvXoGhwy6T4OvJ7hw02zLfU1f8Ga/bahpDWrRSGa2ABQryQehqr4tQt4cvlZCiyLtVSeh9f50p1ZVGqclazOOHv1HLuzzjW/B+t3tm+riDfbiNmVFPzY7H8K86gZkt7ea3klS7gYBl3fMWya+iJ/iRp1lpsUb27O6RLuA6AdK4DwxpularqM+tyQnyjctIkAHykZ4rtoYiai/axsuhNSjKq5WVnE9t06QHQbVgPmaFGwevIGf51zGu6vZadfyG4tfMdUC7eOPc03xJ4idJEtLABHRAWOPu5xgflWDo+lXmuawz3LkoOWYjP8AnrXmUqKinOeiN6GGSXtKuiLd3rvhvVrdIbyMWzMSuW9fwrldQ0LUdLgur22hmaBeUHqPp+Ncl8RdMudE12+tM5DodrHsCNwI9692+Gmpf2/8PdKluR5k3kiOUOO44/liuqq/q1NVIaxZk8RKjNqlseUaN4xCTm1l3Ws5xkjjg+tdVKF/s7ElwZd+dvfHpV74j+AotQ0yW602PbcINwVeDx71xHgTVWVJ7PUIneS0PCOcbiKtOFWHtKfzR0Yesqzs17y/EZLbPcxSnPzBsZ+napNFjms7lI3jfyyhBzxnjrV7wtH9vhMtxhUaZ3bJHr0rf1AxNF5joPIjGwKeDxzmqnUs+VmuJV6130MC5m5KoucAAk/pToIJTCssowByvHWpPDtpJf3TvEm6IHcR7V0msoi2XkLCd5AK8cAVMpqL5UdPNGk1BHISSHzQyKxx0PpUM0rXBQO2D0yegrdtlRAXeJht4YH6Hp+lYswi+1SJG+5SSQcVcZJs2hPndmi/DpsVxEI1kCyKMlj0Off0qjBMiTrCsis2edrA1la1dSx2kcSyOivKBIRk8Dvn0qj4Ts7sagn2xMsGbcVPAQ4wa0UPdbbOGriXTq+ykro6rVGGyJFYMxOAAtW4Y444wlyh3rx8uOlU4YlvLl3YEQq21RnkmqGqeIbC2vpYJL6MyRna2X5yOKys2uVG8moRUW7CaSy3OqJNIql5JMjPYdK7HVbTdHLLgbl+ZWHr6Cud8QfZba5ECo8dzE2Y3AxwB/jWpY3pn04SS7j8uCep69ambbtNCxV5xVSGi2KWlajdhpUuJneFmDHcTjI6Aelb9xrv2eCJwxVs4Ow8n1+lY+sRKlhD5BGB94AY5rLs4JLqQKSfLB5J6UckZ+8Rh8ND2V5HaSyJf30cT/KXyxLfyzXI66h/ti6VU2YfAXNdFC0kEiTtuMedqt/e9RVS4sUu9a3M5jjc8tjJGBnP9Kim+R67WFhqipyb6EGn3VnpsYtp5M3J7Hp9c1Ut0Gpa3vkm/wBFgYMO+TxWB4iiuodRdTG7xkEIQnbOAc+1V5ri9sNAWaFHk3TsGCKc49K6VS6p6s56WJb9pOXQ7/W44jcecBtwAAwPA+lN0o72dS5CxpuUZ+92xUPgWO4fw7qk2tfNEIysIYfdb09ar6Q8gtpBncBhdoxmsbbx7HThqntqOnQ5uLTtXuviOt+9ttslUhnk6MmMcV2f2mPTYrgzRDeY8IPr0pst/DZWYeViZSmPpXD6trNxql4UhIWMfePbHTmtLOq7taI2wmEet9nqMvJ21PUYLdCSWcbiDwR3rvNOv/7Nga20eJI0UcyH+I9+a5rw94WvrkefDDNsbjzSuCw9s9q6uWx+wQBJQ6kLnDDpmio4t8p0YidOo1BO9uhDZwXepTENOMN8wI4xzSXWnX+mMZpmkSMk4ZwdpxVDRdSksvEVsEXzI/NVe3zZPSvYNe8i50K9Fwu1BEzYIxjANc9Wq6U1G2jOHEVXRmo20Z8tax8MV1XxJNruszvqf26Qu0EeY1hX+AZBy3AAyMfSvoX4eQabp+gx6dp1ha2McYy6Qxqm4+px1PvXA6Qs2q2tnaCSWC12fvJVHOAec1oXNtbWjO+hXd0ZoTjaW3F/WlVoxkuTZ/1uczwMVNq+/wDWp6LDDbQzu0cSgE84/pWL40v4baAlthBBHvk1P4IvP7bsZPMYq0LDIA5/OvJ/ilqd3a+NxpbSk2oQSRl+ARj2rGhRc63I3qjOCjTqtVXaxrah4lsLTToEUh7gj5sKAB7fjXGapfz3dyry48oKMBe3P869G8N6LoOv6RBcxxATL8rcg5P0rI8d+GZLV7RI4wkcpKqxGMHriu6lUgp8nU9bDV6F+WO77nffDy7iutL/AHQjV0IVhnnoOa0fFmsx6baqonAlJ6K3Irw63tfEGlypHatKPPPybCQTk9K66LwWyWc15rGpbrqONpZI95LA4+7/AErnnhoKpzyloznr4SlGrzyno+hYv/H8l5/osLeUnCknq341TRptUmS0s4hJJIcgdce9cJZR/aGRovmwWbaT2FejeEdP1lbea9stsSopHK5Le2fyronThRj7uh11KVPDQvCy9S/aRjwjaSkRiXVCBGnOQSx7/jXVeHvDcK6eby8mNzqN4BLNcE85I4A9APSuKtorq+1R1uizTbxgMMc9a6S3vrq2t2gSVkAHIBGVNcdeMmvdevU82vSk17stWJfXdpp09xbSTF5YsFccDn1rxbWJrm71qea62sAzKjNwoJ/+sa9STw/earNLLbqzIcYkb/PNIngiQ3MRk8sRBiW3jOG244/IVvRqU6N7vUyxNo0vZwd27XJvhfYT29zKZCJYgn3hwOcfnVz4g65b6fZS2w8tvM4IJ+6TXSXElr4c0ldvB2hF/wBtsV83+Lb/AFLXtd1FnyHhm+4CB9MDv0rPD0/rVV1HojlpNUl7Sa0WxDq4FyzQTStEApxh8YGc8+1dJ8O9Xt9MuEgdxLb+YGUZ4rznxBBJc3MN2inyjGFbHO1sYwa6PwNB5OtWfmKWDspMYPTC8V6lWC9m0z1KFVYipK0LJrVnrnil0tr+e8tSHWUK7AYwhxTfBXj2wRHgvswuT8rlePxxXKeOXbw9Mwa9/d3KEbRyVB5x/OuF0i7S+b93FLEu/Ypk78Z6dq44YaNWlaQqbo1Kap1XZvbueweP7Kw1ryrosksrL1HO0ds1l/CbXJdI1e80q8UraykPH/s9q6D4e6FDcaZ9ovCZVY7V6gemK5T4m3SS6nJ4Z8BRmXXoVM2oXq8xadDjnce8h7L+Nc8qsFF4eWpz1XSg/ZPU9vt7q2u2lFtcQzGF/LlWNw2xsA7Wx0OCDg+teZfE3w/Bp0kGsWcCp++AnKjqp/ya2/hXpWl+GPAMH2JSqNuuby7mb5ppD96V2P069ABWib/SvHXg2a50S6F3Yz71jlCMAzISpwCAeoP1rhozdGp5bM5KE3QrJvoeO/2wuhW9zEArt9pCwq/A+YZz9KX+3724ma31OGNBK5gWSJsgP6Gsl7NtTaOEgG6Rti7hwWTsfqKt6boGoswlvBGkEMxmEa5JJ+vTivdcKe73O3GKrDErl2dj1LwKILfwvdsdv2hW57nGOBU1yS1izIA8uMY64NUPBU8C+cNzMxAyuB7V0ZaziV/tDbd5BAxyR6ivJqXjUbJr3jVl5nFjbBLKoZWZhlVPb2rm5wqTHy2y2eR15rrNWtbeRZmto3CAHGew7ZNcr9knQ7greo9a7aLurnoUNuZsgKeYcsFZQc4PNbEDwxRyMqKuU+YoOtRWdshyRuLgE5NQatLM/kWFmubq6baoxzz3q5PmdhVUqs0gi1C2tNGluJHXdHnYmep968jlk1GKeUW0SzIzlt525yea+m9H8A6ZBpYj1GJZ5mj2sSOBnuK8o1jw1Y6Vq97ZH5hFKQp9sDFVhcTTlKSiefiIrGz5afQt6uZLllk53rx83Gfet7QowLABlDMBnr0rltTM92AkG523YZF64rQ8AWV1dzSNdI8EfKADgk9uDSqJKne+x2YysouNGxtyRyXk80MOAu0kA+1WbG3WIRgjchUBh+gP4VftraKCeRMqX2kFlOaIoma0ZQyou7bnrt9DXM5dDnc2o8qOck8Taepe3jaSWCN2jZwOA4OOO/FbsMoIR1l5C8Nt6/jXmE9v9gS5sVtZ/tjnAZl+V/8AaHFekabFLBpFvE2CEUDdzwe4+tb1qcYW5TjoVZTbUgv1/ds7goxGFbHFc/4RuxDDM0i+YkFwWBHO/Jpdf1IqTawFjJIPug5xWjpNkmn6SkUqASNmRm7ihRtDXqezSp8tJ83Usaje3V6ZTuKQKcqmcY/xqrpb+QjHO04zkjtSzSo4VA2Yiu5j1rn/ABPr2WawskLTBedvr6VUI391G0YLl5UtCp4gkm1KeR0ci2jbYAo5c+wqPTLOC3vtLkvEcW0siMRu4YZ5Bqloeg6lq+r21taPJFPJHuDPkLGa7+f4S6zcC1jmvoAIGLiRBznjt+Fa1J06S5JSseTUzSc5qMVaB7UkcTQR+SqiPA2hQABXn3xSxZxRPGw+dSpHHH+eabNo3ie0VfJuZ2IAGVlzmuO8UNfibyNVMzkAAbh615mFw6jU5lJM0wmGUanMppnLWet+Rq9vIqM3lPuxjJJr0XxB4/t9T8PyWlrmK4lGxz6V51BoEPnfaILhwUY444Un0ov9OezjiZmcrJnJI4J9jXp1KVOck+qPQjCNaS9uveT0sem+AkgkspbaS5iVJU2IcYPHPBrfh0C106cXdvMjxjq5ORmvGdMh1DULlrO1lbEY5Cn+WK2tPurnTbb7NqVw6QAkhd3H4+9c1WhJybUvkZ18LJyclK1+h23hKT+zPGF3bw/Pb3BBBX061R+MvhqHW2ttTWOeNrTKSTIBkr3H/wBetD4bWdtNJLqUlwGk+7Gu4HA9au+LtfXyr3T4SjloTtJGQzHNc/M44i8N1ucFZKddJK+1yl8HrDT4NKc21x50wcj58EqM8f8A660/iwsTeH1LMBPGd6D6V5Z4Au5NG3XjSsqDDPk4GQ1WvFHjBtVlfcRNEmFG0/pWrw03iPabo6FgXTxKUHojT1DUPLk0xEgbdCu4nPX0wfzq94jltrnTL640+d1vWhCqmeP9r8TzV290v+3/AA5ZaxpKLGFi2+Wf4iOPwrkLXVzb3CM6ApuYPH02kHkVpBKesd0bQ5ai93eJz+jQ2lxcWSKHADATb+MHPP4V9JaV9hgsIYrRo/KAHC968EnsFuNeu5LSR7bSpyGkfbuCZH3c/wCeldppGma/4dvI7qNBf2wQ87iQwPORUYyCqpa28iMxj7bl1t5F/wAWs2l6hHqJTZG7YPHf/wDVVu5e3uo0v1b9zKqkqnG49/pWF458Uw67pcdkttNaBJN1xLMhCxgdvcmsODxTZ2kIikSQWpCqJUyfmBOcj8qiFGcoJtar8jl5lGMVUdn+h6ZH4gt7e1jVLfYqgAoCOPpSWviiykmaFuJnb5FPfgd64WxvRe2zXL4KLng9/en6DDHqmvwCHYqICxJ7Y6VEsLBJtmksHTSbl0O18YaW2paPwWMsZDjB4FcDpfgrSvFVq7sjjVbdwDMr7fLI6H36V6lEVZ9rElh1wcKBXKaPex+HfHF9ZXS+VbartkhkYYHmDIK+2R+tZUas4wahutTjjJypOna/VGM3wvubbR5rS1uIDGW80hwSxfuS1ecahp954f1RfPjMN1Ed49x2I9q9o8dePrDw7Z3QgP2m5ReRGeEz6/4V5LrnixvF2nw6jc2iQF/ki2nkgdc/ma7cJOvNc1RaM6ssxE+f2PRm54k8NSeNvDsGqWjIb2NNrRtwGGOo965q28Kr4X1PSYPE94kFxq1ylpawqejFSQxPpkKv1cVo6F4iudKjW36xKu5QeMHvxXh3xs8X3fiXxtGsUz7NMUQQCNvuyZyxGO+cD/gIoq1KtGPKnp0IxtJ4eXtV30PebrxFq1nqt18P/CEsB1R2PnX7ENHp0R5Le746L61r6zBp/wAMfh3f2elbmlmRvOuZ8GW5lb70rk9Sf0rwn4deI77Q9Rs9H1LTk066uke4+1zuySSE5O+QNk87TycdvxveI9fvfiHqMNtPPLF4dgJBmQEG6YdQv+zn/PphCkpyU932MZOHL7eTvLt5/wBbs9F8ItrHxe0bTtHXzdN8Dacix380ZKyanKvPlJ3EY7n198Y+gNOsbXTbCCy06CO2s4EEcUUahVRR0AFea/AFZ7Tw1cWH2do7SKYm3BwMIR1x9a9RA3kHcRjPHauHFQcaskziae8t2fO+pFdP8UazDHz5N15iFvQn/wCvXYPL59rhJPkdBuUY/IVgfFGGLT/HBkiH7m4iAfHc1h+INX3Q2luJHWEIAyRHG445yfyr2Ix9rGLR7mLqqNCFY7bw6htr6RWdYleM7c9c/wCRW9qBSaPdGemOSeQMeteV+Dbx21Au0kktqu0necgHk4B+n8q37/U3S0mvLiYwW+/b8oJLE9h71NSg+cmMlWgq8nZFy8vXjcQxneOh5p9na3d47bAAg5z35rI8Oz21+8joxdoz86t1X0/GtnxHrlxoNoi2oWGXJ3Puyx7fjRJNPkitQrYqMY3p6osC2S0jkaRPmjGG5IxVP4fsl/42+2zj5VBWDJ7+tcvJ4pmvzeWtwJDI0Sur4Azz/wDX/Sq1zrFzpt9ZWOnJ/pSwm5aQdExk5J/A1XsZcri92RCtB4eVST30PovUb6HTrZ7m5lWOFB1NfPviPVpLrWbq43BfOcvtx0BPH6YpsPiu91m4mi1SZrt4NqxGGTdGxPoOma6Ww8NzNbLI6h5JPmfK5wfT+VY0aKwus92GEdPDU/bPW5hadMIdXZ0YFS+dyn1zXWzbt+9HPHzHB7fhXB6ajraWkzN95QenXmu+gQS2p2k/OB8/4c1rW3udGKXNGE+6EsmWSVniUjK7Qzdc1Q8TXlzpemo8QQTO2Fdug6nPv0/WtWzjjWN4mU5IOGOcKfUVzmra3p2u29zoUdvc3EloGaSWLChB7Z6kYqKavO7Wh5+JnyppMo+H/Elzca2tpeSRzEgMsuwLg9unauj8Q3ZtbAuhAkJxnPU1y/hrw2YZLW9N35toiAxkIQT9a2PFlwjokK8tkHGK1mououXYvL4ym0pj/DeivNqUN3co22Q5XI6j1/StmaKSWG/kY7Ao2de3IrR8E2dxqFtal5NoRSq/7I/x/wAa4Xxh4te38U3OlaUEFtA/lzM4J8wjggY6H3rOLlUqOK6HVXxcY1OWfp+JBq1ybHQ5DGuHZditnHeu7+EHgW3t9MTWNWiE13c/NGr87F9fqa891pG1HV9L0qMcBgWUe9fRukxRQ6fBFCCqIgG3HIrHHVZQgoxerLzKq6VGNOP2t/Q5PxsBpMmnHSBFBfyzfKQoweMcj06VBc+L9b0KLzfEWiBrZCN1zaNlRn1B5FHiB01Dx5Z25wVt2QHPr1NdR4okthot1HcDKzRlAMZzkcVzXSUIzV7/AHnmcqjGEXG7ZXPjDQhaRXEmowpHIgYFm5waxdY17w7qts8Utys28YBUEla5f4a+GLLWZry51ONblbKbyI4m+6cAHJH49K7e58K6LcxvHBb/AGc9MxcDPsKbhRoztd3Ro4UKFTlbd12ODTTtCs1kNs2o3MrtlIYkyGOOuB+FVNQuG1bw++lG2Mc8IJRXX5hzkivVPDeh2mkLI0Y3TOeXJ5I9K4r4k+XpOuW16koid/mboMgcY/KuilXVSpyrXsdNHEKrW5Y3fZs8p068l027E9vMLadcjLHr7VY1KW88T30cl1CZkACho2xtOTk7R1zXJeKbmddYuLmzeN4VlCmFgPmVu4+ler/CLwxNq2hie/nlis2k3bY/lMhH+16V6VaUaMfaMnFV44hzpSVuXr+h2PgCxOhWTLcQstxIABEPT1PYVN4titzFJcLB5bhPvHrkjFN1nwWltY3F3pF7d290q7l3Skocc4Oa8ybxdqk22K7uVaPG0R7MnNebTh7abqQfqLCYVVfepPbuZoykEtvMdqnOcnt+H1qnpXhyOCO5u5dSj+xhCyouT847fyq/qOmXt4iTSxsnQbMdRVG3WaCymtJeEM3mYxjjFeom+XRndWh7XERSW3VHceCvFM2iRWOneVJNasoeVGH3SxHI/CtPxboqyiXWNIjF1ZXLb3WMfMjY9BXEyaZaawsItpsSqBgeYQT6f/qrf03VNW8B3sZvZDc2hGHt0bdgccn3rknT5Zc1P4u3c5JqpRrylpr+J1fw71HT7rRJrGYRpNkhopF6gisvxC+paLeJp/hzV91tjK2svzeXnsD6exrpINN8K+NLcajbgQ3LD5nhkMbqfcD/ADxWJq/w28oQ3Wm6ldy3O4BvNkHIzxz+lcsJ0/aPmdvJrqTCrSdVuel+jWlzL1B/E+seGprC+0V51J8wTxYwfqK8l1C6lhUac6tHOHw4cYC5OOn1PSvpCCx12y01beNpPlwowwOBXAa1oE9tftdXEK/aS+4eYoOT1yDXVhq8U2tLeRnLD08S3ytJ+RPpPhG4t0trG0u2uoHUNKF42nA4598/lXVRJpui3Bju/wB3KB8yr1xVjTdVX+z4IXPkXRcZkGMZPFcf408NXc99BcPdvPtYlWjlABznkj1Ga51J1ZctR2RlVrVUuToek6dd2s8IeyY4DYIP9f8APas3x5pEfiDTY7aGJTdId4cEZRf/ANeK85a9vtK0i5iiZHnRcrnOQf61zOleMtT0zUJpVv3uZxGPMkkJ2H2A9qcMFPm54PYx51TkpbMpah4Q1q2vJZG89WQtuk64z3HPpVixs109rddji3iO35jyeMk17r4V1ay13TleRc/ulZ9wGCx61meKfCWn61o9y9qzW84LNGwHGcHjFaLHNy5Kisd9CvCjN3haT6nz9rWobWYlt8jqDvU/dJJNT6DFomiIFt7GGK6DEyXsgMkhJ65duh61CmkLFpw/tIJAsVyQ8jScyEdFC/Xk5qh5I1KWGFZRO0kxSWHBw6E46fjXoypxkvQwoVqlN3qq7vpf8TznUodb+InjG9uNHsLq+kmkxGsaEhEHC7j0XgDrjmvoL4QaXq+lWt7aeLYtNmFrEkNvDHCC8TdvmGFxjPQHJ716H4UttH8J+GolKxJebSWjiAVV4OAAOMVj+H7yKa4vrq4Kw/apAI2YZBUf/Xrx4RfvPUcKHK5zk3r8r6npXha3gTSkaFQGb75HHP8Ak1rtGvIIb8zWL4S05rC0meSfzHnbfx0A7f59q2vMjLFd4LjtmvNqv33ZnBUfNJs83+K3hNLvQ5r60B863w49cDr+Fea6NZWGs28K3wO8A4ZTg47rX0jcQxzQSRyrujdSpGM5Br5qj09rHxTq2mElTazMYiOMc5H6V6eArSnFwb1R62CaxNGVCp01R09xpUNvZRw6bsjSNclB3J96j1Pw5d6t4cjto3WKaJ/OiZ2wNxBGD+tXNMmNygDcOuBlR345qhqnjq206f7LFbi4jtiVmmDY59Pw55rde0btHVoyxM+Sn7GeiMHwvpOpaRq5/tNFRdhSTYBtY9ePxrsdbjs9RiCzLI0XGN2OPXFO+1Q6lZQXlvKH8xdw3A5xnvWRrl4IbYRQKDcSnaq55GablKpNPZiw+GjNKCON8UahpeihTal5HHCo2Msc5wOOma7Q+AGv7SDU7yd1sms1mmKjDOcfcB9KxPiz4GbTvAGn6rGDJcqV84Y5G48f0FXrbUb690qC1juZWt0gAEbNtU4Xv61o5upBSpS62ZdOCxE5UIWUI/1cq+DLCH+0yLeNY4YlzGo4wScD8a9Os9MvRDgTrHz9wg8d64b4fKv9ozhhhkCtyOce1eufvJQr2jxSREdXO05+lceNqNSsh5g+Spyx0SPHdUsBp8VraggmGNQfQHFbOi3Qa0ZSCzJleSao+IpUe9dkOVP3Peq+mXbwurHLFuCBXQ480D0Z03OgkdRNEFgZS21imBg565rzubTtQsZJgtrNJLKDEpSMlHXHBLg/jzXaXt9Ha6dPeM2FUbj3/SsDRvEU17dr5pzG5wvTv3HOadHmjFtao8HERjKSjJ6m74ftU0/RbeCabDRLyoHBPU4rMijfVdTAdcljjjsKdq98EBQyBIyw4J7+lXfCVhNfX6iBXJIOSvRRxyfSl8MXNnrYeKo03O/Q7vwvKumQmMLhduB9e1fPGjWEl14wvCxZl+0v0HH3iSTX0/Y6XCIxCz/vABzivPdX8NWnh06hcw7jMzFizHjB54rHC14pzS3djzFCNevF/ec/oEfl/EKB5VVzENxwc4GK9Y1nxAljZjyConIwmfXHcV494Iu0t9Su727DMV4UZrX8S6hPqf2Sa3MoRJcKmACPxH4Vdaj7Sor7I9PE041MRGEuiOu8DRvfavPqN6v3TkSdAWPWrvjuTyriHe58kDH0rj/+EumsoUtRHGu4DkcdO9cd4k17Vb27853YxcKFJJ4FTHDzlV53oh08HUnW53ouh0tp4iXwtqc08Ez/AGW6IdkXkPgenr7+9OuPjH8zR2+l7Yw33nk+Ygf/AKq86uPtl8ymZCwAyqjjH5d6teG9Dvbi6Mz2TS2R+WRm4BPXAxXTLD03701qdlbDYeKU6yuzqb34p6pdEtasIOcCNEycepPrVfRtO1rxZqH2m+MkozuZ3XICg9Bmr9hbaHY332meyXAO0RglgfwHeui1vxqxsVXw/GLKGOMm4lmj6dcBf8ah+5pSjv1OaVRUlalBLzPPNb03S21pba5liijLYw4GQfQV6F4N8Rf2DZjTW2tbRsSgJ2ECvNfDNidY8bWavOJZrqXzGmVslI8enbjOa7Dx5G2q+P5bPRpkggFuZJpNwAbYADgnjPP6VdaMZtUpdrnn1MbCpzc0Pd/E2vF3j9JLeS0tkKeZgbickj2xxV34beFLC4MmpXluskg/1YbkA+uPWvIJ70yg2+nxG5+zSsiTH+IHoTx2NepfBzX7ua5+w3o3TMCG+XGMDqe3asq9F0qL9np3HVxNONL2dDRtXPSNa0O01G1ZGiXzVU7CB0rxi0tLaXSNRtdhfVrq9+yxEj5VAYZPp616J4z8b/2Jcz2kEG+aNcksxHUduOteZ6JrSi2ivipDpf8Amujf7R5/z7VhhKdVQbe3QMvnOSlFPazIPE3gjWPDaJexy+fEhBLx8FfqPSqCQ6nrunI2n3Ekl6hPmQ45VeTvz+le0eJ9Y0+TwzdySTRM8sOUiVgSSRwBivDLC+utDv0ltGKTBSDtwcg9RXVh6s6kbyWqOzklmFBxqq0lszpvD9pNomiQX67RcqzLPbg8uuTz7HFbNnqt/ryPbafcTxuWV4kz90jB5/KuKu9UmutTZluNsbxdHBwzE5xj1Hr7123wf1O1e8jjZ0Eu0rtb/GivHlg6jV2Zq0KbTV5R7lrxR8Qta8IG1g1W0tJfNBAkJIHH9ea568+JP9uiIXix26SDaoByuT/WvYPEvhuw8S2nk3io6kYyQG47V5NrPwPSGeM6TcnySdxR+qkelc2GqYWSvNcsjylWtPmSWvysa3gfTYwt9d6hcqtpGuWJfIHuc9K7TTrrw1fosVpd2dzOcYBkBP5V4/dw3pgudKjlEcVtLlozkGQ4+6W7464NczNp2rajqKKRaWTRklLgSkun0IH6e9bTwvtW5OdjWvGpGfLBNo+iLzwjYT3PmsnLjL4GPy9K5vWvhPojlrm0R1kbHyO5K5riH8TatBJNCdRa4+zoAsuTkeuPWn6F8UNXttUitr5ftVmxyzAZdOBWSw+JgrwkaVMHOKi5O/kes6FoMWhWaohUPjnJ46Ve+z3K534ZC2RgY/IU/Q7y21S1+127iUnnGegq/fTRwW7O3QdhXmznLn13OWc589pbnzX8T7cWXjRLq1s2MMZ3mH+8SOo/GqfwotvJ8QC91GN5LdicMQOw4/Hk16Pb25t7nVLvVtE1GW9nZzCwiLxqpOQMjgDmqFrbPp0P2mSNY1uJiRDn7h6cj8K9yNa9P2fyPShRpSqe062tv5WPNtV8U3F340u2uA6af5xSGI9AoPHSunM8z/ZmtZMusTOFYfKDn+Y44rY1XwXo2sWtzeorLdEGQbX2pvH3ciuc8J69p6eIhp2p2/kxyyeTDcj5yJT13egJPUVfNGUfcWxy1faKi4VXs9D2zwLrP9raYY/vGLALqeD6478c10K20aTeaRl8Y5NZfhbQ00WOZQhDE4B68cmtzdvGQQR6g189WlHnbhscOq0EcAA/xegr5/8AHEgt/ijJNtKeevzL0zgY/pXvV5bG4a3ZLiaERSCRljIxIAD8rZB45zx6V4L8U7iNviIjFtqwr8zZxiurL1+8a8j0sp/jP0ZNBOLS5V1yUJJ2jtXASQXltPNDDBJmViGIHyuM5z0r2jw34c0XWtOJivZ3vGTcWB2gZ7gHqK5/VtCfTdUmspZQzKocE9HXBOR+R/KvTpYiKk49TarChjZWTs1+Jl2VybPTo7ZAAqRhS/v3rT8CaG2r62Z7okpEd/P1rj9V1FG8QWNtZh5IkYCQqerZ547iu10bV5tMuW2FldgAcU6sZKLcd2bUpKVOUMP00ueo+LLi2s/Dt213EssQjICsuQWxwPzr5/ldbSUQSK3zEhgO5xkiu78U69NcQRpPOjRKQwzwCR0z681xdz5sjWt2kIkMMxkZwwxKp4IyO9YYOk6UXzdSKEJ4WjOUbcxo6Fcx3WvrHY7gRHuaMjDD0H867yNrsou3c4A7jOPavOvCUyHxWlxGTKrJjamTsU9BuPOa7bxDeaxZ34htLKR4QgwURcd/UZzTxEffSX4nJVxHtYxqSRwutXYto1lCbnJKj2FLpWpifMkcRV0bGCcg0/XrVrmERKFLBuvpVTRLQ2cTxMys27J56CunTlPZvPnt0OiN7HcwzxTRLll2spyM5rmrHSJYNWWQTN5cBzH7Z7e9dKqp9n3sqk4yzZzj8vxqCSSO4RXh+dW/n61MZWTS6nPOhSqS95alW9smvvlLg7DuwT19q9t8F6Mmi6JEpj/0iVRJN7n0x6AV5tpqwR/2eHA2ySKXPTvnH6V7LGc4IxtxxjFebj6rsodDgzCVrRW3+Q7apGSuePTqa8w+LN95McsKOBkDK989q77UdQFpu2gs+CSB1FeQTwTeLvHNvZuR5fmebKV/hUcms8FT5ZOpLZE5fC0/ay2WpZ0zwsIfDiX5lKSeWRJnOMH29feoob/SPsH2CVSt0HBE2eM/T6V3PxB0GQ+ELoaV5zXUQBWNMncB1GPpk15x4F8OJ4l8z7TdssUSDeiR5bPSuylVVSDqTeiZ0UfZ1efETetylrk+jW+fMufOK87txwo9M9/wrL0bWNKbUdsloWBbKtId2Rjriun8SfC29kuFfQbmK4fYVMVxGR34IYd6p+GfhTqv2tm1uRIDGCysEzvbsMg9P/r11e2o8msifr03Plj8K+9lC5uUhbLpk9F2/wCf1o0rUyVSOCRocnkKxA/LvXd+FvBdnqdpKuowNHdRkqGPAb3xTNG8KWMXjj7G4EkduDJtJ9+nX3rN4in7y7Hf9eoyi7p3RJp2gyz2ySrbTMNoweayfEWhTT2slsQcP13dB+Fe0WzIqsq7QqnAA6VnatYxXiBo4wX65JxuFcEMa+bVHlrG8zcZrRnkXgPQH0+7uDEY/tTL5fmlQNo9B9a1tW8Bwm2ea91B7OcBwrQgcKe3P0z+Fafi4P4Ys2ubMiWb7wz3xXm138Sb/Ube4jvLd3TlbgAcxrnnH4d67Ye1rP2lN6GNWpRcuVaRO8+EmiaVdaTeQyW/nr5md0mCTjv9a9A0DwxpWhPM+nWwSWbl5GJLH8a4D4QXNu8cht5U2SklB688fpXpwnHJLH5PQYFcGLlP2kld2FiqfLU93ayPPvivpmmyKJhdiDVZNqgZGSo5yfwBrxG6vpLcLBbxLEg/icklsdyfXNa3j3xVBJrt3FLM7bHb93GmTvHQsewrCs7aS4u3u2UyIyL5W7k+5wPr1r2cNSdOmlN3KwftHUUKW/VnSaIl9qVxFZxMWLHO4j7g7n6126/DCe6gE/2qQOvKiQ9T0rL+HMZSZ22EtJjkjgAV7dDMPJQZGcDv1/zmuDF4mdKVoHp47GVKMkqeh8w+JvDeo6dcfZ7mKRSW+STacN+fWqlvaXkCm4BO5xlPJGAMcV9WTxRzxkXMKPHwdrqDz+NeXnTbO0+IN3YSAJazqJwoOACRyB7Z/nWlHHOpFprYihjIVZupKHvJfeW/hr4rJtorC/Lm6bj5zjHYY/Ouw8Q6ibXSrqfO10XCkHofWvG/il53hnxNHPYDZbuAy8YG4YNMuviHda5aQWNyFjMf+sJBXJ9+azlhPaNVYLR7mEqVOvWUodd0bWo6dHJ4NutRAPmtMCfUjof8+1dH4b8K2VxosMq5DyLnPT2/GuY8Q6ys+gabpcMkUsZk+Z1fqe+a9Y8OWqw6RaxA5VIxUYipOnC/n+BWJqVKUObZt/gea+NvApS3W6sZsTYIbHG7vXJeCNDD6zJDIoW4/wBXgrkHPvXvmvmOPSbqVwvyRNjPr2/WvGdX1UaDdRalEhO6UDA74GcVeFrzqwcepphsVOpSfPuupvTnUfA1u08cbvEMkqhDbh6fWovDnxYt9b1yGz1WwOnQE4Essgxu7Aiun0rxXpPiqAW06eTLIPlDkYYY7H19q8x8ZaDZWOvwRfuVMk4DAkABffHSlTjCq3GtG0zlhF4uST0Z65J4x0dG8mOfeWOF2DiuA+JF9bTySLaMPPZFPyn8z+VOWys9c1Fxp9ukNjZJhjH8okYDt6jOK3dAstLjtryO7hhD7BsdwBuP19aiEKdB86vfsbRp06DU1e66Hl9ld308CWjzCCFgB5sgwPzrP8F+H7iTxrpcdwgaEXYuCQwIk54Ofaum0/xVa2WqXELaXG3lT8MxypAOPp0rQ1vUtGnnt73S/Ls7iJwyvG2CDnocV3ucleKjuaYpLEySaske2sQSeM4PrVcxYcyRHBI+72NQW0sktlDMkxJZQxBHFWY3Z1yQu31BzXznK4niNNGZquuQaVZS3V/+6hjBJIGfwxXzL4+vpde1qefSI5boXcyrGEQscY9BzXp/7SN/cW2gabBCQFlmbcxzzxjH615foou9K0aGexMiyB9wkVSdvft+Ve3l9FRgqq3Z24OPPGolppuexfCrwxqempDe6vHJHII8IkhG5QeNuAf/AK9UviBdHVfE89tZcG3gMO+PqWIyRn2ziuPt/FvjTVL1LOza4niOA5NuYwVxyQ3bHPNdjDa2ukxfvpPNvohkBG4U5ycnuTnrSlTnCp7Spa72SHg4xV5Xu9jyddFv7XVY12Th0YFHCEEH6jt2refXrJLiKNvNDo+xpgP3ZcdV3exr0qHV5LpWnaONHEe1w7YQj1Hoa8gOk6xbteWFuEa0lnZ1mRhnY4wQc966qdX2r99Wt5gnXwv8NXTfqdNrFtLexx5kHkbcrz1HXggda1NGSBdHeyvmS5mkVppJB8gjx0xnr/OodK8q2srW2mXBhVYhKf4yB3HvV6WwiaIyT7VRgduBwT6VjKWnKeg6cZSU5KzK11evHJaz2v2dljIEjKBuPbp+Fd3pniG2ubOOSSZEfoVwTivO20udbZjaozpnDEYOORWQkl984DhAGI2knioqUI1Y2T2KqYWFVWT2PRNW8LMFLH9z6kjg/jXEWelm7vH8uVSoO1WUY6GvRvH3iKGLS3gL5LggRjqx+lcBpl3cRQKqqkY6kjrSw8qjheQ8I6sqfNI1oEt4dscrluASqj9KsxRaYXVIoJFj6joM+prGdZVzkqW65FEl2+7YigHqPb6Vpy36mrgm99TRu49t7AIgCEbIGRzivS/DTxPpsfnNiUj5wW6V5VpZZrz94FZlXoa6K0uJZJltzjYxypYYrDEUueNrnLi6LnFK+xr+PNatLJY4bF0N25IO09qyfgvbefc6rqcjEuWES8dq4y/mebXZYwEYo5Un0HSvQvgtGDoFyckFbhlIHalXpqjh3FdbE1qSoYRpdbHoJLJ8o5z0Feba1c2fhvxrdGz2RfabMSTRoOPM3nBOPUZr0PULY3VrPDGxiaRCgcHlcivnPxbpWreHdaktbmaOR5GDfaOpZSTjJNc+ApRqNpv5Hn4R04tuo9O3c978IXMd5pK3MTbmkclx/dPpW2yqylSMrjvXz/8ADXxjqGk3M6y2U9xFIP3kC9iOjL7EV3Z1fxX4qZoNLsBo9i3BubgHzMe3/wBalXwk4VHd2XcVSjzS54v3X1NPxHrFppt3tW7ijjVPmIblT+Arlfhot7qvii41VUlNs24PNICA2egXPX1rrtK8B6ZbKjagX1CdSGLzH5c+uBXVqohiVIlVI1OAAMAD6UOvCEHCGrfUuWIhCDp09b9SpqME7IVtzt3dSPSmzXdvEUt2BM7ZRV2nng/lxWgc7SDg1BcQ+YC6MAQpGRXInfRnIpdGYHiPw8Nc0wRyTFWA+XB7Y6fnXmY+Et3dXM88UsUMgciQSnKzDHHAr168uIrPTjczSKAgBOa5x/iBpVoERo72eVgC3lQE7fWu2hWrxjanqaqjKom1G5yfh7RLvwDfKLtEeFlLK0fI/lXa23i20mkAkidY/wA/8iug0m9tdZ06K+t1EkMy4G9cHGehrNvPD1jczqViWLBOdhxSlWjVf71am6qwn7taOq0PHvGfwti1bV7nW/CmohZ3y0lrI2wdOxrjtJtp7GxtIJ1JcymNW3BiTnoD6CvddW8IXT3HlWN8I4ZEb5iOc9AK8x8TaBeaBqNtaXqpt3F4nDZU/j27V6eGxCnHkcr/AJm+ChCFW9GWr/I9U8F6Nb22mWxDBwF2vuHU11EWzYYzzIoxkdPauC8La/DDYRJNJ0+9kZ5+lbkniKGG2kdRliN2wEA4+teZWpTlNkYihVlUdzo5LxYrN5pZVAjQu4PoBXzpqPji71Px699BGn7pf3GzPzKh5UnpnmvXrnxpoM9pJbXMpKzq0TIgyeRg14e+mQWWoyC0vJbq3tSxt1aPaRnOQeffrXZgaKjzc61FhcPXjWjaOnX0PU/iSdP8Q+CLe6mKpPKBMhJxt9RXh7aYXK/a/tc9jGu0mBgGJySOT0H+FekahpU954AsJbhlaO2d/kcYAHbPr1q94O0fUrHSbgapoV1dWtyqsjx4DAeuCc9DXRRmqFNpO+oVKSbdJrRPe/4eZ5r4YgncFrouEjfcmeu0YzX1hYLGLK2eBiIjGu05zkY45r5+1rT47G6a/wBKmZrFzteORcMh7qQe9d94F8X2MOhQ6dqF4IZbdsI75+aPqPxHSufHwlWipROvGYeUqEPZttR+86f4gXosvC95JI2fu/L6ncOK5KfwzDrPg+zjuSoVQZdxOCNwOTn2qf4ia7pt14bltLW5SeW5I2Kp5BBGMmpfiBrUGl+CEt1haJ5YAu1ekYx/X2rnoxnCMVFatnLThOMIwtuzyjT9Jms9aNnYTfaYg+4NCx+UA8D86NaTUJdcjhmKy3LLwS3p6+9YC6nqmn6pZMkb2zzRrLHEerRnPzHHY89a7HT9Mvr27/tW9UrGPlBQDIz14PpmvWneLuz0cFOkoynS229Wel+BvDkuk6BPFcbZbqdC3HQA9v1qPRkie5ks9ShVo3Plsrjv2Oa0PDN9e3NokbEttXarc5YdM1keL7HUYJ5LyxDqmA0gPr/eFeQnKU5Rk9WcMajnVlGb1fU831vSDZazcpZRmSLzHARsHCk8VxPiMy2F7bx3FtJAhYIItjAy5PXJ6V6RY6xHbask2oIQm/BfHA+prv8A4j2dnq1z4UhMcUwmvkZHwCNgGSPpXofWHSlGMle/U0x6k+SD+86DwXplxp/h2yS8kkkuPLBcMSdvHT8K2QJkIC/MpPPHNWXGVAAye1MYnI/p1r56U3NuT6njyk5O7PLPj3psWoeHbd5fkngmQxjrnOQRWXpdq9to8NqqjbOo2k4G31J/WtH4uX4u9Y0zSg2BEfPl46emfwrnYZrnWp13yMmnRDYNvBkAJ6+3869igmqEU9tz28LRUKCk9L6v9DRklLs1tpEjTBPle55VAehx61LHaTLC0a33ynKuI8DJ+vekhdLaARJ8sQbCqMDFVJ75nuPLtB5jHIUYOfXir1eiGpSm+WA+LSbS2uEjdXnCkZDyEhv1pz6RYM8XlRiIyFsbCQVGe+OtB0LxBcKJxaz/AN4DOMfhVN5b6xuIl1CGSHbkgOpB96NXtILTesZ3fqXJtBuDF5mm3TzZyNsy/Kw9z2/HNaXhTV3mlh0a8jiZmcxPFIuSjYOP8iq8N4fKVIZSMbmCcdx6elYHiIyW00OpW0p+0wMpYY5xkYJ+lRyua5JfIUXKqvZ1N+nqewQeG9PjiEbRNKgycMxxnvxVW58FaLcSeYYHQ46K3H61qaJqI1bSLW9TC+egbb/dPcfzrhNS8Sa1p2o3NsZPMCSEKREOB6VwU41pycVKzR5DqVIN66nA6jvtohf6mzvuOEAxnPsKt6Fd2N9c+TIgEmFwhbJ57H0rR8U6dJqejSrZx7548Oq+oHH9axfDeksdQjmeFYHCjeSOCR6Huc166lGVO/U7MRi6zq2WxN4svhHqFxDZsyJEpMUanmQjsa27DSYdV0a3u4J1R3j8xlkYDA6kfzqhq2hNJdPMk0SiVi+4g5GRyeP8aS4iFqFtIGTyYovkLfT1PHWh2cYqDMYYitSbk3oN069TTtTVbkkpna4BzxXRefFcDzI2+VjhcenfFcJFBdy2X265tRbYO0fMX3D1zWx4dvd6zW0jcqxKjHb0pzgt0e3TaxFJV1ox5tgdemaMZbGck8Guj+DOoLbavrGkzsUZnE0YLYHcH9MVyuq6jFo93JcX4ZTlUUDqSR/gKdYalDpXjbS9SQ5tbsAMV96itB1Kbj5fkTWUasJUlvY+hTkHO3J9q5/xJ4ctPEM8JuVKPCDhwOea3EfzUBUgqVz1pwwAAvA/pXhwm4O8XqfNmLZ6Xp/h3THe3iWOOJS8j4+dvUk96yF8f6HCi/aHuYY85DPA2MdsYzW/4nTd4d1IMeBAxx9BXl1r4gXTdOCCFLhTEAVxlgcV10aSrpylds7cLh1Wi21sejx+MPD7wpIurWzK3+1yfwrC8b+ObbT9NC6ZL5s8yHDqpwvH5Z5rx83CDVZ5ZohCCMqm3g//AF6jvb5bxlTeEjI2kSsdoyRkcf1rup5fTjJN6nRXyxwhzU7tnSR/Fa80+OSIQPPdAqnmSnCqD1Le+fQV03h34n745Y9Ts3FwDuQp0cZ9/qK4Oz0HSdQ0+8LanClwE2rGVLM+OS2eM9h+FT6Fo9jZKJWmupdgAZ2Iyo9vbNa1MPh5J2WpyUsNWm/ejodDrfi2W7dvtLpFZqxKhjyT6f0rS+HlzZXgv7xpo1bBiILAYz/jXnHxA0e4t7VLiFZJLF+UdBkEE+v5dKxNL1VfDIgkt/Ma4flkYDBHQZzV/V4zpWp9Tvc04umtFbc+gPhdqMcmlXdqZB5ltMy+WOwrp7sSzZVMqH9xx65rx34Z6ms/ihri3maOC4XDxY43dP6V7DLAY0kMEhWVwdufmANeViafs6rfc5cTT9nU5u+p4l40+IOr6dq066XdeR9lnMKwSxhi4A6+pGeOKg8ReKrjxNYWF7qWmSWlzCCjrn5Xz3A6iu3+Guk6Zeazq02pRRz6raznYsgyEX+8B/vZ59qo/Hi6t0Gn28aqblss+P7vbNd0J01VVOMdV1NsDFLFKL1/Q86stRnBeK1jZ3mYCNBz/kV1w8NXqRwtqdxJJNccGKMngds4q/8ABbwxHK0ur36bhgRQqy9fevZREgC7EUYPpWeJxns58kEdWOzD2dT2dNbbnzdruhXthN5bRP5HJWVoyM/iasaboN7PbtcafLHNJEhYoOpA6j/PrXvXiC2jutLnikAO5SOa+edLg1Hwz4rNwglWBMnJPysrdQ3sa1w+IdeDa0a/EVHH1asLRWp2WuapY6r4LtooYvJvLRwZoG+UqR29wa9E8J+KLDXbKDy3EVwUGYXODkdceuK+fbq8udV1i5/s9LZN+5tqybWCA5xg1HpWq3ENnINLKxOsgczMNuxuc8n6duKdTBKpC19f8zjxHsppxjKzTe56F8XEtYPFmnquEMyg3CKPvYPBPvU48KWl/t3sUEgXbtGc56VxmqarLrN+s95L5tyFVXfHXbzjp9a9vs5Le4h065tQvksgZWQdRj2rKq5UIRj1OmpUlQo01BnmVr4T/szXo9P1FAmTmK66qw+nrVH4h+bcXEmnzMJpI5Nh2/d29uPxr0fx+0EttAkoPnB87kOGUV4prmoAauqxuwkVv3gPIbnH51ph5Sq2nI6cHKeIaqS7Gz4Q+GepXey9mnRdqiNTJliFHavQD4IlgtnFpqTC4UfKCvyk+hA7VoeAvEdlq+nxWcJdbiCPDKVwOO/8q0bnxDpNteiyl1C3S7LABWYcZ6Z/+vXLWxFdzce3keZUrVaMnTXupdDI8BaxE8Lw3RSG9V/KkhzyCOMg+ldSVXUpJFI/cnh/XA7V4P8AFKG40zxkXsp8rLIpyjbQGdQc/pXWfB/x9JqjXGlahHm5jOfMzndj3706+Fbh7eBhWcHJuO7scT8U9Kn0LW7i2gWUxy/vUdVz8nf649K1Pg2+o6prWnQaldhrfT0a8t1C53BsqRntjjivbtZ0TT9csnttSt0nibn3H0PrWT4U8GaV4Tmu5dLEmbrG5pPmIA/hB7D2pPHwnQcGveMvb1dr6HTg7uccdPeq2oTpZ2k9zcPiKJC7E8cAU9QQME8da86+MusvFp0GjwSFWuuZSOojHUfjivPo0nVqKKHh6LrVFTXU86tZZ/FniSeeZ9jXknzOTgJED0yegxjk12mmR2skZh0vULK8EYKvDBICyj6dx9K4bU9PubLwXdPbLIJ52RmwCf3API459M1yen4kvLaLS5ljvmYNEYcjaAQOfTPU+1fQey9qvddkjtx2M5aipQ2R6XrjkfuVOxi2Cqjt/wDrr0bwX4Yg0uyhurmFX1Bhvy3OzPYfhXK6ZaLqPi+ySeMMMb5MDIOOc8e4FeqEAd+vbrivLxdVqKguu4sXWcacacdL6sazbSWJ4965DxQYL6K1aa3LZLKCxAOPUV0l5Z+dlxIQ+RjuB+FU9Z0NdQtYYmuXgaNidyKOSa5KUowknc4qclBqR5tr+lxWcn2izldQUz19fX+tNW3i1DT3SRciWMjryCRjOPrXYa1oFrBo4jjVpLjhWfOSeRya4KO+MUz2mSjK5TkY56969OlU9pH3XserCftoJrdHX/B2/abRbnTJ2xcWch4J5we/0zXS6ro1nd3XmzgByMd+fevKLHUP+Ec8T2uqx/8AHpcERXSgdBng9Oor3NG3IGVuGAII7iuPFxdOpzx2Zw42nyz5+kjyU2oh35lVDjIjXLEf5/rVQT+VJH9rhfy5CMSDsD/+qul0uS3jYgZkc/IcrncD71LfmymtpTNFtdSIwhH3R611KetmjoVTW0lcz44YVcMskM8DALktlsUrWUaZVFEkXIQuBz7VgXelTM4awmjBHzFH6Y9MioPt2r2KbZ4JFROBIPnVQfUiteRv4WavDxmvckT+LLiOG3FqgHzYJGMYHcVk6ACmpxyxZDZz689quWunvqqvJuSQnoc5GTW1YaJHZSRNGWZ84KngZ9jWt4wjynfCUKFPke5yfxQ0SXW9PcxuWvGIdFXjp2/Kud0a3vm8FpHdRSrcWMvyB1OcV6zcRRHzRcLlHUqoZMDkj/CsO7WFIFVAS68MVPBHbI/KqhUvFR7HLRglVVVb7eR3nw08VQa9o0ELELeQrtdSfmOO9dlu3N1AI74r5z05v+Eb8W2d9bSN9kMyiUDgc9ePSvoWFoJlSePY3y4Vx6Hrz/npXk4yiqU7x2Zw5hh40anNDZk7RxsrCfawPBU8j8q818V+EjYTT6noqia1JzNa4LMvqU/wr0lW+YbiPxGakGGwARj6daxo1pUndHJRrSoy5onz94kFtc2UJiQGYnChRgj2rX8DeCZtRuo7rUogLSEgxpjh27k+o4qf4si40fUY00y0SYXH74MDt8s55+vOK6/4Wa9a6xoIijYpdW5ZJIj94HNerWrTVBThsz06mP5qVqe/U1tV8IaNqUareWqKF4DR/KR+IrnJfhxaB3Q6hc/Zm5VTgnr0Jr0TaOM849RWH4q12y0Kwa4vZYw5PyR78M30FedSrVr8sWcFGtWvywb1PM5xd6PKNMupUutAMyo0bD54lY8FT6Vh/GPwxplnO1zZyC1TygMMc7j16n8Kz9e8QXGsXl15UbJC7AiNTyFHI/WsnVku/EUckd880rqFG6TOYxXt0qcoyUm7dz2amFnyc++mq7s1/hNpsGst5Vtez2uoIpeKTKshwM8jqa9t8HzzajZzw6m4N/ZzNBMEJGSOjD2IryP4WiLRfEd/eXLSaldJCsdslrHhQuOSx456DpXoNtfz2N7eeIruy+y2d5GsewSDIZc4LDjOScVyYxOc2vu9ex5jjXnDlqKz6HJ/EtP+Ed8V21xosz20skRZmQ88nBHvXJ2tpca1q0pubhnYcyNIdzH8fwp/xEv77U9dE12jRKy7o1xkso6f/XrJ8J6jPbTyajIrNC7lDt547967KdOUaSfU9XC1VFKivjS3PoXRIjpXh6NIYi5RQQo/iPc+tYEnxGf7Y0EGnzzsg+dVAypzXReGZPO0KCZZmYhSRnqB2H6CuE8Q2mpWOprqPlxxTTKTGw6E+jflmvMowhOclNXZ59GEKk5RqK7NU+N/7VlAihlt3iO1kl9cdT7VozzaHa2UN9qTwtHIdzr97gjpXDNYfZ9Stp3vWkuzGJZh/eJB2rgdhk5/CtW38OLrai2mO2OM7y2RlevQVu6VOO2iN50YRjeOiOMtdE8OeLPFl3Ho1+LFgzOgdyGYf7OP5Zqtq/gO50S8MLXLyRR/MGjIZB/vDHB+temw/DnSrORJGmkfYdwXGCPYEdPwrvdJgtYrciCJY1b7ykdfrnrRUx3s9YO6/rqcDrJvnqQT/rufJupB9NnKJGSGCqpGOM9W966LwZ4r1fTJAlqWGdyhSDtcevpXqfxH8B2d1bNf6UohnXlo0Hyn3Hp9K8+0aS20reLu12XTYRGI4z/nBFdcK8K9O9rno4enGrerT2e8T0fRtBnedrvxBMzs6/dVjtQ89f8APavIPFGmGw8WXNvaTLJHNJ+6LjkAnivb/D+raTqenJ/pQlnXCSxM33T0rN1r4baXrmpR3ivNG6nnbIdvA4Pr6Vx0q/s5v2uhnTxk8PNtry8jz1bQ6XobNZ3M1vqgVo3I4WQHrgjr14rio7G8vNLmjC24meRWZ5pm80bR0UdDn3r2zxhpNqmmC3EqqLG32ow+87e5rx57t0LyMSGIwPX0rtoVeaLkjeODp5hFTqN3R0fgrSbrUtP1Kw/sr7eLhNrichVh9wex+ldVoHwn1DQj/aWlawp1NRkQyRZjOP4cg/rWX4H8YvoDO80Kz25T94I+CgGOcmtu5+L9nNvGk27SMeAcGueu8Q5NU1ozixFPkmlC2nW6/U7HwT4kl1Jb2y1W3FpqVi+yWIHIwehFdRLgrhTkE5yO9cf4C0y6ihvtT1BFa41KQSuc5wAMKK2fEutQ6HpM15Ou7yl4TpuP1ryatNOramjirKKm+U098NpASxVI4wWOT265rwPWb9vE/i15hgW/mbVYDjYMCq3ijVtdn1eG6vb5Ua6X93BGxKCNvpWl4as22zSQRM0kfyJt7EivSoYb6vFzbu2ell8FCnKs99kdHZDMgMWGUD7p4xx2HeqFyLO1uHkjtoYbqUlCUiUZPvgZxVm3mVD5LyK02MMm7kfhUWmwoPE1pNexF4pGDYcZHtQtLsUIxk25a2Op8BaC9rNJf3LHew2IpHQHBJrtHZEUs7KB6sQAK53UdQv7WMy2sCSdiB1AHfipdVs11bTIVu5Fzw+3HfFebV5qkuafU4KrdSfNI17d1lt0k3Ek9DiklmEYCk5JFULAm0sEhLqDGcDHIIzxj8O1RXAlF9NI8mIVGAOuPf8AWslG7M1C7KV1ewyPNbSlWUMFIXr681xnjfT/AC5baeOJgfuEH25HT/PFdZaWklxK1xaRJIGOSznAJGRn+dYPiu5uLfzFukRyP4AThR64ruoaTSid+GfLVSRyV6j6tplymxU2r26A9eK7z4d+K7ZvC9tHqUkn2mAmE8dQOn6Vx+mRgQNJIQEc7sA8muevHl066mihU+WzFx36111KMaycGdsqEa96fZnUPq72l6wCAYUBlcdSK04b77WrNw285Zt2ce1bD6VYaxcXkjN/q13cg/Njvnr3rE0XRZTCbyMlbB5RHIGUqQCcZH4/zrPng1fZo5vaUZx10ZYW7trKAmTKjJYIw+83+AqxpB+1wEySEQuwaQg4yM+9Tav4BnuJke1vuMDiRRn6HFYWlibS7+5065UNIDnB/TFKPJON4PUUVTnC8HqifUtEsorxn0yV7SQYJkjbG4ntt70kEHiS2gN1LHHfWajLeWwVwPXFbNhbv9ohUIvmu2AW5P69OlR+KvE+k+Gri1gcyXF/yskMTA7Aeue1PnnJqCV2ZyxTh7stfUz7a7s9SimnZGkdU27JThkPuKrX0Nu8kNvb2yiaVVVXjQ5bHUVJqMllq9t/bOgMYplCiSA5DOp6oc9x1H86NH1hrdhNZgAlSpVl6jvVpO119x0wftI89M5/WLB5LCePDiUdPQgV3Pw18Ti/023s5BiaPEeRyTx161ztxP595LFIAxY7izDGN3aub8A3w034hQwSEpFJKyYzwCRjNVWpqrSae61OitR+sUJX3Wp9AmNy6MrFcHJxUjBUXcSWI7ZxU6hTzgc9cVGIuOrflzXiLQ+cuc9rWm2upQyXFxHuMSkgA5J7457V5BeavHBOb3SWFrPFJtLwnJP+8D1r1L4ha3J4e0GS7ttjzlhGkXHzZyB+HrXiWgRzXWp3FxfEtcyPk4UAZP04BzXtYKLdNylsb0+b2keXqehaVqnjHxKqxR6ilrATgukYDkdz7Vu23hLR9LD3+rmbU51OPNunL5PYAGqGianNpqGWJCHC7QNuRirV9e3uuYWGymkjXJ/doQCfr+FZzUua0fdj5HpTg1K0bRj9xUudOh1rVIZlsxFbRnDvEmDgc4AHU1F4budN0vxLeNqLCOJ22o0y4xzxnPTiu+8J262+mICgE3O8dx9feuX+J1np66ZePEkQvHhJPqeRzUQrKcnS6bGca6nN0emxe8Q2FvZkazpLW9u4TLFFG1vf0Neda94pfVGtZ5l3WsMqy3CKQFXnHSn6ZqUy+G/9LJ8uBflLZO72rgdbb+0niV7VrWHdkiPjepPqa7MPQSdp626nbDDypQbtzOOx9BTz+EvEWlw+dNZlAAY9zBWRh3B6g/jg1zdv4f0xoZNN0nyXeV2IIw3ynq34814beQCyNuIN724LB4mYgKD0OR3zW14T1W80nWUubRz5EO3ZzwTk5H5VX1OUIvkmebhoP2rSTUvM9Vso9b8G+STi+0tQd+1cMh/p/wDrpmu/ETSdXXTYzaTuyTb3gC5yQCAAR2556dK2tW1OTX/DzNDMmZ/vRp945Hf8v5V4vNp81rqMqJ5jMrgoI+GIz2/HOayo0o1XzVFaSNpxlODm4++u3+R0z6q17rckdxZJYPHIHKZDHGfUfrXqfg8qYZ5sHeRg4xj8q8nvtITw9p8d5rl60l9cEtBDHgkL1w3vXffD/wAQRalFJHGjj5QSMYxjIOf50sVFOneGxKqSq4fll8SO4CJcEclWPAz3NWdkdshHO4DOPXNZ/mMrqYA8iqfvDkD6VBJPNJKPMVic98dP8/55ry+Vs43BvroaKyF4FYDO49DjFeJ/FeS00W+SOeEzecMRBf4cE5z+de02suYwZOIwOoHNeafG7R2vrWC/s0bzrZxhgBkjPI/WurAyUaqT2ZpRqTpt+z36HnkNs8EKahpVxNFKDghgeR6e9eieE/HEt1pQtZZI4buPILM2N3GeOeteK2MGoXdnqEzLeNJauBbhW+RGzkg+p4PNbaPs1CynYiNZ4Vkl3HhSRyf516tahGatLU76eJ/tCnJOPvRPXfGOo6ZpngmczBLrULuL5SWBYZ7j2HNeMXKP9jjdl+crtzn+I11fji8tdXvbaDTWE0UEKp5gTbuPBNc5PCIdNW8uJsmB9uwDkH1x9cVnh6fJHzZ3UIrDYdznfuzpvBfhK812ACT9zZzxkNkY7dOucdK0NE+Hl7BrKfbFSKEvtMoGAoA4Ax16VyXhvxNqyavZ+RFL9mEymQQg859D+tfRqYubPdan5cfxnJzWWLrVaDt0Z80nGfvJGjbxRxWyRoMRooAx3Fc/8RIwfCt9IY1dETeR7A8mtG3M4kQCUMxzyRkE1H4k2poV09zN8kaEtgdfQV49NctRPzFyXlyrqfNvh8PqOrJLcf6uIM6KQBxyV/nXceHGI0a4WMr5xlYqG9fXiufj04XGjXtx5rx3t1L+6AwMLnrW58PGjgnubGQbygyN3PHc17tZ80W+x7jpqnRdKK0VtSqnhzWUvfNf5VLBi2cFOPXrXT2shvL9bDdklQgc8478GrMl7Cd6w3HmyLwWA3cj+nFZZnks9XivGVd5cDag+8AewFczm6i13OTD0lqkdgp+wxrEkxcKMZPU01ryXYEBYgnOP/r1PG1tfxSXELBAiklW4IPeq0Nq967FpjHCpIUL1bHXNcWn2jO6W4pu58AFSxBGMr0p81/PNbMqx7owCGUDrn3pklhdWkDyGJmVeS2/O4etQXV9FYabM06hUZgVK9c/0otF7K4rKXwq51GmXFo9lEtsyoirjy+hXHtXG+ObNNU1O1lsrhSYoysuORjPfH41hXWqTy3UM1uY5IEJwHGByOQTTrUG0hlbdt8xjna33STnjFaQw/s5c99TSFD2L576mNfahFp9zJaovnNEMswOB+OetV757e4aKWORUDRgkZ6nJqTWLK1WZriUyO5bKx46ms2/uoI5wL5XMpUELEDtQdh0rvgk0mjbDOUJOpUdkexyaXeXdg9xbXdvFvjISONeCh52lj+X4UXN7NfaPBaW1m6CUeVI7DhDwCR6mqSazp1zp6Payk3PKbFbaFPuKualc3kGmQvAqJCBjcxO4v7e1eXaV1fe55vJJaSRBqpvo9QgjnuzmNv3TgYDkDOD6E1z3iaOVb2HVI5A7Rbt7d+vp9a17IveSpHIwlbzPMZh1DYxwa6J7DdayoYwLfyyHBXJIxWiqKk0mbRqexkm0cvod0byNdVuSzFW3eWB973H414p4mj1Cz1G8W8tHnupJnkjZ85cZ4APp3r2doRHoV1crMqG0UhIiecYz07niucg1ZtVlha5iYqvygsOh/HpXbhpuDlJK6CeGeIvKHQh8A6bPaeGjJeBI5biXe0Lkkrxjmr1/ZSAyS2MuyVsMUPKOcenb6ijXLpdNiWCCYKGXOevXt9c1X8PvcXrlXkJt9nzN1Ofan72tRl0qvsnyRJLW4gv7GVHhMVyhxIh42t3x+FcT4usbjSruHVrWT5hMCvYqRyD+Nd1rcKabm5toAoRQZQX3b19fTIrL1q2Oq6HNHEASQGU+uOR/hVU5dVsz2MPNXutnue0eGNVi1nQbLUImDJPErEgdG7j86084XqCfWvF/gN4jeOSbQLwjbky2+ex/iX+v5165dQ3UvyrIqIT0749K8etR9lUcDwMVh3QrOm9v0OK+MWnm90BZrcBpY5FJXrkCuf+H+gNeRXUzL+8Cgqr9R9Pxr0OLTsSl7geYhBUK3zFq5+w8Na/okk13otzbujZ/wBEnzyM8fN2NdVOval7NPUuEowjo9TFu2ureRogvlur7TmtvQvED2TKlwNxYc8Y/GsjUNTfWb90ayktdUiwJofQ+o9c1WuBKJNjghs5HHQ84rdxU42kj0OSNWCU0X/if4hu7Ozt5NKZ7SSbI3n/AJaf7I/x4qbRfBceu6Pb32rX11NeToCTnhPYVieJp21exgjugrS2koKqF7Hv+Na8vie6bRWsNHVLaZY/L84j7vXkD1pcs1CKp6PqzmjRqxVqe5y99pyzahPYRu/2WAhZWQYUkd8471ufD/w3YazeX19dr5tvbyiG2Q8dBncRj6VLo9k1toLW0Uke+4DGVpDuYse/P1pfC+qDwuDb3DRMjYZsnn8KupKUoOMHqdVWdSpBxg9To/FdnodlpU8l1ZW4JjZVZYgDnH0rifBfhI3ulW8M8fkrIS4cjBX6fpWle6kfF2uQwgpFYRuAxJwDznFdr4u1htC8NzX0EaNJEFWMAjGSQPyxXOpTpRVNfE/wOZSqUIqmvil+B59r3hd9GsvtWjXEyvE2Jgz5BPpiuV0LVLVfE9nfapEfs3zI6qckEDAJH416D4f8JJrOny6jrrfaLq+JkRN52xg85xnrVDxJ8L5HYPoBjjKrzHI2AT9a6IV4K8Jy17nXSxNKN6dWWvcyvibZW3iHT7S/0u9G+FsrkHPPXnH0qp8OlTTtTKXLhHl6KmdvuDUcMWoaAy22s2zxA4G8glSfY9KopKx1N2gk/iJAJ+8Petox/d+zT0NaeDp2bi91ufQlu0c9vGVxxg4B6Gs/xCyQQLLkBxwBnH1rE8Ma4lzpKyNKsYiHlszcfifer9whv1WdD5qEYBByCPb+VeP7NwnqeJ7L2dS0uha0W3ElorsxwR0/z9f1rmfihK+nafFJBGW3bg24ZDcfd5rpbK4+xx7JCOOg6Y//AFVleKobTXdPeyuhuVzlWU8oR3FXSdqqk9hNT5rxPG9c0bQdRuYtS0/zBFcxb5LWOTYFkHBDDB96r3F5bwHyk05boRvtZumAo+6B/npXWxeGlW61JLRnkkRPkTHLFccD9c1554kt7iO6BtScO24wsCVLZ5+nvXtU5Rl7rex6KpVfZf7OrTe/c6K31TTLq4jsdNs7qyldN8j3CjG3IwR7VveJdA0q88NGGxjebV2585DgOx7Y9v6VmeCPCWs+KdSl1O9f7NanEbOQR8o6IintXuOlaLZabGiQxAuo++wya48TiI0ZJReqMqlZ04pVneXVdPmcd8MfAMHh/S0k1LNxfuxdg4GEOOgH07+9dzJG4GYMAZyVAxkVNIVTdIx2gDB9PrXGeK/H+n6Z/o2msL3UGHCRHIX6mvOcquJndas4KNKdWXLTRs6nq2n6NJHJqNzHCmCQWPP5V514r8SXnjJ/sGhwSJpu7Ely6kBq5ebUPtOqPfasVvLtj8sQ+cJW5Brmqrpr+RpVwI34R/LKge/vXfTwqpNS3f4HrUsJ7FqSV5ee3yLNrYLNPZ2WzfFAvlkbep7k/lVPxZYP4f1a31G0QJAfkkUHoDxVfw54m/s25drpG3vzukGPyrofFWu2OtW8McRZmb5WyhCj861fPGok1odNqlOqote71IreKJYQtvEpWQh9yjBbj+VQavDNLgxq0csfIZfXHbFVrC7bSytpclmtTxHIRjjPAJqfXdYls9Oll3FlRflz3OOmR2qOWSlocc70Jc3QteH7m4UPFdYWA8NvOGcn1Heuk0S/tjJNJA2UBKneT+X6V4fpviXUrq5WRbpnjPzMhHQZxjB/nXYfYb0sPKbEb/NtLYGTVV8N/M7XIpzp4pybdj06XUoJtysyLC/BLNjGO1cp4zaFtMRopGmhHClTkK1YD6dM52vcAKGxnkikm0qdN6wzK3bB4yP/ANdZQoxhJNSN6NGlTkmplHU9W/s/w6jQoPNJ2gnt71gaT4vu3cNqSxiPORtUgt2z9a6i+06GbTFtZ8q/LBgeh7Z9q5a28MvPcRBZ0uFVQv3flXk12U/ZtPmOStTrTqt09jr7BoNRunlL74wPkyMg5qPWPC9tfXYmaSVH2BWEblBx7VauZYPD2lwwooww4bbya58X+q3uZrVJnjzjODxWSUnrF2R6H1f20U38PmXY9+nXrKwAI9ec1v6rrhu9Oto45m89fk2gYAHrUOq263aI6hfMOMgHH5VhOrW82yVcOnahKNSze6HFRxFnLdHeaIJLG3WR9pdMfMByOOuO9bK+Ir8M/m2inKjZhsFm+lcp4fu/ttq8xBLxN9xTjcMcZruNC08KHuJ/mnkGd2fug9cVw11GN3NXPLxEVGT51qVbXQ0ktGa+jje7kbewB6e1Z91bqySTNHG0UbBdoTaRxj866m5mS1DLk7yNwA6/hWDd2V1O4bzisRcOq5wDis6c29WzKFRnG+KdGaWxEseWKoGKD7yj/GsvR9UMMEVsqKIh8oPQj616SzTX93O0kUUUixbQhP3uetcn4j8Mstuby3UieNN8yZ4wa7KVZSShM7cNUpy9yotX1HtbCaAtz5Q/8eH0rzfx6+qeH7W2udNkYmxfeYf4ZoD2PuOn5V6D4cvFmgaCV9sq4CgnlqTXNMa6tSsaruj+dWfkMfQ57HpitqcuSVpbGk4tXpN28/yZ56FmX7F4k0UvCZQtxtGcqcZr2vwX8QLHXdLZrz9xewrmWM9+2RXI6dClxYRPFGihV+5jhMdRj9K5bxFpy6VeC609mjST7y5xg9SPp060p04V/dluup01aUcVD2cvjS0Z7xZ63p9xMFWdUmY8K/ynHtWs0gA5OfpXytrF9NF4f+1+c32jeFVd3T2Fe0/CLxRHrnh2K3mZhqEA+ZH+8Vz19648TgXRj7SLuj5v7Ti90WPFun3Vvrdv4i0+DMsK+VNGw++gzz9ea569ubzV9R8+BPvHoq9BXc+NPEdnoOkSNckPPKu2OEclieOlcXpXjZLq0SPTtMa1Y4V5HwTnjp+tVQ53Dm5fK56OFnO2kbvodZ4e8L28ViX1CLfPMdzBuoqnqngK3lmWWwmeFj94Z4NVdP8AFd0175ZQMAfmxngV3lvMs8CSRnIYZrGpOtSlzN7kVJ16MuZvc8p8ReF9TTcyozxJ12n/AArmdNiAneC7tykijOG6175I8auVLAN3HtXG+O9DtZrRLoR+VOr43p1wc8H15xW9HFuXuSR00Mwb92aOH8J+HbbWdRuVupJEhRQ6KhPXPauwl+H9vc2D26XV1Hn+9KWXHbg9a47R9Zm8N6l58wPlhdr59K6/Tfidpt3dlTDKLbcEMyjIVj61pX9vzc1PYvE1KznzUnoZ+nvqfgvUrWHVszWMo8rzUOU/2T7H+dekWN5BeWyy28gZcc88j61534o8eeHJ/tWj3e67kkXcuxcheODk9KyvA0d9rFoH069RXQFJV34IweOPp/Ksp0XUh7Sa5X+ZzOMcSnKbtJbnp2raZYanpskGoqjQyA8k4K/Q+1eAeIrFvDeqzxK5v0Rl2SBtoGfX3xXp0vgzUruR47y/dk6gq52j2xWT4h8FzWFneTmQNamPcy56N+P0rTCyhSfLzXv0OnBzjSvBVNzz8apLFZmOcn7HJJvdT6dBn6ZzXoXwr1S63XGl3EcSQRxBo2X1yc8fQivPtGeH+1Y7fU4vOsmk2TKe6Hgk49K9M8BaLp+n6zrdpYN9oaCTasrPuYIQML+GRXRi3H2bi0RmOH5aymtrHXxrFMC6uN/3SCe30qstssIzKM4JH0zV2JSz+Sqojudpbv3q4NNj2YeSRmP3iT1ryeaxxOoonJ+IoItH1bTtQgZQ80nlyKD1HriuN16wgF9cw3YAkDb454yF2Nxz+NdB8VJYNLjhkZ2ZnQiIEk7SD1/UVU+HER1PVJ49ZiMuIFkj3jhs5H6DFd1J8tL2rOynXjSjGbd3Yg8O+MdV0u1W3nt7a8QjcHE2w5468Y98VTu/iV4rurp47LRobOFM5lmBYHnHGcVn+JL7SrfxnqOnaaRutcM6dVXI5wfTmqFqLnxBerbROxgRdpznB9hWyo03+8cdzqjQo10q0UkupT1TWfEevTzLqWo3MkanHk2nyJx24q7ovhqTYhmJRX+VkH5ZPrXcaf4fGh20MVxF87/NG55Gccg1evZo9J0ySeMIZmwRG/3WHoKTrpe7SQqmNjCNqK0MG1trHRNLuJhal2j6Ecknpgn0rko/iN4j/ttonazS1RiDbeXuQr2GcZ59a7zwmI/EtldebhCpAZF6E5P6Vf0f4daPp+rG7eEzTFxKoK8KR/8Ar6VHtqVNyVZXZ4+JqSqyUkypruio6rcXEUYWZVwhB43AcfmTXnviT+zdMne3srmRZYuJNrZjJ9PrXs+v2VxqSTorjagHlBTghh3rxAeGPElldX0F5p8slopPk7F3mTJyTn9aeDmpL3n8jb65WpxXIzZ0y6MUSxalG81nONis44RupHv1p97p032J1s2+0Wmc+W33lI7qT/Wrek6Vdp4Qh0+9UqRI0wJHzBumT9BiqM+ozLpBKNIJ7dikwXk4xwQfTvWt7y93ud3tXUo88lfuv1Kuk6fYW1550sjm5yAElTaV78f/AFq6dnR1++q7hj2FZOlTR6to7S3hD7CUzIv3hj+dT6R4In1iRTZSzWtuPvOWPH0FTVa1c3awqVOhyc6fKiaW4VAGMiqccjruqjea3ArAQANKBjANdSnwm09kP2zVdRmYHOVcKM/TFUfFngPT9E0S6v8ATRcySW8Zcq77ifpWMK9CUlG9yY18NF6ts5qwtLjVJi1zJgZyEZsZ74robO0tltyzTi1gQ5JAyQM14TpF5q8+uSSK90BkErvOBn+deqNJLerBAGPm4AbHQnua661Jx6m9GssUm43jFFrVJYtcuxZ2gdrOE5kuH6tj0rYWx8lESAmOMAYBHX3qSztI7O1+VWAIxtH4c59aillTeTJJJuPtmuVyvpHoZVJ865Y7Iwke+0K/Ola6m1s/u5SOG+hq1qdt9qBlg5KgZr13xBoGn6/ZG2v4Q6/wupwyH1B/OvJtT0u/8K3i2moEzWchxBcr39m9DRRrxq6rSXb/ACFQxKqyutJfgzGt7i4sJN8RIl5H1Fej6b47shpKtMrLMihfLA6kcViaZpUOpwnzVRwnOA3b61hXmkNbas8ca4hY5XJqpxp1naW6OifscTpUVmj0DTdQa7uo77UWVY5QfLReqr2BrZTVLKZg8rKqBj1bgAen5Zrl4ovMiKKgZXVUZRj06CrkWl20csu4BiDsIDZIGAeK5J04vU8qcYuVtjX1nyJprKW3C+XuPzI2Cx7D+dVpr2KBXhuwWlkU5Qc8ds1i27xLr0XnXAWCM7whPLHkD+vSt2+kVjJe2oHmquPQ9MYo5eW0WNw5LI85sNKuY7/eQBGrDkg856Vv3VzYWsqxXGoQCYtnY7Yx3PFXLnUAY/Od4pLlU9OA2MfjXhV7b6hNOrLb3Et6JC7BIyxfJwR716FKm6+snaxeKxk202j1iSSGzuRcRyK1lcOA7A5Cs3Qj2Pf8KoeJtJuL2MiIZMZ+XB+8DjH41leEdP1Ka21BdTgkhtplKJFKckMTnI9MYrTsvEVhothazaxHLPvDQmNDg717n0/+vT5ZRl7urR10MVan7Z6NHDSte2gMcsEUjwSBwsiZ59D+FaOm3cmn6lZeINGaG1WAEzxs5+Zu6Fa6bSJbLX7W5uUjKpuwxbllPYH/ADzXL6zCukXF0VhWRSmQG6Z6g/hXQpc94MMXhqeMXt6Okt35/wDBPX/BOh2evmTxDfxee1ySY45PmCg9a7C10bTYDmGziTB4G39a8r+B3ju1uNNXRb6VYpI3byN3HBOdpr2fjHvXiYpVIVHGWn+R5decua6ej29DntZ8Ox3TedYsIJ8Yx0U+9c/Lp/iKw+W0y4xk7W4r0E4xkdaGIzk4Az1qIV5RVnqOGKnFWeq8zybWbTWNLl/tG482aVsSSBWJG3uPwrrxqNr4ghtY9KnjbK733HlRjpj1yaxPiP4wisy+l6bH9qucB5HQ5WMc8H3ry6bVIrHSm1F7qS3Z38tI05Jb2rvhRlWipSVn0PQjT9tSVWp7tj0XxJpltHMIZTFJK43MJMD/ADxXMaVpNqZGtLV0S3mfdIsXr6153ZeKItSv1hmglcSShTI773yfQV6JokS+HPEl22rTfYo44xKu9cbwOcCuh05Uo2b1NKMqLg5Qkm15HBeKdA8t7g3QldiQqSocbsev4VY0Oa+06KGe1lnhuYh+7uA2GI7hvWvQZfFGgeJdMXSnT7KXJKSOBvduwH+e1cpbxCF5Le4kRkiBxJ1/D61tGcpR5Zo3wqpVpuqlZ9ezOm0T4rahZNIur2wumLAHZwRwBkevStTU/iXp2s6XPaS21xbrKuCSAQD1rE8P+CLzxDpK31qsMEbcR7urY6muWs9D1K91p9JtIQ95GzI+5vlXHqa5vY4dybW6L9hg5zbWjj57CmZTe5VgwcMoJBAzjg8/lXdeA76aC0leMsL2AnajMMyw9QCfUdK5TUvCOu6PEJdQtv8AR423GVGyAM459qvi5a01mztdLimlnaMPNOAcDJ6L/wDXrSfLVjaOosbKi0qnNdPTuj2vS9V0y8tIZoZ4wxXdtc4YHHOQe9X5bqCKMyPKgQfxZ4ryi4tY7W8eW4CzoybieMAn9KmuZJbuOEQssducblduMV5rwqbunoeY8Cm7qWgvjK5tdYvbS4ul3WKylCT/AAjjn2p3xN1dfD2nafa6CpgnmYB5oeSkePX1PGKyNdkgjuI7eGRWV+HPvRcNcbnjt1DRbMuGGQAB1yeldcaaXK+i6HTVwinGKTtZM8/0fQHl1OV0EjTXX3SeWbuzMa9g0nTYtCs4ltCN2zdvUclq5jwO0jalLdBUEnMSbhwo4z+Neg6jpl3c2MdtaTxiRQWeTbjP0/Sniqzc1F7GddfV4KhHYxtf1mT7MhnAdlBILcYGK57StXg8Tar/AGRMcTAYG0Hp65/pWnpvhPxFJeQW+s3NtNaO+5sZ3KME8e9dp4e8LadoVxLLEivcP/y0ZRkD0rnlUp0Y2Wr6WPOdRvbYy/DnhyDw4LgtLiMjOT94nOa6KwJuizyeaEXhSRtDZ+n4VanjjkciRQy57irCJ8vJGRwcdK8+pVc9ZbkcysVVCRziPbtXqCe/NS3Dqu0KMuegHc1JLGkqYY9e4rNibY7vI3CH7xPSoWuoLXUzvEWnxxwK5AZpHCMgH381514j05bSRpUHlvHw6ngmrfiH4iyQ+I4re1tBefZmYbAcDp19z147Umu+MdL8T6CFhga21EYZ42HIGccHuK9WhTq0+VtaM7MJXcaqgtTPWNEtI5dp3SEFRjGemSMV0+k6w2mwgiYMjLjY3RT615TfXN7PrSRQu+YSECgkY7M34nP5V1MVnOYgkyncBy7ZOfpXTVopxSk9zvjONfmU9kzv7DxpbfavJvnjVSPlYdM1Y17xLpYsnht7uGaVztKjsMc15lPpUghDFlbtg0y03WNwd8YRvda5/qlPm5osX1KjJ80H8hZ9JtbSSW8tYzG7/KPftkenWr/hm1TzZppcFvupz371V1S4zCPNYs7MM85AHtV3wvrOnRWstncDcWPmeZjIUen/ANat6nM4GtWKo0Hyq12bN1iRCuCGAwBmmJFGwLNAZSf4iKNTmi023a/Yh4AuVzwGB/pXn2o+KfE6XJ+xJb/Z2AZQAvAI6ZPWsaVOU/hPLlWjT3PpG2ljnhEkMgKN6HvTdRsrXUrR7a+hEsLggq3b3rhvCmszxxRKACkgDbSfumu+tmMkKs3UivMqU5UpaHNVpSoyszy7UbO68F3nloxk0u4O2KZuTGf7rH+tRsfOlVgBk9OvevQfEccF7Y3NldQiSKSMjr09xXmGgykxyRc4jbrnk130J+0hzPc7qUnVg5vdHQfa106bznjEqbfkHXnoDUmnz300DliYVmLbg4yQPUVOiJp2hteFFnlzuIk6YA3Ae1ecSePtYl1O5kYxeRK6xmHb/CfeqhSlUvyo5alVRlZndRaAZ9S/tCE+YIjgtjnj0FdDb3Frdwyl4wSQRIFHSq9rqbWWnyeXErHlgSelS+Es3PhrzydsskruzfieP0rnnJyXM/RG1SUnG8umiOb1bw9FqKXU9hIYJo2AjU8h/b+dYOhT3EF1LbXTFGiJ6rjBHvXoD2ws5o5VbcZDgjGAMf8A6q8/mnMviKSQjBZjnnrXXRm5Jp7Hbh5ucXCWqOil8t4nk2Ntx1HeuU1LQIdXvpbJj5bXGJoGbs3Q/wBK6u5uzHarlQ2U5HQcAdq5rxTM0NtBfxfJPbyqybeO/T9Kuk2noRTipXpy66G/4P8ACCeGNKuLK8Zbm8uiJHO3AUgcBTXM+LLJLiOWQjY6Nswxxkd69SlvWuNEt7p1HnSR8t6cV59qUa3cF5vzna3J55wef0qMPUlOTlLcnAydG76I8z0jQ5hdPPp37u5tphIOfvD0x6/4V7JafGDw5Y2KQ6xdNBfxrhoypOT25rjP2f5Te60xuAHCwsMHnoetd58Tvhf4f8UabcXMlutpfRoXFxCuCcDuOAa0xU6c6vs63TqcmMjGnLlprSVpLyuZmmfEK+uonubVI5onOUR26ZNZ/iHWNfvoN97ei2hI+ZIDj5epOay/gh4cjukmtby4aWGCc4G3BYDsTmvU9W8PWUOi3MSJ95GAZuStZzlRo1OVI3lWpRScY2k0eS+GfGOi6U1zbyWE7/aFHlyTAMCe5J+tdn4R8DaL4l8FWkmsQNcRyyNOm1yu3qOorzW8sIrq4hUkqrs2QOmRxxXrXwnv3t/D9xprLvSxlZEfOCwPPT2zWuLXs4c1J2fU5fa1KtOUX5G34c8B+G/Djh9L0yGOQch3+cg+uT0rhfjvYz6le6RaWMYmu5AzLF3bB/8Ar16tLelP4M5964fwhOdZ+ImtXt0oL2kSQwDr5anJOK4KFSam60ne3/DE0qbSlJ7JHN6P8LbnWLi2vPESR2AiwVhtm+YDHTPat7xB8OQ1uYtFYLuU/wCtY9fc16WcbfxpKUsbVcr3Io1pUXeB5foh8ZadpR0aDR0jZiQt00oKRg9SP5/jXU+FPCNpokZmlJuNRl+aadj1J9Paun7UHtWU8Q5p20vvYupiZTv0vvbqcd8VrkWXgi9IJBl2xADvuI/wrgtNttRk0y5nltmtItP2LMpbDtkZyvbHr9a6f4v3Befw1ppB8m6vl3nPYEDp+NZXxMvbpDq9nBN5VvIiK6qOvGOv0FduGuoRiuv/AAEehhZONFRS3u/yRn6Pr+nXN9Lp736lZk2AHBAYjoW6A/4VHc2sy2s7W8qXcCyFVkhYSYCnHzY6V5Fp+n/ar6Sy81kVSTuxnNejfCuE6Pf36LI0irHtVR8o5zyR3ruq0VSTlF/I56GOqqa91WZIJLe1D3l0xYw7jvPC8VN4M1BruzuL+WVZrN2dmQ9Rjt9KreKQLy5ewdUWL5W4X17VDpSLp2kvZ2w2oX6/U4PH4Umk4anquNSpJN/C0dF4CSK+aaRt0O8kxjsfXmvRrJ3jtlVZMsBwD9K8n3PpMsMcDkohLBeg+ldtp+ryXHlyPGAVTAwa48TTcnzLY58bRcnzLY3Jb24g1COWcFYlyAAcjPer9rq9vfny0c7j0x3/ABrhfFmo3DeFL5gwVkw4IHPXpmsfRb64soIJkkLM5875uoz2+lY/VueHM9zyakkmtD18p5MTYAwvPJqxHIjIpB4IqpE5eJC38ShsfUf/AF6nEY37AcAc157S6kNdyRiBuJ6445rB15XWwmMPBbGcfWszx34km8NaS11BCszh8AO2O2a4HRPHGoa1qjQXccexlDYHQceldWHws2udbIuC5ZK5kavpV9pV3enSUE17LN5lvKQSBnr9DS6bYz/a1utTjiS5jjVGjhPGc8knvmup1Rzb6d5kfDyE8+lcP4h1OXT/AC1hH+sbBOea9enKU1Y78Nh40lLEN3tsV7i6uIrqeWxUwsWG0sAep6/nXoulW0xtoJNSh+8gLMDjaSPSuB8HznUr3dcqCHDcehAGD+lemSSSyx7Zn3grtBIxgAcVOKdrRsY0pym3NvcrX1qtsCRICFIIJ9KqzW8coKttUnjcTTbyRpEZTwPlX9P/AK1UbeUzMxbPyEEDPHFYJNK52qDS5rlLU4ZFbyHUZTo4/i+lZ1vDFBfrJIpx/Guetdfd26XMUjOMBRuA9DXOanbfZ7koHLHZu3H+VbQnfQ66VSNaPs5HTaokWsaXDYmU7SpGCoIGPu/04rGbwZrW1FuLa0uCi7VdmAO3txVDTb97e3lcDcY4mkXJ6ECskX+pXIE0mpXKs4DYRsAZHQCphTnF2i18zxMbRVOfIz//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut G Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_56_11145=[""].join("\n");
var outline_f10_56_11145=null;
var title_f10_56_11146="Dissociative identity disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis";
var content_f10_56_11146=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Dissociative identity disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/56/11146/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/56/11146/contributors\">",
"     Brad Foote, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/56/11146/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/56/11146/contributors\">",
"     David Spiegel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/56/11146/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/56/11146/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/56/11146/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1244359\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dissociative identity disorder (DID), formerly known as multiple personality disorder, is a complex, chronic condition characterized by disruption in autobiographical memory and in the sense of having a unified identity. The disorder has been most commonly conceptualized as originating in the context of severe trauma during the patient&rsquo;s childhood. &nbsp;",
"   </p>",
"   <p>",
"    The prevalence of DID has been estimated at approximately one percent in community based studies. High rates of co-occurring psychiatric disorders have been reported, including posttraumatic stress disorder (PTSD), borderline personality disorder, substance abuse, depression, and somatoform disorder.",
"   </p>",
"   <p>",
"    The epidemiology, pathogenesis, clinical manifestations, course, and diagnosis of DID are presented here. The epidemiology, pathogenesis, clinical manifestations, and diagnosis of PTSD with dissociative features are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/32/522?source=see_link\">",
"     \"Dissociative aspects of posttraumatic stress disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H349015232\">",
"    <span class=\"h1\">",
"     DISSOCIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dissociative identity disorder (DID) is one of several dissociative disorders. Dissociation has been defined as a disruption of",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    discontinuity in the normal integration of consciousness, memory, identity, emotion, perception, body representation, motor control, and behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/1\">",
"     1",
"    </a>",
"    ]. When one or more of these functions are disrupted, characteristic impairments can be seen in these functions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Consciousness &mdash; Impaired consciousness is characterized by decreased responsiveness to external stimuli.",
"     </li>",
"     <li>",
"      Memory &mdash; Memory impairment, referred to as &ldquo;dissociative amnesia,&rdquo; affects the ability to recall autobiographical information, which is often of a traumatic or stressful nature.",
"     </li>",
"     <li>",
"      Identity &mdash; Dissociation can cause confusion about or discontinuities in one&rsquo;s identity. (See",
"      <a class=\"local\" href=\"#H1550386\">",
"       'Identity'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Awareness of body, self, or environment &mdash; Symptoms of impairment include depersonalization and derealization (See",
"      <a class=\"local\" href=\"#H1551497\">",
"       'Other dissociative symptoms'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1244373\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of dissociative identity disorder (DID) has been estimated to be approximately one percent in community-based studies. The prevalence of DID is higher among patients receiving mental health care, but with wide variation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no epidemiologic studies of the national prevalence of DID. Samples drawn from the general population in Winnipeg, Canada and from adult women in central Turkey found prevalence rates for DID of 1.3 and 1.1 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. These findings suggest that DID is not a rare disorder, but instead may have a population prevalence comparable to that of schizophrenia.",
"   </p>",
"   <p>",
"    Twelve studies of inpatient psychiatric patients in nine countries (Norway, Finland, Switzerland, Turkey, Germany, Netherlands, Canada, United States, and China) found that the prevalence of DID in these inpatient samples ranged between 0 and 12 percent, with a median of 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/4-15\">",
"     4-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Five studies of outpatients receiving mental health care in the United States and Turkey found the prevalence of DID to range from 0 to 7 percent, with a median of 2.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/16-20\">",
"     16-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Retrospective studies of patients with DID in mixed settings (inpatient, outpatient and community) have reported the following sociodemographic characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Seven studies of 388 patients reported a median age of 31.3 years (22.8 to 34.5 years) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/3,12,14,21-24\">",
"       3,12,14,21-24",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Eleven studies of 737 patients found a median of 89 percent female (range 70 to 95 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/6,7,12,16,19,21-26\">",
"       6,7,12,16,19,21-26",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H663938821\">",
"    <span class=\"h2\">",
"     Comorbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;DID has high rates of psychiatric comorbidity. Disorders reported to co-occur at high rates in patients with DID, and the prevalences reported, include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      PTSD, 79 to 98 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/12,21,25,27,28\">",
"       12,21,25,27,28",
"      </a>",
"      ] (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=see_link\">",
"       \"Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Depression, 83 to 96 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/12,22,26,27,29-31\">",
"       12,22,26,27,29-31",
"      </a>",
"      ] (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37481?source=see_link\">",
"       \"Unipolar depression in adults: Epidemiology, pathogenesis, and neurobiology\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Substance abuse, 83 to 96 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/12,21,25-27\">",
"       12,21,25-27",
"      </a>",
"      ] (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2409?source=see_link\">",
"       \"Alcohol abuse and dependence: Epidemiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Somatoform conditions (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=see_link\">",
"       \"Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Headaches, 79 to 91 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/26,31,32\">",
"       26,31,32",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Non-epileptic seizures [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Conversion symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/28\">",
"       28",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Somatoform disorder, 35 to 61 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/22,25,26,28,30-32\">",
"       22,25,26,28,30-32",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Borderline personality disorder, 31 to 83 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/12,22,25-27,30,31\">",
"       12,22,25-27,30,31",
"      </a>",
"      ] (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/19/10553?source=see_link\">",
"       \"Borderline personality disorder: Epidemiology, clinical features, diagnosis, and differential diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H663938688\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retrospective studies have found that a high proportion of patients with DID report a history of severe childhood trauma, usually childhood physical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sexual abuse. Ten studies with an aggregate sample of 658 patients with DID found the following rates of childhood trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/12,21-25,27,31,33,34\">",
"     12,21-25,27,31,33,34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Childhood sexual abuse, 70 to 100 percent (median 83 percent)",
"     </li>",
"     <li>",
"      Childhood physical abuse, 60 to 95 percent (median 81 percent)",
"     </li>",
"     <li>",
"      Childhood trauma of any type: 77 to 100 percent (median 94 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, rates of childhood abuse reported by adults in the US general population range from [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/35-39\">",
"     35-39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      8 to 17 percent of all respondents for physical abuse",
"     </li>",
"     <li>",
"      6 to 17 percent of women for sexual abuse",
"     </li>",
"     <li>",
"      6 to 11 percent of men for sexual abuse",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The proportion of adults with a history of childhood abuse who subsequently experience symptoms of DID has not been studied.",
"   </p>",
"   <p>",
"    There has been limited systematic study of the nature of childhood abuse suffered by patients with DID, but available data suggest that the abuse was early, extensive, and prolonged [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/12,23,25,33,34\">",
"     12,23,25,33,34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In 117 patients with DID, the majority of patients reported child abuse prior to the age of 6 years [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/12,33\">",
"       12,33",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In 130 patients with DID who experienced physical",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      sexual abuse [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/25\">",
"       25",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      50 percent reported having been physically abused by four or more perpetrators",
"     </li>",
"     <li>",
"      76 percent reported having experienced four or more types of sexual abuse",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In 102 patients with DID who reported experiencing sexual",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      physical abuse, the mean duration of abuse was 10 years [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/33\">",
"       33",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1244380\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dissociative identity disorder (DID) is a controversial diagnosis. Its pathogenesis is not known. Conceptual models for the development of DID include a trauma model, supported by evidence on the association between a history of severe childhood trauma and dissociative symptoms, and a sociocognitive model.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18659852\">",
"    <span class=\"h2\">",
"     Trauma model",
"    </span>",
"    &nbsp;&mdash;&nbsp;This conceptualization of DID is based on a stress-diathesis model, which formulates certain illnesses as occurring in individuals with a predisposition to the illness (the diathesis) who experience a significant &ldquo;stress&rdquo;, which can be an environmental factor or a life event. Predisposing factors proposed in DID include a person&rsquo;s inborn tendency to dissociate, known as &ldquo;dissociativity&rdquo;. The primary stressors giving rise to DID in patients with high dissociativity are believed to be sexual abuse, physical abuse, or other severe trauma occurring during childhood. These factors are discussed further below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H663939132\">",
"    <span class=\"h3\">",
"     Dissociativity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dissociation is a common occurrence among people without mental illness. Normal dissociation is viewed as a capacity for a combination of intense focus (absorption) and detachment from distraction that can be mobilized and controlled [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Individuals&rsquo; tendency to dissociate has been found to vary widely within various populations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The concept of dissociation as a response to trauma is derived in part from an animal model of defensive response to life-threatening stress, such as an attack by a predator. Under such circumstances, animals have displayed freezing, tonic immobility, passivity, hypoarousal, and analgesia, all of which have analogies in human dissociative symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/44\">",
"     44",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Research evidence, as summarized below, suggests that genetic and other biologic factors may influence dissociative reactions to stress.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Three out of four large studies of healthy twin pairs drawn from the general population suggested a moderate to substantial genetic component to variation in dissociativity [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/45-48\">",
"       45-48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Studies have found evidence linking levels of dissociation with genes associated with dopamine metabolism, with neuronal growth and repair, with glucocorticoid response to trauma, and with serotonin transport [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/48-50\">",
"       48-50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Studies have reported mixed findings of a possible association between dissociative disorders and smaller hippocampus and amygdala volumes:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In a study that compared 15 patients with DID to 23 subjects without a psychiatric disorder, the hippocampus and amygdala were found to be smaller in volume in DID patients [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study comparing 10 patients with DID, 13 patients with dissociative disorder, not otherwise specified (DDNOS), and 20 healthy controls, mean volumes of the hippocampus, parahippocampal gyrus, and amygdala were found to be smaller in patients with either dissociative disorder compared to the healthy controls, with greater differences found between the DID and control groups [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/52\">",
"       52",
"      </a>",
"      ]. The DID group was compared to a separate sample of 10 patients who had previously been diagnosed with DID but were reported to have recovered; the active DID group had smaller hippocampal volumes than the recovered group.",
"     </li>",
"     <li>",
"      A study of 58 patients, including patients with PTSD and no dissociative disorder, patients with a dissociative disorder but no PTSD, patients with both disorders, and subjects without a psychiatric disorder, found that smaller volumes of the hippocampus and amygdala were associated with PTSD, but not with a dissociative disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/53,54\">",
"       53,54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Several studies have found evidence of a smaller hippocampus and other brain structures in patients who have suffered childhood sexual abuse or PTSD [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/55-57\">",
"       55-57",
"      </a>",
"      ]; however, one study suggested that smaller hippocampal volume might be a risk factor for PTSD, present before the trauma, rather than a consequence of the trauma [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H577186680\">",
"    <span class=\"h3\">",
"     Childhood trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly reported &ldquo;stress&rdquo; postulated in this model is a history of severe childhood physical or sexual abuse, or other severe trauma. Data on the prevalence and severity of a childhood trauma history in patients with DID is described above. (See",
"    <a class=\"local\" href=\"#H663938688\">",
"     'Risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    DID is thought to be a potential outcome of physical or sexual abuse during childhood. Individuals who experience such abuse as adults may develop acute or posttraumatic stress disorder, but are not known to have developed DID. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7080?source=see_link\">",
"     \"Acute stress disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=see_link\">",
"     \"Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/32/522?source=see_link\">",
"     \"Dissociative aspects of posttraumatic stress disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The existence of a moderate to strong association between traumatic experience, especially childhood abuse, and dissociative symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a dissociative disorder diagnosis has been replicated in hundreds of studies, with almost no contrary evidence [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H577186687\">",
"    <span class=\"h3\">",
"     Poor infant attachment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poor mother-infant attachment has been postulated as an additional factor that may lead to DID in predisposed individuals. Two longitudinal studies described cohorts of 168 and 56 poor, high-risk children who had been referred for social service intervention during infancy and who were followed through age 19. Both studies found that the quality of the infant-mother attachment, as measured in the first two years of life, was a stronger predictor of self-reported dissociative experiences in late adolescence than was childhood trauma. Neither study evaluated participants for the presence of a dissociative disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/61-63\">",
"     61-63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87907603\">",
"    <span class=\"h3\">",
"     Proposed mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;DID is proposed to occur in individuals predisposed to dissociation who experience sexual or physical abuse, or other severe repetitive childhood trauma. Dissociation and amnesia are hypothesized to arise as a defensive or adaptive reaction to trauma, based in part on the conflict between fear of the abuser and, in many cases, dependence on the abuser [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/64\">",
"     64",
"    </a>",
"    ]. Dissociation can provide detachment from physical pain and a means of emotion regulation in the face of traumatic experiences and memories. &nbsp;",
"   </p>",
"   <p>",
"    Dissociative amnesia has been proposed to be associated with warnings from the abuser to keep the abuse secret. Fragmentation of identity is said to be more likely when trauma occurs during developmental periods of identity consolidation. &nbsp;",
"   </p>",
"   <p>",
"    Chronic abuse may lead to further dissociation through learning or habit formation. If the child&rsquo;s use of dissociation is repeatedly reinforced because it reduces psychological pain and cognitive dissonance that arises from the abuse experiences, the dissociative response may become more automatic and more complete, eventually impeding integration of disparate aspects of identity, memory, and personality. The child could come to experience a subjective reality of two or more self-states, some with memories of the abuse and some without. The child could eventually come to use this dissociative splitting of the personality to deal with other, present-day traumatic events, internal conflicts, intense affects, or troubling realities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H315539289\">",
"    <span class=\"h2\">",
"     Sociocognitive model",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative model of DID, the &ldquo;sociocognitive model&rdquo;, posits that an individual&rsquo;s symptoms of DID represent a role enactment consistent with cultural and interpersonal expectations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/65\">",
"     65",
"    </a>",
"    ]. Patients are proposed as learning to construe themselves as possessing multiple selves and coming to believe in fantasies that they were physically or sexually abused. DID symptoms are believed to be absorbed by patients through representations of DID in movies, books, and other media.",
"   </p>",
"   <p>",
"    An overlapping model, the &ldquo;fantasy model&rdquo; of dissociation, focuses on a possible connection between the patient&rsquo;s fantasy-proneness and dissociation, suggesting that dissociation is associated with a tendency to fantasize a history of trauma.",
"   </p>",
"   <p>",
"    An iatrogenic contribution to the patient&rsquo;s development of DID is postulated, suggesting that some clinicians who treat DID may inadvertently contribute to patients&rsquo; manifestations of the disorder through suggestive psychotherapeutic techniques.",
"   </p>",
"   <p>",
"    Proponents of this model have cited the following lines of research in support:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A marked rise in the number of reported cases of DID in the 1980s and 1990s, accompanied by more frequent media depictions of the disorder.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      It has been estimated that prior to 1980, only 200 DID cases had been reported in the world psychiatric literature, while several large series of cases with a total of 843 patients were published between 1981 and 1990 [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/2\">",
"       2",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      A study found journal articles on DID to be published at a rate of nine per year between 1971 and 1980, increasing to 60 per year between 1981 and 1990 [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Research findings that individuals in hypnotic and other socially-influenced situations can be influenced to enact suggested roles [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/65\">",
"       65",
"      </a>",
"      ], including the roles of separate personality states [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A number of studies that have found an association between measures of dissociation and measures of fantasy-proneness [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1244387\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;DSM-IV-TR diagnostic criteria for dissociative identity disorder (DID) focus on the presence of two or more distinct identities or personality states that recurrently take control of the person&rsquo;s behavior, and the presence of amnesias [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/69\">",
"     69",
"    </a>",
"    ]. Other dissociative symptoms common in DID are described below. (See",
"    <a class=\"local\" href=\"#H1244401\">",
"     'Assessment and diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1550386\">",
"    <span class=\"h2\">",
"     Identity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distinct personality states in DID are reported to be experienced by the patient, and sometimes by others, as having markedly different characteristics, for example, different ages, genders, sexual orientation, and abilities. Reports have suggested that the original personality state often constitutes the dominant presence. Four studies of 428 total subjects with DID reported a median number of personality states between 5 and 10 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/21,23,24,34\">",
"     21,23,24,34",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    In people with DID, individual personality states have been reported to be associated with traumatic experiences, as well as with specific mood states, roles, or behaviors, for example:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A terrified, crying child [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/70\">",
"       70",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      An angry, persecutory figure [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/71,72\">",
"       71,72",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A state that feels impervious to physical pain [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/73\">",
"       73",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A state that is calm, detached, and helpful to the therapist [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/74\">",
"       74",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A state that is chronically suicidal [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/74\">",
"       74",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some clinician researchers have suggested that DID is better conceptualized as a fragmentation of identity, with discontinuities in memory experienced by the patient as intrusions into consciousness, rather than as &ldquo;switching&rdquo; among distinct personalities [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/75,76\">",
"     75,76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1551497\">",
"    <span class=\"h2\">",
"     Other dissociative symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other dissociative symptoms are common in patients with DID and are often more readily observed. These symptoms are described below.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Amnesia &mdash; Individuals with DID experience recurrent episodes of amnesia. The presence of amnesia is required by DSM-IV-TR diagnostic criteria for DID. Patients typically report that they have periods of time (most often hours) that they cannot remember. From secondary reports, these periods may be associated with certain mood states or behaviors (eg, angry outbursts).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Depersonalization &mdash; Depersonalization is a feeling of detachment or estrangement from one&rsquo;s self, for example, feeling outside of one&rsquo;s body, or that one is observing oneself from the outside. A review of seven studies of an aggregate sample of 443 patients with DID found a median of 77 percent (range 38 to 100) reported depersonalization [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Derealization &mdash; Derealization is a feeling that the external world is strange or unreal. A review of seven studies of an aggregate sample of 458 patients with DID found a median of 63 percent (range 53 to 93) reported derealization [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Auditory hallucinations &mdash; Many individuals with DID report hearing voices, for example, a voice giving suggestions or commands. Auditory hallucinations in DID have been described as chronic and typically present since childhood [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/77\">",
"       77",
"      </a>",
"      ]. Dissociation can present with other first-rank or psychotic symptoms. A review of nine studies of an aggregate sample of 771 patients with DID found a median of 92 percent (range 64 to 100) reported auditory hallucinations [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Self-alteration &mdash; Self-alteration is the sense that one part of one&rsquo;s self is markedly different from another part of one&rsquo;s self. A review of four studies of an aggregate sample of 353 patients with DID found a median of 98 percent (range 94 to 100) reported self-alteration [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Trance state &mdash; A dissociative trance state involves a narrowing of awareness of one&rsquo;s immediate surroundings or stereotyped behaviors or movements that are experienced as being beyond one's control [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/69\">",
"       69",
"      </a>",
"      ]. A review of seven studies of an aggregate sample of 693 patients with DID found a median of 91 percent (range 45 to 100) reported trance states [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Somatoform symptoms &mdash; Somatoform symptoms are physical symptoms that suggest&nbsp;a general medical illness that cannot be explained by a presence of a general medical condition, substance use, or other mental disorder. A review of seven studies of an aggregate sample of 520 patients with DID found a median of 83 percent (range 40 to 92) reported somatoform symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=see_link\">",
"       \"Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many people with DID experience suicidal ideation and behavior. In six studies of with a total of 553 patients with DID, 66 to 80 percent reported a history of suicide attempts [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/21,23,24,27,31\">",
"     21,23,24,27,31",
"    </a>",
"    ]; suicidal ideation was more common (92 to 100 percent), measured in four studies of 218 patients with DID [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/21,26,27,34\">",
"     21,26,27,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1244394\">",
"    <span class=\"h1\">",
"     COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;While there are case reports and case series describing patients with dissociative identity disorder (DID), there are no systematic, prospective longitudinal studies providing data on the course of the disorder. DID appears to have a fluctuating, typically chronic course, with periods of higher and lower severity of symptoms and functional impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/78,79\">",
"     78,79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients with DID have reported that symptoms of the disorder first appeared during childhood. Four studies including 199 patients reported a mean age of onset between 5 and 7.8 years old. [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/23,34,80,81\">",
"     23,34,80,81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1244401\">",
"    <span class=\"h1\">",
"     ASSESSMENT AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;DSM-IV-TR diagnostic criteria for dissociative identity disorder (DID) are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/69\">",
"     69",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of two or more distinct identities or personality states (each with its own relatively enduring pattern of perceiving, relating to, and thinking about the environment and self).",
"     </li>",
"     <li>",
"      At least two of these identities or personality states recurrently take control of the person's behavior.",
"     </li>",
"     <li>",
"      Inability to recall important personal information that is too extensive to be explained by ordinary forgetfulness.",
"     </li>",
"     <li>",
"      The disturbance is not directly due to substance use or a general medical condition",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    DID can be difficult to detect. Patients diagnosed with DID have been reported in several studies to have received mental health care for an average of seven years prior to being diagnosed with the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/21,23,24,34\">",
"     21,23,24,34",
"    </a>",
"    ]. Several factors can make diagnosis of DID difficult, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients infrequently present with clearly visible switching among distinct personality states, and this presentation can be difficult to discern [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/1,76,82\">",
"       1,76,82",
"      </a>",
"      ]. Patients later diagnosed with DID more commonly first present with other dissociative symptoms. (See",
"      <a class=\"local\" href=\"#H1550386\">",
"       'Identity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1551497\">",
"       'Other dissociative symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some patients experiencing dissociation may not be able to articulate their internal state in a coherent way, describing baffling experiences such as &ldquo;losing time&rdquo; or not remembering behavior with others, who have described activities they have shared. Others may describe altered behavior:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      &ldquo;Sometimes I act so strangely, I don&rsquo;t understand it. It doesn&rsquo;t seem like it&rsquo;s me.&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;Sometimes people tell me I act totally differently&rdquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Warnings from a perpetrator of childhood abuse to keep the experience a secret may lead a traumatized patient to not disclose symptoms associated with abuse. This may be particularly common on initial evaluation or early in treatment, when the patient does not know and trust the clinician. (See",
"      <a class=\"local\" href=\"#H663938688\">",
"       'Risk factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H577186680\">",
"       'Childhood trauma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      High rates of comorbidity associated with DID can lead patients to present for treatment emphasizing symptoms leading to other psychiatric diagnoses, such as depression, chaotic interpersonal relations, and somatoform symptoms. (See",
"      <a class=\"local\" href=\"#H663938821\">",
"       'Comorbidity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A diagnostic assessment of possible DID thus typically begins with the identification of amnesia and evaluation for other dissociative symptoms characteristic of the disorder, including depersonalization, derealization, auditory hallucinations, self-alteration, trance states, and somatoform symptoms. (See",
"    <a class=\"local\" href=\"#H1551497\">",
"     'Other dissociative symptoms'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Assessment for amnesia, which is required to be present for a DID diagnosis, can proceed from an initial screening question to more detailed inquiry if the initial response is affirmative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Do you have periods of time that you can&rsquo;t account for? &nbsp;",
"     </li>",
"     <li>",
"      Do you have any knowledge of what happened during these periods?",
"     </li>",
"     <li>",
"      What have you been told about these episodes by others who were present?",
"     </li>",
"     <li>",
"      Is there a typical circumstance (eg, a certain place, feeling, or interaction) that tends to precede or trigger the episodes?",
"     </li>",
"     <li>",
"      Are there behaviors that you can&rsquo;t recall but circumstances suggest you may have done? (Examples include discovering new possessions that you don&rsquo;t remember buying, or finding yourself somewhere and not knowing how you got there.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other components of the psychiatric assessment of a patient with possible DID include evaluation for:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Suicidal ideation or behavior",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A history of childhood sexual or physical abuse (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35258?source=see_link\">",
"       \"Evaluation of sexual abuse in children and adolescents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=see_link\">",
"       \"Physical abuse in children: Diagnostic evaluation and management\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Use of alcohol and other drugs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A medical history and physical exam should be performed with follow-up on any initial findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H578546\">",
"    <span class=\"h2\">",
"     Addressing diagnostic challenges",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clinician uncertain of the nature and etiology of DID should consider adopting a participant-observation stance when evaluating a patient presenting with DID symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/83\">",
"     83",
"    </a>",
"    ]. This involves acknowledging the patient&rsquo;s experience as fragmented while observing its manifestations and the patient&rsquo;s efforts to function in its presence. The approach gives the clinician and patient opportunities to enter a dialogue in terms that are meaningful to both parties, while preserving the clinician&rsquo;s options to offer further perspective at a later date. &nbsp;",
"   </p>",
"   <p>",
"    Clinicians with strong biases for or against the disorder should take care to avoid either underdetection or overdiagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/84\">",
"     84",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A clinician who places too much emphasis on a fear of iatrogenesis may fail to assess the patient for dissociative experiences.",
"     </li>",
"     <li>",
"      A clinician with a strong investment in DID may diagnose the disorder on the basis of weak evidence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2268364\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;DID should be distinguished from other conditions with overlapping features. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1493078\">",
"    <span class=\"h3\">",
"     Intoxication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intoxication with alcohol or benzodiazepines can lead to episodes of amnesia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/85\">",
"     85",
"    </a>",
"    ]. Cannabis, hallucinogens,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    , and ecstasy have been found to induce depersonalization [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/86\">",
"     86",
"    </a>",
"    ]. A thorough assessment of a patient&rsquo;s substance use, abuse, and dependence can help to differentiate these causes of dissociation from DID. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2409?source=see_link\">",
"     \"Alcohol abuse and dependence: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5033?source=see_link\">",
"     \"Substance use disorders: Principles for recognition and assessment in general medical care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1493085\">",
"    <span class=\"h3\">",
"     General medical conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amnesia can be caused by general medical conditions, including various forms of dementia, and epileptic seizures. Patients should undergo a medical history and physical exam prior to a diagnosis of DID. Based on the findings, more extensive evaluation may be needed.",
"   </p>",
"   <p>",
"    An observation which often proves helpful in distinguishing dissociative amnesia from amnesia due to medical causes is that a patient with dissociative amnesia will generally perform adequately on cognitive testing. He or she will likely demonstrate a well-preserved fund of general knowledge, but exhibit specific deficits for autobiographical information. Patients with dementia or other organic amnesias will usually show the reverse, with autobiographical information preserved even as other memory deficits worsen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=see_link\">",
"     \"Evaluation of cognitive impairment and dementia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25753?source=see_link\">",
"     \"Evaluation of the first seizure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H578641\">",
"    <span class=\"h3\">",
"     Posttraumatic stress disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posttraumatic stress disorder (PTSD) and DID have been found to frequently co-occur and share a history of childhood physical and sexual abuse in many cases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/79,87,88\">",
"     79,87,88",
"    </a>",
"    ]. PTSD is distinguished from DID by the presence of multiple symptoms of re-experiencing, avoidance, and hyperarousal, where DID alone requires the presence of amnesia and multiple personality states. A dissociative subtype of PTSD shares prominent symptoms of amnesia and numbing with DID [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/89\">",
"     89",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H663938821\">",
"     'Comorbidity'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/32/522?source=see_link\">",
"     \"Dissociative aspects of posttraumatic stress disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1493042\">",
"    <span class=\"h3\">",
"     Borderline personality disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Borderline personality disorder and DID have been found to frequently co-occur and share a history of childhood physical and sexual abuse in many cases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/27,90\">",
"     27,90",
"    </a>",
"    ]. The identity disturbance which is a criterion for borderline personality falls short of the severe fragmentation of identity, with amnesia between personality states, found in DID. (See",
"    <a class=\"local\" href=\"#H663938821\">",
"     'Comorbidity'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/19/10553?source=see_link\">",
"     \"Borderline personality disorder: Epidemiology, clinical features, diagnosis, and differential diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1493053\">",
"    <span class=\"h3\">",
"     Schizophrenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Auditory hallucinations and other first rank symptoms of psychosis are shared by DID and schizophrenia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/21,30,91\">",
"     21,30,91",
"    </a>",
"    ]. Auditory hallucinations in DID are typically highly personified, ie, related to a particular identity state, and are usually experienced as a voice inside rather than outside the head. Patients with DID have generally reported hearing voices beginning in childhood and while the disorder causes distress or functional impairment, the course typically fluctuates over time. In contrast, patients with schizophrenia typically experience hallucinations in concert with other psychotic symptoms such as disordered thinking, a flat affect, and pervasive deterioration in functioning beginning in their late teens to early twenties. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34552?source=see_link\">",
"     \"Schizophrenia: Clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some patients presenting with auditory hallucinations, the clinician may not be able to differentiate between DID and schizophrenia initially. A longer interval may be needed before the patient&rsquo;s diagnosis can be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1493060\">",
"    <span class=\"h3\">",
"     Bipolar disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changes in mood caused by switching of personality status in DID can present as depression or can have characteristics of mania, such as hypersexuality or aggression. DID is the more likely diagnosis if these mood states do not last more than a few hours and begin and end abruptly, often in response to environmental stimuli. A bipolar patient typically does not switch from depression to mania in a few seconds, but this would be characteristic of behavioral state changes occurring in DID.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1493101\">",
"    <span class=\"h3\">",
"     Factitious disorder and malingering",
"    </span>",
"    &nbsp;&mdash;&nbsp;A factitious disorder is diagnosed when the patient intentionally feigns medical or psychiatric symptoms for the purpose of assuming the sick role (eg, receiving caretaking or sympathy). Malingering adds to this presentation the purpose of achieving some specific external advantage, such as a disability income or avoiding work responsibility. Features of the presentation that can help identify factitious disorder or malingering, distinguishing them from DID, include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The presence of an obvious benefit of the symptoms to the patient (eg, evading responsibility for a criminal act)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A patient&rsquo;s high degree of attention seeking, including flaunting symptoms of DID [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/84\">",
"       84",
"      </a>",
"      ]. Patients who have DID do not typically display symptoms ostentatiously or seem enthusiastic about discussing them",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The presence of well-known symptoms of DID (switches to different personality states and amnesia) in the absence of other, lesser known dissociative symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?10/56/11146/abstract/76,92\">",
"       76,92",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7512?source=see_link\">",
"       \"Factitious disorder and Munchausen syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H578737\">",
"    <span class=\"h3\">",
"     Non-pathologic behavior",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient&rsquo;s descriptions of ordinary forgetfulness &mdash; &ldquo;I can never remember where I put my car keys!&rdquo; &mdash; need to be distinguished from amnesia, which involves the absence of memory of extended periods of time, often hours.",
"   </p>",
"   <p>",
"    A patient&rsquo;s metaphorical descriptions of her or himself &mdash; &ldquo;When I&rsquo;m out at the nightclub, I feel like a totally different person,&rdquo; or &ldquo;I am of two minds about my work&rdquo; &mdash; should not be misinterpreted as a symptom of DID.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H189780\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dissociative identity disorder (DID), formerly known as multiple personality disorder, is a complex, chronic dissociative condition characterized by disruption in autobiographical memory and in the sense of having a unified identity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevalence of dissociative identity disorder (DID) has been estimated at approximately one percent in limited, community based studies. The rate of DID appears to be significantly higher among patients receiving mental health care, but with wide variation. (See",
"      <a class=\"local\" href=\"#H1244373\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Psychiatric conditions commonly comorbid with DID include PTSD, borderline personality disorder, substance abuse, depression, and somatoform disorder. (See",
"      <a class=\"local\" href=\"#H1244373\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The disorder has been most commonly conceptualized as occurring among individuals predisposed to dissociation who experience severe trauma during childhood. However, the disorder is controversial, and there are alternative perspectives on its etiology. &nbsp;(See",
"      <a class=\"local\" href=\"#H1244380\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic criteria for DID include switching among two or more distinct personality states and an extensive inability to recall important personal information. These symptoms are frequently accompanied by other manifestations of dissociation, including depersonalization, derealization, auditory hallucinations,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      other dissociative symptoms. (See",
"      <a class=\"local\" href=\"#H1244387\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1244401\">",
"       'Assessment and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A clinician evaluating or treating a patient for possible DID should strike a balance between the need to ask questions about DID symptoms to identify whether or not the disorder is present and avoiding overly suggestive questions about multiple distinct personality states. (See",
"      <a class=\"local\" href=\"#H1244401\">",
"       'Assessment and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of DID includes intoxication, borderline personality disorder, schizophrenia, bipolar disorder, factitious disorder, and malingering. (See",
"      <a class=\"local\" href=\"#H2268364\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/1\">",
"      Spiegel D, Loewenstein RJ, Lewis-Fern&aacute;ndez R, et al. Dissociative disorders in DSM-5. Depress Anxiety 2011; 28:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/2\">",
"      Ross CA. Epidemiology of multiple personality disorder and dissociation. Psychiatr Clin North Am 1991; 14:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/3\">",
"      Sar V, Aky&uuml;z G, Do��an O. Prevalence of dissociative disorders among women in the general population. Psychiatry Res 2007; 149:169.",
"     </a>",
"    </li>",
"    <li>",
"     Knudsen SA, Draijer N, Haslerud J, et al. Prevalence of dissociative disorders in a Norwegian general psychiatric department. In: Fifth Annual Spring Conference of the International Society for the Study of Dissociation, Van der Hart O, Boon S, Draijer N.  (Eds), International Society for the Study of Dissociation, Amsterdam 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/5\">",
"      Lipsanen T, Korkeila J, Peltola P, et al. Dissociative disorders among psychiatric patients. Eur Psychiatry 2004; 19:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/6\">",
"      Modestin J, Ebner G, Junghan M, Erni T. Dissociative experiences and dissociative disorders in acute psychiatric inpatients. Compr Psychiatry 1996; 37:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/7\">",
"      Tutkun H, Sar V, Yargi&ccedil; LI, et al. Frequency of dissociative disorders among psychiatric inpatients in a Turkish University Clinic. Am J Psychiatry 1998; 155:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/8\">",
"      Gast U, Rodewald F, Nickel V, Emrich HM. Prevalence of dissociative disorders among psychiatric inpatients in a German university clinic. J Nerv Ment Dis 2001; 189:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/9\">",
"      Friedl MC, Draijer N. Dissociative disorders in Dutch psychiatric inpatients. Am J Psychiatry 2000; 157:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/10\">",
"      Horen SA, Leichner PP, Lawson JS. Prevalence of dissociative symptoms and disorders in an adult psychiatric inpatient population in Canada. Can J Psychiatry 1995; 40:185.",
"     </a>",
"    </li>",
"    <li>",
"     Ross CA. History, phenomenology, and epidemiology of dissociation. In: Handbook of Dissociation, Michelson LK, Ray WJ.  (Eds), Plenum, New York 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/12\">",
"      Saxe GN, van der Kolk BA, Berkowitz R, et al. Dissociative disorders in psychiatric inpatients. Am J Psychiatry 1993; 150:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/13\">",
"      Rifkin A, Ghisalbert D, Dimatou S, et al. Dissociative identity disorder in psychiatric inpatients. Am J Psychiatry 1998; 155:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/14\">",
"      Latz TT, Kramer SI, Hughes DL. Multiple personality disorder among female inpatients in a state hospital. Am J Psychiatry 1995; 152:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/15\">",
"      Yu J, Ross CA, Keyes BB, et al. Dissociative disorders among Chinese inpatients diagnosed with schizophrenia. J Trauma Dissociation 2010; 11:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/16\">",
"      Graves SM. Dissociative disorders and dissociative symptoms at a community mental health center. Dissociation 1989; 2:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/17\">",
"      Mezzich JE, Fabrega H Jr, Coffman GA, Haley R. DSM-III disorders in a large sample of psychiatric patients: frequency and specificity of diagnoses. Am J Psychiatry 1989; 146:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/18\">",
"      Lussier RG, Steiner J, Grey A, Hansen C. Prevalence of dissociative disorders in an acute care day hospital population. Psychiatr Serv 1997; 48:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/19\">",
"      Sar V, Tutkun H, Alyanak B, et al. Frequency of dissociative disorders among psychiatric outpatients in Turkey. Compr Psychiatry 2000; 41:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/20\">",
"      Foote B, Smolin Y, Kaplan M, et al. Prevalence of dissociative disorders in psychiatric outpatients. Am J Psychiatry 2006; 163:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/21\">",
"      Boon S, Draijer N. Multiple personality disorder in The Netherlands: a clinical investigation of 71 patients. Am J Psychiatry 1993; 150:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/22\">",
"      Sar V, Yargi&ccedil; LI, Tutkun H. Structured interview data on 35 cases of dissociative identity disorder in Turkey. Am J Psychiatry 1996; 153:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/23\">",
"      Putnam FW, Guroff JJ, Silberman EK, et al. The clinical phenomenology of multiple personality disorder: review of 100 recent cases. J Clin Psychiatry 1986; 47:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/24\">",
"      Ross CA, Norton GR, Wozney K. Multiple personality disorder: an analysis of 236 cases. Can J Psychiatry 1989; 34:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/25\">",
"      Ellason JW, Ross CA, Fuchs DL. Lifetime axis I and II comorbidity and childhood trauma history in dissociative identity disorder. Psychiatry 1996; 59:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/26\">",
"      Ross CA, Miller SD, Reagor P, et al. Structured interview data on 102 cases of multiple personality disorder from four centers. Am J Psychiatry 1990; 147:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/27\">",
"      Foote B, Smolin Y, Neft DI, Lipschitz D. Dissociative disorders and suicidality in psychiatric outpatients. J Nerv Ment Dis 2008; 196:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/28\">",
"      Rodewald F, Wilhelm-G&ouml;ling C, Emrich HM, et al. Axis-I comorbidity in female patients with dissociative identity disorder and dissociative identity disorder not otherwise specified. J Nerv Ment Dis 2011; 199:122.",
"     </a>",
"    </li>",
"    <li>",
"     Foote B, Park J. Dissociative identity disorder and schizophrenia: differential diagnosis and theoretical issues. Curr Psychiatry Rep. Jun 2008;10(3):217-222.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/30\">",
"      Ross CA, Heber S, Norton GR, Anderson G. Differences between multiple personality disorder and other diagnostic groups on structured interview. J Nerv Ment Dis 1989; 177:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/31\">",
"      Yargi&ccedil; LI, Sar V, Tutkun H, Alyanak B. Comparison of dissociative identity disorder with other diagnostic groups using a structured interview in Turkey. Compr Psychiatry 1998; 39:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/32\">",
"      Saxe GN, Chinman G, Berkowitz R, et al. Somatization in patients with dissociative disorders. Am J Psychiatry 1994; 151:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/33\">",
"      Ross CA, Miller SD, Bjornson L, et al. Abuse histories in 102 cases of multiple personality disorder. Can J Psychiatry 1991; 36:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/34\">",
"      Loewenstein RJ, Putnam FW. The clnical phenomenology of males with MPD: A report of 21 cases. Dissociation 1990; 3:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/35\">",
"      Putnam FW. Ten-year research update review: child sexual abuse. J Am Acad Child Adolesc Psychiatry 2003; 42:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/36\">",
"      Finkelhor D, Turner H, Ormrod R, Hamby SL. Violence, abuse, and crime exposure in a national sample of children and youth. Pediatrics 2009; 124:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/37\">",
"      Green JG, McLaughlin KA, Berglund PA, et al. Childhood adversities and adult psychiatric disorders in the national comorbidity survey replication I: associations with first onset of DSM-IV disorders. Arch Gen Psychiatry 2010; 67:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/38\">",
"      Afifi TO, Mather A, Boman J, et al. Childhood adversity and personality disorders: results from a nationally representative population-based study. J Psychiatr Res 2011; 45:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/39\">",
"      Sugaya L, Hasin DS, Olfson M, et al. Child physical abuse and adult mental health: a national study. J Trauma Stress 2012; 25:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/40\">",
"      Tellegen A, Atkinson G. Openness to absorbing and self-altering experiences (\"absorption\"), a trait related to hypnotic susceptibility. J Abnorm Psychol 1974; 83:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/41\">",
"      Tellegen A. Practicing the two disciplines for relaxation and enlightenment: comment on \"Role of the feedback signal in electromyograph biofeedback: the relevance of attention\" by Qualls and Sheehan. J Exp Psychol Gen 1981; 110:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/42\">",
"      Ross CA, Joshi S, Currie R. Dissociative experiences in the general population. Am J Psychiatry 1990; 147:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/43\">",
"      Xiao Z, Yan H, Wang Z, et al. Dissociative experiences in China. J Trauma Dissociation 2006; 7:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/44\">",
"      Nijenhuis ER, Vanderlinden J, Spinhoven P. Animal defensive reactions as a model for trauma-induced dissociative reactions. J Trauma Stress 1998; 11:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/45\">",
"      Becker-Blease KA, Deater-Deckard K, Eley T, et al. A genetic analysis of individual differences in dissociative behaviors in childhood and adolescence. J Child Psychol Psychiatry 2004; 45:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/46\">",
"      Waller NG, Ross CA. The prevalence and biometric structure of pathological dissociation in the general population: taxometric and behavior genetic findings. J Abnorm Psychol 1997; 106:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/47\">",
"      Jang KL, Paris J, Zweig-Frank H, Livesley WJ. Twin study of dissociative experience. J Nerv Ment Dis 1998; 186:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/48\">",
"      Pieper S, Out D, Bakermans-Kranenburg MJ, van Ijzendoorn MH. Behavioral and molecular genetics of dissociation: the role of the serotonin transporter gene promoter polymorphism (5-HTTLPR). J Trauma Stress 2011; 24:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/49\">",
"      Savitz JB, van der Merwe L, Newman TK, et al. The relationship between childhood abuse and dissociation. Is it influenced by catechol-O-methyltransferase (COMT) activity? Int J Neuropsychopharmacol 2008; 11:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/50\">",
"      Koenen KC, Saxe G, Purcell S, et al. Polymorphisms in FKBP5 are associated with peritraumatic dissociation in medically injured children. Mol Psychiatry 2005; 10:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/51\">",
"      Vermetten E, Schmahl C, Lindner S, et al. Hippocampal and amygdalar volumes in dissociative identity disorder. Am J Psychiatry 2006; 163:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/52\">",
"      Ehling T, Nijenhuis ER, Krikke AP. Volume of discrete brain structures in complex dissociative disorders: preliminary findings. Prog Brain Res 2008; 167:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/53\">",
"      Weniger G, Lange C, Sachsse U, Irle E. Amygdala and hippocampal volumes and cognition in adult survivors of childhood abuse with dissociative disorders. Acta Psychiatr Scand 2008; 118:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/54\">",
"      Irle E, Lange C, Sachsse U, Weniger G. Further evidence that post-traumatic stress disorder but not dissociative disorders are related to amygdala and hippocampal size reduction in trauma-exposed individuals. Acta Psychiatr Scand 2009; 119:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/55\">",
"      Bremner JD, Randall P, Scott TM, et al. MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder. Am J Psychiatry 1995; 152:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/56\">",
"      Bremner JD, Randall P, Vermetten E, et al. Magnetic resonance imaging-based measurement of hippocampal volume in posttraumatic stress disorder related to childhood physical and sexual abuse--a preliminary report. Biol Psychiatry 1997; 41:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/57\">",
"      Stein MB, Koverola C, Hanna C, et al. Hippocampal volume in women victimized by childhood sexual abuse. Psychol Med 1997; 27:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/58\">",
"      Gilbertson MW, Shenton ME, Ciszewski A, et al. Smaller hippocampal volume predicts pathologic vulnerability to psychological trauma. Nat Neurosci 2002; 5:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/59\">",
"      Dalenberg CJ, Brand BL, Gleaves DH, et al. Evaluation of the evidence for the trauma and fantasy models of dissociation. Psychol Bull 2012; 138:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/60\">",
"      Ross CA, Ness L. Symptom patterns in dissociative identity disorder patients and the general population. J Trauma Dissociation 2010; 11:458.",
"     </a>",
"    </li>",
"    <li>",
"     Dutra L, Bianchi I, Siegel DJ, Lyons-Ruth K. he relational context of dissociative phenomena. In: Dissociation and the Dissociative Disorders: DSM-V and Beyond, Dell PF, O'Neill JA.  (Eds), Routledge, New York 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/62\">",
"      Ogawa JR, Sroufe LA, Weinfield NS, et al. Development and the fragmented self: longitudinal study of dissociative symptomatology in a nonclinical sample. Dev Psychopathol 1997; 9:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/63\">",
"      Dutra L, Bureau JF, Holmes B, et al. Quality of early care and childhood trauma: a prospective study of developmental pathways to dissociation. J Nerv Ment Dis 2009; 197:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/64\">",
"      Freyd JJ. Blind to betrayal: new perspectives on memory for trauma. Harv Ment Health Lett 1999; 15:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/65\">",
"      Spanos NP. Multiple identity enactments and multiple personality disorder: a sociocognitive perspective. Psychol Bull 1994; 116:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/66\">",
"      Hartocollis L. The making of multiple personality disorder: a social constructionist view. Clin Soc Work J 1998; 26:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/67\">",
"      Spanos NP, Weekes JR, Bertrand LD. Multiple personality: a social psychological perspective. J Abnorm Psychol 1985; 94:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/68\">",
"      Giesbrecht T, Lynn SJ, Lilienfeld SO, Merckelbach H. Cognitive processes in dissociation: an analysis of core theoretical assumptions. Psychol Bull 2008; 134:617.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/70\">",
"      Shusta-Hochberg SR. Therapeutic hazards of treating child alters as real children in dissociative identity disorder. J Trauma and Dissociation 2004; 5:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/71\">",
"      Goodman  L, Peters J. Persecutory alters and ego states: protectors, friends, and allies. Dissociation 1995; 8:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/72\">",
"      Blizard RA. Therapeutic alliance with abuser alters in DID: The paradox of attachment to the abuser. Dissociation 1997; 10:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/73\">",
"      Kluft RP. Dealing with alters: a pragmatic clinical perspective. Psychiatr Clin North Am 2006; 29:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/74\">",
"      Loewenstein RJ. DID 101: a hands-on clinical guide to the stabilization phase of dissociative identity disorder treatment. Psychiatr Clin North Am 2006; 29:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/75\">",
"      Spiegel D. Dissociation in the DSM5. J Trauma Dissociation 2010; 11:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/76\">",
"      Dell PF. A new model of dissociative identity disorder. Psychiatr Clin North Am 2006; 29:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/77\">",
"      Dorahy MJ, Shannon C, Seagar L, et al. Auditory hallucinations in dissociative identity disorder and schizophrenia with and without a childhood trauma history: similarities and differences. J Nerv Ment Dis 2009; 197:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/78\">",
"      Kluft RP. Clinical presentations of multiple personality disorder. Psychiatr Clin North Am 1991; 14:605.",
"     </a>",
"    </li>",
"    <li>",
"     Kluft RP. The natural history of multiple personality disorder. In: Childhood Antecedents of Multiple Personality, Kluft RP.  (Ed), American Psychiatric Publishing, Washington, DC 1985.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/80\">",
"      Stern CR. The etiology of multiple personalities. Psychiatr Clin North Am 1984; 7:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/81\">",
"      Bliss EL. Multiple personalities. A report of 14 cases with implications for Schizophrenia and hysteria. Arch Gen Psychiatry 1980; 37:1388.",
"     </a>",
"    </li>",
"    <li>",
"     Kluft RP. Making the diagnosis of multiple personality disorder. In: Directions in Psychiatry, Flach F.  (Ed), Hatherleigh, New York 1985.",
"    </li>",
"    <li>",
"     Sullivan HS. The Interpersonal Theory of Psychiatry, W.W. Norton, New York 1953.",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR (Text Revision), 4th ed, American Psychiatric Press, Washington, DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/85\">",
"      Welch KA. Neurological complications of alcohol and misuse of drugs. Pract Neurol 2011; 11:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/86\">",
"      Simeon D, Kozin DS, Segal K, Lerch B. Is depersonalization disorder initiated by illicit drug use any different? A survey of 394 adults. J Clin Psychiatry 2009; 70:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/87\">",
"      Spiegel D. Multiple personality as a post-traumatic stress disorder. Psychiatr Clin North Am 1984; 7:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/88\">",
"      Spiegel D, Carde&ntilde;a E. Disintegrated experience: the dissociative disorders revisited. J Abnorm Psychol 1991; 100:366.",
"     </a>",
"    </li>",
"    <li>",
"     Lanius RA, Vermetten E, Loewenstein RJ, et al. Emotion modulation in PTSD: Clinical and neurobiological evidence for a dissociative subtype. Am J Psychiatry. Jun 2010;167(6):640-647.",
"    </li>",
"    <li>",
"     Ross CA. Dissociative Identity Disorder: Diagnosis, Clinical Features, and Treatment of Multiple Personality, John Wiley and Sons, New York 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/91\">",
"      Dell PF. Dissociative phenomenology of dissociative identity disorder. J Nerv Ment Dis 2002; 190:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/56/11146/abstract/92\">",
"      Brand BL, McNary SW, Loewenstein RJ, et al. Assessment of genuine and simulated dissociative identity disorder on the structured interview of reported symptoms. J Trauma Dissociation 2006; 7:63.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14700 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-210.101.131.231-DF96EE1385-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_56_11146=[""].join("\n");
var outline_f10_56_11146=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H189780\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1244359\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H349015232\">",
"      DISSOCIATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1244373\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H663938821\">",
"      Comorbidity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H663938688\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1244380\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18659852\">",
"      Trauma model",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H663939132\">",
"      - Dissociativity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H577186680\">",
"      - Childhood trauma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H577186687\">",
"      - Poor infant attachment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H87907603\">",
"      - Proposed mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H315539289\">",
"      Sociocognitive model",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1244387\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1550386\">",
"      Identity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1551497\">",
"      Other dissociative symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1244394\">",
"      COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1244401\">",
"      ASSESSMENT AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H578546\">",
"      Addressing diagnostic challenges",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2268364\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1493078\">",
"      - Intoxication",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1493085\">",
"      - General medical conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H578641\">",
"      - Posttraumatic stress disorder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1493042\">",
"      - Borderline personality disorder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1493053\">",
"      - Schizophrenia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1493060\">",
"      - Bipolar disorder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1493101\">",
"      - Factitious disorder and malingering",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H578737\">",
"      - Non-pathologic behavior",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H189780\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7080?source=related_link\">",
"      Acute stress disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2409?source=related_link\">",
"      Alcohol abuse and dependence: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/19/10553?source=related_link\">",
"      Borderline personality disorder: Epidemiology, clinical features, diagnosis, and differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/32/522?source=related_link\">",
"      Dissociative aspects of posttraumatic stress disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=related_link\">",
"      Evaluation of cognitive impairment and dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35258?source=related_link\">",
"      Evaluation of sexual abuse in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25753?source=related_link\">",
"      Evaluation of the first seizure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7512?source=related_link\">",
"      Factitious disorder and Munchausen syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=related_link\">",
"      Physical abuse in children: Diagnostic evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=related_link\">",
"      Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34552?source=related_link\">",
"      Schizophrenia: Clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=related_link\">",
"      Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5033?source=related_link\">",
"      Substance use disorders: Principles for recognition and assessment in general medical care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37481?source=related_link\">",
"      Unipolar depression in adults: Epidemiology, pathogenesis, and neurobiology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_56_11147="NCEP very high risk";
var content_f10_56_11147=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F54585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F54585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Definition of \"very high risk\" in NCEP guidelines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Established coronary heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        PLUS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Multiple major risk factors (especially diabetes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        &nbsp;OR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Severe and poorly controlled risk factors (especially continued smoking)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        &nbsp;OR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Multple risk factors of the metabolic syndrome (especially triglycerides &ge;200 plus non-HDL-C &ge;130 plus HDL-C &lt;40)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        &nbsp;OR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Acute coronary syndrome",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Grundy SM, Cleeman JI, Merz NB, et al. Circulation 2004; 110:227.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_56_11147=[""].join("\n");
var outline_f10_56_11147=null;
var title_f10_56_11148="Entecavir versus lamivudine I";
var content_f10_56_11148=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F59012&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F59012&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected virologic, biochemical, and serologic endpoints at week 48, nucleoside-naive patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"34%\">",
"     </colgroup>",
"     <colgroup span=\"4\" width=\"16%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        (HBeAg-positive)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        (HBeAg-negative)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Entecavir 0.5 mg",
"        <br/>",
"        (n = 354)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Lamivudine 100 mg",
"        <br/>",
"        (n = 355)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Entecavir 0.5 mg",
"        <br/>",
"        (n = 325)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Lamivudine 100 mg",
"        <br/>",
"        (n = 313)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"5\">",
"        HBV DNA*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Proportion undetectable (&lt;300 copies/mL)",
"       </td>",
"       <td class=\"sublist_other\">",
"        67 percent",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        36 percent",
"       </td>",
"       <td class=\"sublist_other\">",
"        90 percent",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        72 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mean changes from baseline (log10 copies/mL)",
"       </td>",
"       <td class=\"sublist_other\">",
"        -6.86",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        -5.39",
"       </td>",
"       <td class=\"sublist_other\">",
"        -5.04",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        -4.53",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ALT normalization (&le;1 X ULN)",
"       </td>",
"       <td>",
"        68 percent",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        60 percent",
"       </td>",
"       <td>",
"        78 percent",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        71 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HBeAg seroconversion",
"       </td>",
"       <td>",
"        21 percent",
"       </td>",
"       <td>",
"        18 percent",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Roche COBAS Amplicor PCR assay (LLOQ = 300 copies/mL).",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     p&lt;0.05.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_56_11148=[""].join("\n");
var outline_f10_56_11148=null;
var title_f10_56_11149="Staging of cutaneous lymphoma other than MF SS";
var content_f10_56_11149=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F65110&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F65110&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ISCL/EORTC proposal on TNM classification of cutaneous lymphoma other than mycosis fungoides or S&eacute;zary syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        T",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        T1: Solitary skin involvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T1a: A solitary lesion &lt;5 cm diameter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T1b: A solitary lesion &gt;5 cm diameter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        T2: Regional skin involvement: multiple lesions limited to&nbsp;one body region or&nbsp;two contiguous body regions*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T2a: All-disease-encompassed in a &lt;15 cm-diameter circular area",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T2b: All-disease-encompassed in a &gt;15 cm-&nbsp;and &lt;30 cm-diameter circular area",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T2c: All-disease-encompassed in a &gt;30 cm-diameter circular area",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        T3: Generalized skin involvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T3a: Multiple lesions involving&nbsp;two noncontiguous body regions*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T3b: Multiple lesions involving &ge;3 body regions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N0: No clinical or pathologic lymph node involvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N1: Involvement of&nbsp;one peripheral lymph node region that drains an area of current or prior skin involvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N2: Involvement of&nbsp;two or more peripheral lymph node regions or involvement of any lymph node region",
"        <sup>",
"         &bull;",
"        </sup>",
"        that does not drain an area of current or prior skin involvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N3: Involvement of central lymph nodes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        M",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M0: No evidence of extracutaneous non-lymph node disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M1: Extracutaneous non-lymph node disease present",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Definition of body regions:",
"     <br>",
"      - Head and neck: inferior border- superior border of clavicles, T1 spinous process.",
"      <br>",
"       - Chest: superior border- superior border of clavicles; inferior border- inferior margin of rib cage; lateral borders- mid-axillary lines, glenohumeral joints (inclusive of axillae).",
"       <br>",
"        - Abdomen/genital: superior border- inferior margin of rib cage; inferior border- inguinal folds, anterior perineum; lateral borders- mid-axillary lines.",
"        <br>",
"         - Upper back: superior border- T1 spinous process; inferior border- inferior margin of rib cage; lateral borders- mid-axillary lines.",
"         <br>",
"          - Lower back/buttocks: superior border- inferior margin of rib cage; inferior border- inferior gluteal fold, anterior perineum (inclusive of perineum); lateral borders- mid-axillary lines.",
"          <br>",
"           - Each upper arm: superior borders- glenohumeral joints (exclusive of axillae); inferior borders- ulnar/radial-humeral (elbow) joint.",
"           <br>",
"            - Each lower arm/hand: superior borders- ulnar/radial-humeral (elbow) joint.",
"            <br>",
"             - Each upper leg (thigh): superior borders- inguinal folds, inferior gluteal folds; inferior borders- mid-patellae, mid-popliteal fossae.",
"             <br>",
"              - Each lower leg/foot: superior borders- mid-patellae, mid-popliteal fossae.",
"              <br>",
"               <font class=\"bullet\">",
"                <sup>",
"                 &bull;",
"                </sup>",
"               </font>",
"               Definition of lymph node regions is consistent with the Ann Arbor system: Peripheral sites: antecubital, cervical, supraclavicular, axillary, inguinal-femoral, and popliteal. Central sites: mediastinal, pulmonary hilar, paraortic, iliac.",
"              </br>",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     This research was originally published in Blood. Kim YH, Willemze R, Pimpinelli N, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110:479.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_56_11149=[""].join("\n");
var outline_f10_56_11149=null;
var title_f10_56_11150="Infant mortality birth wt";
var content_f10_56_11150=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 629px\">",
"   <div class=\"ttl\">",
"    Infant mortality rates by birthweight: United States, 2004",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 609px; height: 304px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Matthews TJ, MacDorman MF. Infant mortality statistics from the 2004 period linked birth/infant death data set. National Center for Health Statistics. Vital Health Stat Series No. 55 (14). 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_56_11150=[""].join("\n");
var outline_f10_56_11150=null;
var title_f10_56_11151="Neck rotation exercise";
var content_f10_56_11151=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F80744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F80744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Neck rotation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 367px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Slowly turn your head to the right. Place tension on your chin with your fingertips. Hold for a few seconds and return to the center. Repeat to the left.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_56_11151=[""].join("\n");
var outline_f10_56_11151=null;
